When EGFR-TKI resistance leads to progression in EGFRm mNSCLC*.

*EGFR mutations include exon 19 del or exon 21 L858R.

EPGR, epidermal growth factor receptor; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; exon 19 del, exon 19 deletions; exon 21 L858R, exon 21 leucine to arginine substitution; mNSCLC, metastatic non-small cell lung cancer.


TABLE OF CONTENTS
IASLC 2023 World Conference on Lung Cancer

<table>
<thead>
<tr>
<th>Overview</th>
<th>01</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Messages</td>
<td>08</td>
</tr>
<tr>
<td>Important Information</td>
<td>10</td>
</tr>
<tr>
<td>IASLC Staff &amp; WCLC Committees</td>
<td>15</td>
</tr>
<tr>
<td>IASLC &amp; Conference Awards</td>
<td>26</td>
</tr>
<tr>
<td>Program at a Glance</td>
<td>35</td>
</tr>
<tr>
<td>Scientific Program - Saturday, September 9</td>
<td>02</td>
</tr>
<tr>
<td>Scientific Program - Sunday, September 10</td>
<td>03</td>
</tr>
<tr>
<td>Scientific Program - Monday, September 11</td>
<td>04</td>
</tr>
<tr>
<td>Scientific Program - Tuesday, September 12</td>
<td>05</td>
</tr>
<tr>
<td>Posters</td>
<td>06</td>
</tr>
<tr>
<td>Posters – Sunday, September 10</td>
<td>120</td>
</tr>
<tr>
<td>Posters – Monday, September 11</td>
<td>136</td>
</tr>
<tr>
<td>ePosters</td>
<td>156</td>
</tr>
<tr>
<td>General Information</td>
<td>07</td>
</tr>
<tr>
<td>Exhibit and Supporter Information</td>
<td>208</td>
</tr>
<tr>
<td>CME Satellite and Industry Sponsored Symposia</td>
<td>222</td>
</tr>
<tr>
<td>Conference Information</td>
<td>238</td>
</tr>
<tr>
<td>Venue Floor Plans</td>
<td>242</td>
</tr>
</tbody>
</table>

CONFERENCE SECRETARIAT
International Conference Services Ltd. (ICS)
Suite 710, 1201 West Pender Street, Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153
www.icsevents.com
DID YOU KNOW...

The Early Lung Imaging Confederation is an international alliance developing a globally distributed, privacy-secured, lung cancer imaging database and computational analysis environment.

Detect lung cancer and discriminate benign and malignant nodules using:
› Deep learning methods
› Artificial intelligence approaches
CONFERECE OVERVIEW
Welcome Message from the WCLC 2023 Conference Chairs

Dear Colleagues from around the World,

On behalf of the International Association for the Study of Lung Cancer (IASLC) it is our great pleasure to welcome you to the IASLC 2023 World Conference on Lung Cancer (#WCLC23) in Singapore.

From September 9 to 12, WCLC 2023 will offer four days of ground-breaking scientific activity bringing together more than 6,000 delegates globally from all fields in basic and clinical sciences related to thoracic malignancies. We are proud to have received more than 1,800 abstracts which will be presented in oral, mini-oral, and poster sessions. More than 350 invited lectures, 150 oral and mini-oral presentations as well as over 1,500 posters and ePosters will contribute to the exchange of new information among delegates.

To facilitate discussions and networking opportunities, we offer a virtual platform available on desktop and mobile devices that will allow delegates to ask questions and chat with other participants during the sessions.

We encourage you to participate actively in the discussions but also take some time to enjoy the beauty of Singapore. It is a melting pot of ethnicities, culture and cuisine. A cosmopolitan country that is rapidly evolving and constantly reinventing itself. A gateway to Asia with its share of attractions that must not be missed.

We also would like to extend our gratitude to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them, this Conference would not be possible.

Thank you for joining us in Singapore or also online. We wish all delegates an enjoyable and productive Conference.

Yours sincerely,

Fiona Hegi-Johnson, MD
Conference Co-Chair

Pyng Lee, MD
Conference Co-Chair

Chee Lee, Professor
Conference Co-Chair

---

CONFERECE OVERVIEW
Welcome Message from the IASLC President and CEO

Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2023 World Conference on Lung Cancer (#WCLC23) in beautiful Singapore. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating, and collaborative meeting.

This year marks the 24th WCLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past four decades. During that time, we’ve seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques, and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients.

Throughout its long history, the WCLC has played a strong role in facilitating that progress – providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships; connecting established researchers with young investigators, and serving as a foundational meeting for healthcare professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases. This enduring importance is illustrated in how the WCLC has evolved over time – growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts over 7,500 international participants. Such growth in size, impact, and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers, and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC – from its formative years to the present day.

But while the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of thoracic cancers. That is why for WCLC 2023, we are proud to announce that the conference organizers have put together an incredible scientific program. We want to thank them for their hard work and we are especially grateful for the dedication of our Conference Chairs: Drs. Fiona Hegi-Johnson, Chee Lee, and Pyng Lee. We have no doubt that you will find WCLC 2023 to be an exceptional educational experience.

Thank you for attending WCLC 2023, and thank you for your engagement with the IASLC. We hope you enjoy the meeting; have the opportunity to explore Singapore; find opportunities to develop new relationships and collaborations; and, finally gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients – both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment, and engagement of those who attend it. In short, your participation is one of the main reasons for why the event has remained the world’s leading thoracic cancer conference for almost 50 years. We appreciate you being a part of our ongoing story.

Heather Wakelee, MD
President
International Association for the Study of Lung Cancer (IASLC)

Karen Kelly, MD
Chief Executive Officer
International Association for the Study of Lung Cancer (IASLC)
WIFI DETAILS
Please join the network below to access free wifi for the duration of the Conference. No password required.

WCLC23_FREE_WiFi@SuntecSingapore

DISCLAIMER
The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources.

Although every effort has been made to ensure the accuracy, currency, and reliability of the content, the organizers accept no responsibility in that regard.

IASLC WCLC 2023 VIRTUAL PLATFORM
All sessions will be audio recorded and made available on the Virtual Platform within 24 hours. The Virtual Platform also includes presentation slides, abstracts and posters.

Log-in details were sent to your registered email. If you need assistance, visit the Virtual Platform Help Desk located at Level 3 Concourse or send an email to wclc2023-registration@icsevents.com.

WCLC 2023 VIRTUAL PLATFORM: MEETINGSAPP.IASLC.ORG/EVENT/WCLC2023

VIRTUAL PLATFORM FEATURES:
• Full Scientific Schedule
• Abstract Book, Program Book
• Venue and Exhibit Floor Plan
• Presentation Slides and Recordings (Within 24 Hours)
• ePosters (Online View During the Conference) and Downloadable PDFs for all Traditional Posters and ePosters after the Conference
• Opportunity to Create Personalized Calendar
• Networking Features to Connect with Delegates and Faculty
• Notification Alerts

FOLLOW IASLC ON SOCIAL MEDIA
facebook.com/IASLC
@IASLC
IASLC
IASLC
iaslungcancer
IASLC

AMAZING CASE RACE
The 2023 IASLC Academy class is going to be part of the 1st Amazing Case Race! Every member of the 2023 Academy has produced one case summary based on real-life patients and using the testing and treatment options available in their countries and using protocols for their institutions. As a WCLC attendee, you will vote on your favorite case summaries.

At the end of the meeting, the top 5 cases will be included in the IASLC 1st case-based simulation course. So, don’t forget to vote for your favorites and take the course to see who won the Amazing Case Race!
Attend the special plenary session
TNM for Lung, Mesothelioma and Thymic Cancers –
Update on the Proposals for the
9th Edition of TNM Staging to preview
the new 9th edition recommendations.

Monday, September 11, 17:00 Singapore Time

Help change the landscape of lung cancer treatment for future patients!
- New clinical and molecular elements have been added
- International participation is crucial to the project’s success
- 10th edition lung cancer staging project launching in 2024

STRONGER TOGETHER

Research and patient advocates are an integral part of the IASLC. Their contributions reflect the reality of what research is aiming for – HOPE.

Please visit the Patient Advocacy Lounge to find resources and to network.

Scan the QR code for more information
International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.

By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.

The IASLC mission is:

1. To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
2. To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
3. To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

IASLC BOARD OF DIRECTORS 2021 – 2023

President: Heather Wakelee, USA
Past President: Tetsuya Mitsudomi, Japan
President-Elect: Paul Van Schil, Belgium
Secretary: Andrea Bezjak, Canada
Treasurer: Erik Thunnissen, Netherlands
Chief Executive Officer: Karen Kelly, USA

BOARD MEMBERS

Joachim Aerts, Netherlands
Carlos Gil Moreira Ferreira, Brazil
Jhanelle Gray, USA
Roy Herbst, USA
Young Tae Kim, Republic of Korea
Morten Quist, Denmark
Lecia Sequist, USA
Ming-Sound Tsao, Canada
Paula Ugalde, USA
Caiun Zhou, China

Accelerating the pace of thoracic malignancy research and funding the next generation of lung cancer luminaries. The IASLC Foundation, LLC (IASLC Foundation) inspires hope through research.
For more information visit: https://www.iaslc.org/foundation
## Program Committee

### Risk Factors, Risk Reduction & Tobacco Control
- Carolyn Dresler, Chair, USA
- Emily Stone, Co-Chair, Australia
- Csaba Degi, Romania
- Joelle Fathi, USA
- Jacek Jassem, Poland
- Manfred Neuberger, Austria
- Jamie Ostroff, USA
- Pan-Chyr Yang, Taiwan

### Screening & Early Detection
- Monica Castro, Chair, Argentina
- Gerard Silvestri, Co-Chair, USA
- Christine Berg, USA
- Terri Byrne, Australia
- Debra Dyer, USA
- Wentao Fang, China
- Anna Kerpel-Fronius, Hungary
- Annette McWilliams, Australia

### Pulmonology & Staging
- Anne Hsu, Chair, Singapore
- Douglas Arencberg, Co-Chair, USA
- John Edwards, UK
- David Fellerkopman, USA
- Carla Lamb, USA
- Edith Marom, Israel
- Takahiro Nakajima, Japan
- Daniel Sterman, USA

### Pathology & Biomarkers
- Wendy Cooper, Chair, Australia
- Keith Kerr, Co-Chair, UK
- Sabina Berovzowska, Switzerland
- Teh-Ying Chou, Taiwan
- Anjali Saqi, USA
- Lynette Sholl, USA
- Jan Von Der Thuesen, Netherlands
- Yasushi Yatabe, Japan

### Tumor Biology - Preclinical Biology
- Anne-Marie Baird, Chair, Ireland
- Trevor Bivona, Co-Chair, USA
- Alfredo Addeo, Switzerland
- Marie-Liesse Asselin Labat, Australia
- Alice Berger, USA
- Magnus Dillon, UK
- Katerina Politli, USA
- Karin Schelch, Austria

### Tumor Biology - Translational Biology
- Daniel Tan, Chair, Singapore
- Pasi A. Järne, Co-Chair, USA
- Esra Akbay, USA
- Nicolaus Andratschke, Switzerland
- Christine Lovly, USA
- Ken O’Byrne, Australia
- Jonathan Ostrem, USA
- Robert Rintoul, UK
- Kate Sutherland, Australia

### Tumor Biology - Immunotherapy
- Tom John, Chair, Australia
- Ross Soo, Co-Chair, Singapore
- Clarissa Baldotto, Brazil
- Puey Ling Chia, Singapore
- Mary Duffy, Australia
- Marina Garassino, USA
- Pilar Garrido, Spain
- Luciana Holtz, Brazil
- Alexandra Louie, Canada
- Sanjay Popat, UK
**Metastatic Non-small Cell Lung Cancer - Targeted Therapy**
Benjamin Solomon, Chair, Australia
Helena Yu, Co-Chair, USA
Paula De Vega, Australia
Ivy Elkins, USA
Bob Li, USA
Fiona McDonald, UK
Antony Mersiades, Australia
David Planchard, France
Qing Zhou, China

**Multidisciplinary Care: Nursing, Allied Health & Palliative Care**
Michael Franco, Chair, Australia
Anne Fraser, Co-Chair, New Zealand
Elizabeth Ivimey, Co-Chair, Australia
Andreas Charalambous, Cyprus
Polly Dufton, Australia
Simon Dunne, Ireland
Maria Ftanou, Australia
Laura Petrito, USA
Ewelina Szmytke, Germany
Felicia Zhang, Canada

**Small Cell Lung Cancer & Neuroendocrine Tumors**
Stephen Liu, Chair, USA
Aaron Tan, Co-Chair, Singapore
Upal Basu Roy, USA
Corinne Favre-Finn, UK
Lynnette Fernandez-Cuesta, France
Julie George, Germany
Miyako Satouchi, Japan
Misty Shields, USA
Sumitra Thongprasert, Thailand

**Patient Advocacy**
Lillian Leigh, Chair, Australia
Jill Feldman, Co-Chair, USA
Andrew Ciutepek, USA
Dusty Donaldson, USA
Caleb Egwuenu, Nigeria
Angeline Low, Australia
Stefania Vallone, Spain

**Global Health, Health Services & Health Economics**
Yiqing Huang, Chair, Singapore
Shalini Vinod, Co-Chair, Australia
Pedro Aguilar, Brazil
Paolo Boffetta, USA
Anne Fraser, New Zealand
Wee Yao Koh, Singapore
Gilberto Lopes, USA
Melody Qu, Canada

**International Abstract Review Committee**
Prasad Adusumilli, USA
Joachim Aerts, Netherlands
Pedro Aguilar Jr, Brazil
Hiroaki Akamatsu, Japan
Esra Akbay, USA
Mihaela Aldea, France
Raid Aljumaily, USA
Ihsan Alloubi, Morocco
Mehmet Altan, USA
Chiara Ambrogio, Italy
Sita Andarini, Indonesia
Nicolaus Andratchke, Switzerland
Delphine Antoni, France
António Araújo, Portugal
Douglas Arengberg, USA
Marie-Liesse Asselin-Labat, Australia
Paul Baas, Netherlands
Leah Backhus, USA
Shahed Badiyan, USA
Anne-Marie Baird, Ireland
Haval Balata, UK
Clarissa Baldotto, Brazil
Andrew Bang, Canada
Upal Basu Roy, USA
Lyudmila Bazzheno, USA
Mary Beth Beasley, USA
Deepti Behl, USA
Sabina Berezowska, Switzerland
Christine Berg, USA
Eric Bemicker, USA
Christine Bestvina, USA
Paolo Boffetta, USA
Alain Charles Borczuk, USA
Horsein Borghaei, USA
Andrea K. Borondy-Kitts, USA
Michael Boyer, Australia
Luka Brcic, Austria
Caitlin Broderick, Australia
Odd Terje Brustugun, Norway
Lukas Bubendorf, Switzerland
Jennifer Carlisle, USA

Tina Cascone, USA
Mónica Castro, Argentina
Milena Cavic, Serbia
Jamie Chaff, USA
Sze Wai Chan, South Africa
Andreas Charalambous, Cyprus
Puey Ling Chia, Singapore
Teh-Ying Chou, Taiwan
Kevin Chua, Singapore
Stephen Chun, USA
Jin-Haeng Chung, Republic of Korea
Andrew Ciutepek, USA
Wendi Cooper, Australia
Jose Corina-Cruz, Mexico
Seamus Cotter, Ireland
Melissa Culligan, USA
Sanja Dacic, USA
Roselle De Guzman, Philippines
Marc De Perrot, Canada
Paula De Vega, Australia
Aakash Desai, USA
Cassandra Dickens, Australia
Magnus Dillon, UK
Dusty Donaldson, USA
Carolyn Dresler, USA
Elizabeth Dudnik, Israel
Mary Duffy, Australia
Debra Dyer, USA
Jazmin Eckhaus, Australia
Martin Edelman, USA
John Edwards, UK
Caleb Egwuenu, Nigeria
Ivy Elkins, USA
Lawson Eng, Canada
Vinicius Ernani, USA
Bill Evans, Canada
Corinne Favre-Finn, UK
Wentao Fang, China
Nick Faris, USA
Babalola Faseru, USA
Joelle Fathi, USA
01 CONFERENCE OVERVIEW
IASLC and WCLC Committees

Edith Marom, Israel
Thomas Marron, USA
Clarissa Mathias, Brazil
Annette McWilliams, Australia
Antony Mersadiades, Australia
Andrzej Milewski, Poland
Yuko Minami, Japan
Mari Mino-Kenudson, USA
Deebya Raj Mishra, Nepal
Tetsuya Mitsudomi, Japan
Satoru Miura, Japan
James Mulshine, USA
Sudish Murthy, USA
Misako Nagasaka, USA
Yasushi Nagata, Japan
Jarushka Naidoo, Ireland
Takahiro Nakajima, Japan
Joel Neal, USA
Manfred Neuberger, Austria
Calvin S H Ne, Hong Kong
Andrew Nicholson, UK
Kim Norris, USA
Anna Katherine Nowak, Australia
Kenneth O’Byrne, Australia
Emma O’Dowd, UK
Isabelle Opitz, Switzerland
Raymond Osarogiagbon, USA
Dwight Owen, USA
Mauro Papotti, Italy
Seong Yong Park, Republic of Korea
Jyoti Patel, USA
Manish Patel, USA
Sandip Patel, USA
Nick Pavelakis, Australia
Tobias Peikert, USA
Nir Peled, Israel
Laura Petrillo, USA
Zofia Piotrowska, USA
Lecia Sequist, USA
Abhishek Shankar, India
Misty Shields, USA
Shani Shilo, Israel
Hyo Sup Shim, Republic of Korea
Lynette Sholl, USA
Elaine Shum, USA
Alan Shihoe, China
Gerard Silvestri, USA
Navneet Singh, India
Christina Sit, Canada
Shankar Siva, Australia

01 CONFERENCE OVERVIEW
IASLC and WCLC Committees

Jill Feldman, USA
Emanuela Felley-Bosco, Switzerland
Lynnette Fernandez-Cuesta, France
Carlos Gil Ferreira, Brazil
Mary Jo Fidler, USA
John Field, UK
Narjust Flores (Duma), USA
Kwun Fong, Australia
Anne Fraser, New Zealand
Jacqui Frowen, Australia
Shirish Gadegeek, USA
Justin Gainor, Australia
Francoise Galateau-Salle, France
Apar Kishor Ganti, USA
Pilar Garrido, Spain
Meadow Gardner, Canada
Sarah Goldberg, USA
Maciej Goniewicz, USA
Yasushi Goto, Japan
Balazs Halmos, USA
Yuchen Han, China
Gerard Hanna, UK
Desiree Hao, Canada
Ken Harada, Japan
Matthew Hatton, USA
Hidetoshi Hayashi, Japan
Fiona Hegi-Johnson, Australia
Rebecca Heist, USA
Kristin Higgins, USA
Fred R. Hirsch, USA
Paul Hofman, France
Luciana Holtz, Brazil
Hidehito Horinouchi, Japan
Stefanie Houseknecht, USA
Anne Hsu, Singapore
Yiqing Huang, Singapore
Rudolf Huber, Germany
David Hwang, Canada
Deepalli Jain, India
Seung Hun Jang, Republic of Korea
Jacek Jassem, Poland
James R. Jett, USA
Long Jiang, China
Saba Jiwnani, India
Tom John, Australia
Melissa Johnson, USA
Philippe Joubert, Canada
Govind Babu Kanakasetty, India
Steven Kao, Australia
Yuki Katsuya, Japan
Aytay Kayi Cancir, Turkey
Karen Kelly, USA
Hirotugu Kondo, Japan
Anna Kerpel-Fronius, Hungary
Jamal Khader, Jordan
Chul Kim, USA
Hyojin Kim, Republic of Korea
Yeoil Kim, Republic of Korea
Young Tae Kim, Republic of Korea
Nicole Kiss, Australia
Wee-Yao Koh, Singapore
Feng-Yong Kong, Hong Kong
Robert Kalzke, USA
Amir Kulkarni, USA
Yeurn-Hur Lai, Taiwan
Stephen Lam, Canada
Sylvie Lantejoul, France
John Le Quesne, UK
Chee Lee, Australia
Kirsty Lee, Hong Kong
Pyng Lee, Singapore
Lillian Leight, Canada
Whitney Lewis, USA
Bob Li, USA
Zhongxing Liao, USA
Stephen Liu, USA
Herbert Ho-fung Loong, Hong Kong
Gilberto Lopes, USA
Fernando Lopez-Rios, Spain
Alexander Louise, Canada
Christine Lovly, USA
Michael MacManus, Australia
Rami Manochakian, USA
Aaron Mansfield, USA
Daniel Przybysz, USA
Paul Martin Putora, Switzerland
Melody Qu, Canada
Morton Quist, Denmark
Ahmed M. Rabaa, Egypt
Luis Raez, MD, FACS, USA
Karen Reckamp, USA
Noemi Reguart, Spain
Natalasha Rekhtman, USA
Joshua Reuss, USA
Carole Ridge, UK
Anja Roden, USA
Christian Rolfo, USA
John Ruckdeschel, USA
Witold Rzym, Poland
Ricardo Sales Santos, Brazil
Rachel Sanborn, USA
Jacob Sands, USA
Beth Sandy, USA
Edgaro Santos, USA
Anjali Saqi, USA
Takaaki Sasaki, Japan
Miyako Satouchi, Japan
Charles Sauer, Austria
Toshiyuki Sawa, Japan
Marco Scarci, UK
Karin Schelch, Austria
Yoshitaka Sekido, Japan
Lecia Sequist, USA
Abhishek Shankar, India
Misty Shields, USA
Shani Shilo, Israel
Hyo Sup Shim, Republic of Korea
Lynette Sholl, USA
Elaine Shum, USA
Alan Shihoe, China
Gerard Silvestri, USA
Navneet Singh, India
Christina Sit, Canada
Shankar Siva, Australia
CONFERENCE OVERVIEW
IASLC and WCLC Committees

Walk, Run, Rest, Repeat!
Eat, Sleep, Stretch, Repeat!
Step, Scan, Play, Compete!
Join #WCLC23Well and move your feet!

IASLC WELLNESS CHALLENGE 2023 • Singapore

Register for the IASLC 2023 Wellness Challenge and support lung cancer research.

Sponsored by REGENERON®
2024 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 21-24, 2024 • SANTA MONICA, CALIFORNIA

SAVE THE DATE
#TTLC24

Visit the IASLC Membership Booth and Join Today!

WCLC SPECIAL OFFER
New Members Join During WCLC for a Special Rate!

Scan the QR code & enter WCLCNewMember2023
Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr. Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.

Suresh Ramalingam is the Executive Director of the Winship Cancer Institute of Emory University (Atlanta, USA). He serves as Professor and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine. Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for metastatic NSCLC. He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 400 peer reviewed publications, with over 36,000 citations and a H-index of 80. His research has been published in leading journals including the NEJM, Lancet, Science, Nature, PNAS, JCI, JCO and JTO. He serves as the principal investigator for the Emory University Lung Cancer SPORE award from the NCI. Dr. Ramalingam serves as Deputy Chair for Therapeutics Programs at ECOG-ACRIN, and is a former chair of the ECOG-ACRIN Thoracic Malignancies Committee. He is the Editor-in-chief for ‘Cancer’ journal (American Cancer Society). Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI ‘Clinical Investigators Team Leadership Award’ (2010-12). Dr. Ramalingam served as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) (2017-21) and as a member of the NCI Thoracic Malignancies Steering Committee (2012-2021). He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.
The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session 1 on Saturday, September 9 (18:15 – 20:00).

### Myung-Ju Ahn

**Republic of Korea**

Myung-Ju Ahn is Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She is a member of numerous research associations and societies, including the IASLC, AACR, and ASCO and is currently Chief of the Executive Committee and Chairperson of Lung Cancer Disease Committee of the KCSG. She is the current president of the KSMO and was chairperson of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the KCA, KSMO and KALC, and is on the editorial board of Journal of Thoracic Oncology. Prof Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, and has authored over 250 cancer research publications. Her research interests include the development of predictive and prognostic markers for personalised lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and reposition of targeted drugs and the development of a NSCLC genome atlas. Her accolades for her dedication to cancer research include Best Researcher Award, KMWA (2003); Best Researcher Award, KACO (2015); Boryoung Scientific Award, Korean Cancer Research Foundation (2018), and Highly Cited Researcher, Clarivate analytics (2019); Daniel C. Ihde Lectureship Award for Medical Oncology (IASLC, 2020).

### William Evans

**Canada**

William Evans’ interest in thoracic oncology developed in his early career (1975–1985) working at the Toronto General Hospital with an impressive group of thoracic surgeons. Dr. Evans participated with them in the adjuvant clinical trials of North American Lung Cancer Study Group, in NIH funded studies of nutritional support in lung cancer and numerous trials of systemic therapy for NSCLC and SCLC. He initiated the first trials of etoposide-cisplatin in SCLC and made the first presentation on this regimen at WCLC. In 1985, he became the Head of Medical Oncology and in 1988, the CEO of the Ottawa Regional Cancer Centre. His administrative role enabled collaboration with Statistics Canada on modelling of lung cancer and determination of costs of care; leading to the concept of diagnostic assessment units for lung and other cancers. Eventually, Dr. Evans implemented lung DAUs for more efficient diagnostic work up across the province of Ontario. In 2010, he promoted the need for smoking cessation in regional cancer centers to improve the clinical outcomes of cancer patients, and he led the Cancer Care Ontario Steering Committee to create and implement a framework for smoking cessation (SC) within the 14 regional cancer centres in Ontario. This led to pan-Canadian efforts through the Canadian Partnership Against Cancer (CPAC) to implement SC in provincial cancer centres. Dr. Evans participated in the launch of the CPAC initiative and spoke at numerous cancer centers across Canada. Over 90% of cancer centres now have SC programs. Additionally, he collaborated with Statistics Canada and CPAC to model lung cancer, including LDCT screening with and without SC, influencing design of the Ontario Screening Pilot. Currently, Dr. Evans is the Clinical Lead for Smoking Cessation at Ontario Health (CCO) and continues to drive change: extension of SC to screening programs, DAUs, inpatient oncology and to enhance data capture on smoking status over patients’ clinical journey. Dr. Evans has over 300 peer-reviewed publications, 20 specifically focused on screening and aspects of SC since 2014.
The IASLC Lectureship Awards will be presented during the IASLC Lectureship Award Presentations Plenary Session on Sunday, September 10 (08:30 – 10:30).

- **Clifton F. Mountain Lectureship Award** for Staging
  - **Navneet Singh**, India

- **Daniel C. Ihde Lectureship Award** for Medical Oncology
  - **D. Ross Camidge**, USA

- **Heine H. Hansen Lectureship Award** for Small Cell Lung Cancer
  - **Jie Wang**, China

- **IASLC Lectureship Award for Tobacco Control and Smoking Cessation**
  - **Silvia Noello**, Italy

- **Fred R. Hirsch Lectureship Award** for Translational Research
  - **Wendy Cooper**, Australia

- **Robert J. Ginsberg Lectureship Award** for Surgery
  - **Jessica Donington**, USA

- **Tsuguo Naruke Lectureship Award** for Surgery
  - **Alan Siho, Hong Kong

- **IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)**
  - **Melissa Culligan**, UK

- **James D. Cox Lectureship Award** for Radiation Oncology
  - **Rafal Dziadziszko, Poland

WCLC 2023 Education Awards

All WCLC 2023 Education Award Winners will be presented with their award during the IASLC Award Ceremony on Saturday, September 9 (17:00 - 18:00).

- **Nour Al-bzour, Jordan**
  - MA20.10: A 9-Gene Inflammation Signature Predicts Survival and Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

- **Jia-yi Deng, China**
  - P2.05-16: Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy

- **Muhammed Elfaiituri, Libya**
  - P1.01-09: Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis

- **Chinmay Satish Haridas, India**
  - MA18.06: Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503

- **Yang-Si Li, China**
  - P1.09-02: Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR Mutant NSCLC

- **Yin Li, China**
  - P1.09-04: Characterization of the Immunosuppressive Function of UPPIhigh Tumor Cells In Lung Adenocarcinoma and Its Association with Immunotherapy

- **Si-cong Ma, China**
  - OA19.06: CRTAM Acts as a Checkpoint of Immune-related Adverse Events Uncoupling Efficacy and Toxicity During Immunotherapy

- **Zhenbin Qiu, China**
  - P1.03-01: Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio

- **Duo Xu, China**
  - MA17.08: Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma

- **Chao Zhang, China**
  - P1.27-03: Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis
WCLC 2023 Education Awards

EARLY CAREER RESEARCHERS

JACQUELINE AREDO, USA
MA02.06: Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening

XIAOSHUANG FENG, FRANCE
MA19.05: Performance of Risk Prediction Models to Select Individuals for Lung Cancer Screening in the European Population

Pатрик Гудли, UK
OA07.03: Performance of PLCoM2012-based Screening Eligibility in the Manchester Lung Health Check Pilot Cohort after 6 Years

ADAM GRIPPIN, USA
MA15.04: Timing of Pre-biopsy COVID-19 mRNA Vaccination and PD-L1 Expression in Advanced Non-small Cell Lung Cancer

ILIAS HOUDA, NETHERLANDS
OA06.03: An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer

MATTHEW LEE, USA
P2.09.04: Treatment Adherence Disparities and Clinical Outcomes of Osimertinib Among Ethnic-Minority Patients with EGFR-mutated NSCLC

ANLIN LI, CHINA
OA09.03: STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials

SESHIRU NAKAZAWA, USA
OA19.05: Activating MET Tyrosine Kinase Domain Mutations as De Novo Oncogenic Drivers in Non-small Cell Lung Cancer

PRIYANKA SENTHIL, USA

NEIL WALLACE, AUSTRALIA
MA03.03: Does Smoking Status Affect Survival After Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer?
The International Mentorship Program participants will be acknowledged during the IASLC Award Ceremony on Saturday, September 9 (17:00 - 18:00).

RUI FU, CHINA  
P2.03-05: Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer

EDWIN NUGROHO NJOTO, INDONESIA  
P1.22-12: Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia

JAYSON PARAGAS, PHIILIPPINES  
P2.02-05: Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen

RAGHDA TALEB, EGYPT  
EP06.06-05: Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion

YANG WO, CHINA  
EP07.05-01: Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma

MEIMEI ZHENG, CHINA  
P1.23-09: Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
01 CONFERECE OVERVIEW
Program at a Glance

Sunday, September 10, 2023

07:30 - 08:00
Coference Meet the Expert (MTE) Sessions

08:00 - 09:00
Plenary Session 2: IASLC Lectureship Award Presentations

09:00 - 10:30
Concurrent Oral Abstract Sessions 11:30 - 13:30

10:30 - 11:00
Coffee Break

11:00 - 11:30
Lunch & Refreshments Provided

12:00 - 13:30
Concurrent Oral Abstract Sessions 11:30 - 13:30

13:30 - 14:00
Lunch Break

14:00 - 14:30
Gender Equity in Thoracic Oncology

14:30 - 15:45
Concurrent Industry Symposia 14:30 - 14:45

15:45 - 16:15
Poster Viewing Networking Reception (Poster Session 1)

16:15 - 17:30
JTO and JTO CCR Editorial Reception (By Invitation Only)

17:30 - 19:30
Concurrent Industry Symposia 17:30 - 19:30

19:30 - 20:30
Faculty Dinner (By Invitation Only)

20:30 - 23:00

01 CONFERECE OVERVIEW
Program at a Glance

Monday, September 11, 2023

07:30 - 08:00
Coference Meet the Expert (MTE) Sessions

08:00 - 09:00
Plenary Session 3: Presidential Symposium

09:00 - 10:30
Concurrent Oral Abstract Sessions 10:45 - 11:45

10:30 - 11:00
Coffee Break

11:00 - 11:30
Meet the IASLC Committee

11:30 - 12:00
IASLC Board Office Hours

12:00 - 13:30
Concurrent Oral Abstract Sessions 10:45 - 11:45

13:30 - 14:00
Lunch Break

14:00 - 14:45
Creating Workplace Well-being for Yourself and Others

14:45 - 15:45
Concurrent Industry Symposia 14:45 - 15:45

15:45 - 16:45
Special Plenary Session 4: TNM for Lung, Mesothelioma and Thymic Cancers - Update on the Proposals for the 9th Edition of TNM Staging

16:45 - 18:00
Poster Viewing Networking Reception (Poster Session 2)

18:00 - 21:00
Concurrent Industry Symposia 16:45 - 18:00

21:00 - 23:00

IASLC Benefit Supporting Early Career Researchers

20:30 - 22:00

In-Person Only  Live-Streamed  Ticketed Event  ACCME Accredited by IASLC

Refreshments Provided  Lunch Provided  Breakfast & Refreshments Provided  Lunch & Refreshments Provided

In-Person Only  Live-Streamed  Ticketed Event  ACCME Accredited by IASLC

Refreshments Provided  Lunch Provided  Breakfast & Refreshments Provided  Lunch & Refreshments Provided
**CONFERENCE OVERVIEW**

Program at a Glance

**Tuesday, September 12, 2023**

- 07:30: Concurrent Meet the Expert (MTE) Sessions
- 08:00: Plenary Session: Transforming Discovery into Treatments in Lower Middle Income Regions
- 08:30: Coffee Break
- 09:00: Concurrent Oral Abstract Sessions 10:45 - 11:45
- 09:30: IASLC Business Meeting 10:00 - 10:45
- 10:00: Press Conference 10:05 - 11:00
- 10:30: Concurrent Oral Abstract Sessions 12:00 - 13:00
- 12:30: Lunch Break 13:15 - 14:45
- 13:00: Satellite CME Symposium 13:15 - 14:15
- 14:30: Concurrent Oral Abstract Sessions 14:30 - 15:30
- 15:00: Concurrent Mini Oral Abstract Sessions 14:30 - 15:30
- 16:00: Concurrent Education Sessions 14:30 - 15:30
- 17:00: Closing Plenary 6: Advances in Lung Cancer Pathology 15:45 - 16:45

**Saturday, September 9, 2023**

- 10:45 - 11:45: Industry Sponsored Symposium by AbbVie: The Expanding Role of Precision Medicine with Antibody Drug Conjugates in NSCLC
- 14:30 - 15:30: Industry Sponsored Symposium by Boehringer Ingelheim: Past, Present, and Future of Personalized Care in Lung Cancer: HER2 and DLL3 Targeted Therapies in Focus
- 15:45 - 16:45: Industry Sponsored Symposium by Pfizer: Maximising the Potential in ALK+ NSCLC: Enhancing Outcomes and Improving Patient Care

**Sunday, September 10, 2023**

- 13:45 - 14:45: Industry Sponsored Symposium by AstaZenea: Navigating Opportunities in Resectable NSCLC

**Monday, September 11, 2023**

- 13:15 - 14:15: Industry Sponsored Symposium by Daiichi Sankyo: ADCs in Lung Cancer: Where We Are and Where We Are Going
- 19:00 - 20:00: Industry Sponsored Symposium by Daiichi-Sankyo and AstraZeneca: Taking Aim at HER2-Driven NSCLC

Download the free official WCLC 2023 virtual platform available for desktop and mobile devices for a convenient way to stay up-to-date on the latest Conference information. View the full scientific schedule, abstracts, exhibit information, and general Conference and venue information on our easy-to-use platform!
CONFERENCE OVERVIEW
Program at a Glance – Satellite CME Symposia

Saturday, September 9, 2023
12:00 - 13:00
Satellite CME Symposium by PeerView Institute for Medical Education, Supported by Gilead – A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

15:45 - 16:45
Satellite CME Symposium by Medscape Oncology Global, Supported by Lilly: Unlocking the Power of Genomic Testing in NSCLC: Implementing Personalized Therapy to Impact Outcomes

Sunday, September 10, 2023
13:45 - 14:45

18:30 - 19:30
Satellite CME Symposium by AGILE, Supported by Merck KGaA: MET Inhibition in Metastatic NSCLC "In the Spotlight"

Monday, September 11, 2023
19:00 - 20:00
Satellite CME Symposium by Med Learning Group, Supported by Regeneron Pharmaceuticals: Applying Multidisciplinary Expertise and Heterogeneous Skills in Clinical Practice: Transforming Non-Small Cell Lung Cancer Treatment with Immunotherapy

Tuesday, September 12, 2023
13:15 - 14:15
Satellite CME Symposium by PVI, PeerView Institute for Medical Education, Supported by Daiichi Sankyo, Inc.: Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens

ACCME Accredited by Other Provider
02 WCLC 2023 FULL PROGRAM

Saturday, September 9, 2023

08:00 – 09:00  Social Media & Communications Workshop

ROOM: 327, LEVEL 3

08:00 Welcome
08:02 Promoting Health Equity in Science Communication
     Narjust Florez (Duma), USA
08:10 How to Give a Great Presentation: Demystifying the Data, Figures and Message
     Jarushka Naidoo, Ireland
08:18 Simplifying Stats & Methods in Science Communication
     Matthew Smeltzer, USA
08:26 Scholarly Communication: Tips & Tracks for Manuscript Reviewing, Reviewer Responses & the Editorial Process
     Martin Edelman, USA
08:34 Scientific Communication with the Press: Do's & Don'ts
     Brendon Stiles, USA
08:42 Science Through Social Media: Communications 2.0
     Stephen V. Liu, USA
08:50 Panel Discussion

09:02 Networking Break

Not for CME Credit

Recommended for Early Career Researchers

08:00 - 11:30  WS01: Early Career & First Time Attendee Workshop

ROOM: NICOLL 2, LEVEL 3  

Chairs: Chee Lee, Australia & Fiona Hegi-Johnson, Australia

08:00 Welcome & Introduction
     Chee Lee, Australia & Fiona Hegi-Johnson, Australia
08:02 WS01.03: Making the Most of WCLC: A Guide for First Time Attendees
     Narjust Naidoo, Ireland
08:17 WS01.04: Early Career Researcher Experience - Opportunities and Challenges
     Aaron Tan, Singapore
08:32 WS01.05: Engaging with the Pharmaceutical Industry
     James Chih-Hsin Yang, Taiwan
08:47 WS01.06: How to Set up an Investigator Initiated Trial
     Myung-Ju Ahn, Republic of Korea
09:02 WS01.07: Seeking and Preparing a Successful Grant Application
     Narjust Florez (Duma), USA
09:17 Networking Break

09:45 WS01.08: Tips of Getting Your Paper Published
     Young Tae Kim, Republic of Korea
10:00 WS01.09: How to Deliver an Engaging Presentation
     Tony Mok, China
10:15 WS01.10: Role of IASLC in Developing Countries
     Clarissa Mathias, Brazil
10:30 WS01.11: Benefits of Joining IASLC as an Early Career Physician/Researcher
     Karen Kelly, USA
10:45 Q&A

11:00 Networking with Faculty and Other Early Career Researchers

08:00 – 12:00  WS02: Joint IASLC-CSCO-CAALC Session - Innovation Drives Lung Cancer Management

ROOM: SUMMIT 1, LEVEL 3  

Chairs: Yi-Long Wu, China & Chun-Xue Bai, China & Caicun Zhou, China & Karen Kelly, USA

08:00 WS02.05: Welcome
     Karen Kelly, USA
08:10 WS02.06: Artificial Intelligence in Early Detection for Lung Cancer - Chinese Perspective
     Chun-Xue Bai, China
08:30 WS02.07: Beyond Checkmate 816: What Is the Future in Perioperative Immuno-Oncology (IO) Treatment - European Perspective
     Solange Peters, Switzerland
08:50 WS02.08: New IO Drug (Beyond PD-1/L1) Development in China - Chinese Perspective
     Fei Zhou, China
09:10 WS02.09: How to Successfully Conduct Clinical Trials for Patients with Uncommon Driver Mutation Positive Tumors - North American Perspective
     Thomas Stinchcombe, USA
09:30 Networking and Poster Viewing

10:30 WS02.11: HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window
     Yunan Tian, China
10:40 WS02.12: Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)
     Hua Lin Chen, China
10:50 WS02.13: PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
     Si-Yang Liu, China
11:00 WS02.14: Oral Abstracts Discussant (WS02.11 – WS02.15)
     Daniel Tan, Singapore
11:15 WS02.21: Poster Discussant (WS02.15 – WS02.20)
     Jie Hu, China

Discussing the following Posters:
WS02.15: Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer
     Chen-Guang Liu, China

Breakfast and Refreshments Provided

Not for CME Credit

Recommended for Early Career Researchers
WS02.16: Proteomics-based Predictive Model for the Increased Brain Metastasis Risk in Resected Lung Adenocarcinoma with EGFR Mutation
Haihong Yang, China

WS02.17: A Novel Blood-Based DNAMethylation Panel for Detection of Lung Cancer at Very Early Stage
Rongxi Yang, China

WS02.18: Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
Mei-Mei Zheng, China

WS02.19: Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study
Xue Lin, China

WS02.20: Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC
Hui Kang Xie, China

11:30  WS02.22: Concluding Remarks

08:00 - 11:00  WS03: Radiation Oncology Workshop
ROOM: SUMMIT 2, LEVEL 3
Chairs: Kristin Higgins, USA & Fiona McDonald, UK

08:00  Welcome & Introduction
Kristin Higgins, USA & Fiona McDonald, UK

08:02  WS03.03: SBRT Lung with a Focus on OARs (Brachial Plexus, Central Structures, Bronchial Tree, Chest Wall)
Anil Tibdewal, India

08:42  WS03.04: Locally Advanced Stage IIIc or IIIB NSCLC with a Focus on Defining GTV
Nonette Cupino, Philippines

09:22  WS03.05: SBRT for Oligoprogression in the Lung on Systemic Therapy
Connie Yip, Singapore

10:02  WS03.06: Stage II-III Unresectable NSCLC with Associated Lung Collapse
Ivy Ng, Singapore

10:42  Q&A

09:00 - 15:40  WS04: 2023 IASLC CT Screening Symposium
ROOM: NICOLL 3, LEVEL 3
Chairs: Kristin Higgins, USA & Fiona McDonald, UK

TOPIC 1: WHO SHOULD BE SCREENED
9:10  WS04.01: Welcome
Pyng Lee, Singapore

9:15  WS04.02: Lung Cancer Screening - Asian Perspective
Haiquan Chen, China

9:25  WS04.03: Pro: Never and Light Smokers Should Be Screened
Stephen Lam, Canada

9:30  WS04.04: Con: Never and Light Smokers Should Not Be Screened
Hilary Robbins, France

9:35  WS04.05: Pro: Never and Light Smokers Should Be Screened
Pan Chyr Yang, Taiwan

9:40  WS04.06: Con: Never and Light Smokers Should Not Be Screened
Jin Mo Goo, Republic of Korea

9:45  Pro/Con Debate + Q&A

10:00  WS04.08: Conclusion
Raymond Osarogiagbon, USA

10:05  Lunch Break

TOPIC 2: LUNG CANCER RISK ASSESSMENT
10:40  WS04.10: Welcome
Stephen Lam, Canada

10:45  WS04.11: Environmental Factors
Renelle Myers, Canada

10:55  WS04.12: Tumor Biology Based Biomarkers
Rayjean Hung, Canada

11:05  WS04.13: Next Generation Lung Cancer Risk Prediction Model
Chao A Hsiung, Taiwan

11:15  WS04.14: Modifying Lung Cancer Risk (e.g. Smoking Cessation, Radon Exposure)
Rachael Murray, UK

11:25  Panel Discussion + Q&A

11:50  WS04.16: Conclusion
Rafaal Meza, USA

11:55  Lunch Break

TOPIC 3: DIAGNOSTIC STRATEGY
12:55  WS04.18: Welcome
Marjolein Heuvelmans, Netherlands

13:00  WS04.19: Bronchoscopic Diagnosis
Carla Lamb, USA

13:10  WS04.20: CT Guided Lung Biopsy
Peter Goh, Singapore

13:20  WS04.21: Management of Multiple Lung Nodules
Thirugnanam Agasthian, Singapore

13:30  WS04.22: 4-In-The-Lung-Run Trial
Matthijs Oudkerk, Netherlands

13:40  WS04.23: Watch the Spot Trial
Michael Gould, USA

13:50  Panel Discussion + Q&A

14:05  WS04.25: Conclusion
Annette McWilliams, Australia

14:10  Break

TOPIC 4: APPLICATION OF AI IN LUNG SCREENING
14:20  WS04.27: Welcome
Chi-Fu Yang, USA
**SCIENTIFIC PROGRAM - SATURDAY, SEPTEMBER 9, 2023**

**14:25** WS04.28: Predicting Lung Cancer Risk from a Single Chest CT  
Lecia Sequist, USA

**14:35** WS04.29: Optimizing Workflow Using AI  
Marjolein Heuvelmans, Netherlands

**14:45** WS04.30: Clinical Impact of Identifying Additional (Incidental) Findings on Screening LDCT  
David Yankelevitz, USA

**14:55** WS04.31: Towards Developing Universal Quality Indicators To Measure Performance of Screening Program  
Ella Kazerooni, USA

**15:05** Panel Discussion + Q&A

**15:25** WS04.33: Session Conclusion  
Ella Kazerooni, USA

**15:30** WS04.34: Workshop Summary/Conclusion  
John Field, UK

---

**10:45 – 11:45** Industry Sponsored Symposium

For further information, please see page 222.

---

**12:00 – 13:00** Satellite CME Symposium

For further information, please see page 226.

---

**12:00 – 16:30** WS05: Preceptorship Workshop

**Room:** Summit 2, Level 3  
**Chair:** Nick Pavlakis, Australia

- **12:00** WS05.01: Welcome & Introduction  
  Nick Pavlakis, Australia

- **12:15** WS05.02: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening - NLST  
  Jamie Feng, Canada

- **12:25** WS05.03: Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial - NELSON Trial  
  Monica Chen, USA

- **13:00** WS05.04: Mentor: Lung Cancer Screening  
  Emily Stone, Australia

- **13:00** WS05.05: Stereotactic Ablative Radiotherapy versus Standard Radiotherapy in Stage 1 Non-small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial  
  Diane Lim, Australia

- **13:10** WS05.06: Postoperative Radiotherapy versus No Postoperative Radiotherapy in Patients with Completely Resected Non-small-Cell Lung Cancer and Proven Mediastinal N2 Involvement (Lung ART): An Open-Label, Randomised, Phase 3 Trial  
  Philippa Johnstone, Australia

- **13:20** WS05.07: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer - PACIFIC Trial  
  Joe Wei, Australia

---

**13:30** WS05.08: Mentor: Early-Stage NSCLC - Radiotherapy  
Dasantha Jayamanne, Australia

**13:30** WS05.09: Mentor: Early-Stage NSCLC - Radiotherapy  
Aaron Tan, Singapore

**13:55** WS05.10: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma- IPASS Trial  
Rajat Rai, Australia

**14:05** WS05.11: Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer - FLAURA Trial  
Deborah Zhou, Australia

**14:15** WS05.12: Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer - ADAURA Trial  
Arianna Marinello, France

**14:25** WS05.13: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC  
Tom John, Australia

**14:25** WS05.14: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC  
Kirsty Lee, Hong Kong

**14:50** Break

Shalini Subramaniam, Australia

**15:30** WS05.17: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer - Checkmate 816 Trial  
Lauren Brown, Australia

**15:40** WS05.18: Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial  
Nicholas McNamee, Australia

**15:50** WS05.19: Mentor: Immunotherapy - Advanced to Early NSCLC  
Melissa Moore, Australia

**15:50** WS05.20: Mentor: Immunotherapy - Advanced to Early NSCLC  
Malinda Itchins, Australia

**16:15** WS05.21: Closing Remarks  
Nick Pavlakis, Australia

---

**12:00 - 15:00** WS06: IASLC/iMig Workshop

**Room:** Nicoll 2, Level 3  
**Chairs:** Paul Baas, Netherlands

- **12:00** Welcome & Introduction  
  Paul Baas, Netherlands & Kenneth O’Byrne, Australia

- **12:05** WS06.02: History of MPM Subgroups: Is It Useful?  
  Sanja Dacic, USA

- **12:30** WS06.03: Can Blood and Fluid Biomarkers Make a Difference in Diagnosis or Therapy  
  Jenette Creaney, Australia

- **12:55** WS06.04: Genomics of Cancer: Deep Sequencing and Treatment Options in MPM  
  Thomas Marron, USA

**13:30** WS05.08: Mentor: Early-Stage NSCLC - Radiotherapy  
Dasantha Jayamanne, Australia

**13:30** WS05.09: Mentor: Early-Stage NSCLC - Radiotherapy  
Aaron Tan, Singapore

**13:55** WS05.10: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma- IPASS Trial  
Rajat Rai, Australia

**14:05** WS05.11: Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer - FLAURA Trial  
Deborah Zhou, Australia

**14:15** WS05.12: Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer - ADAURA Trial  
Arianna Marinello, France

**14:25** WS05.13: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC  
Tom John, Australia

**14:25** WS05.14: Mentor: Sensitizing EGFR Mutations - Advanced to Early NSCLC  
Kirsty Lee, Hong Kong

**14:50** Break

Shalini Subramaniam, Australia

**15:30** WS05.17: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer - Checkmate 816 Trial  
Lauren Brown, Australia

**15:40** WS05.18: Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial  
Nicholas McNamee, Australia

**15:50** WS05.19: Mentor: Immunotherapy - Advanced to Early NSCLC  
Melissa Moore, Australia

**15:50** WS05.20: Mentor: Immunotherapy - Advanced to Early NSCLC  
Malinda Itchins, Australia

**16:15** WS05.21: Closing Remarks  
Nick Pavlakis, Australia

---

**12:00 - 16:30** WS05: Preceptorship Workshop

**Room:** Summit 2, Level 3  
**Chair:** Nick Pavlakis, Australia

- **12:00** WS05.01: Welcome & Introduction  
  Nick Pavlakis, Australia

- **12:15** WS05.02: Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening - NLST  
  Jamie Feng, Canada

- **12:25** WS05.03: Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial - NELSON Trial  
  Monica Chen, USA

- **13:00** WS05.04: Mentor: Lung Cancer Screening  
  Emily Stone, Australia

- **13:00** WS05.05: Stereotactic Ablative Radiotherapy versus Standard Radiotherapy in Stage 1 Non-small-Cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial  
  Diane Lim, Australia

- **13:10** WS05.06: Postoperative Radiotherapy versus No Postoperative Radiotherapy in Patients with Completely Resected Non-small-Cell Lung Cancer and Proven Mediastinal N2 Involvement (Lung ART): An Open-Label, Randomised, Phase 3 Trial  
  Philippa Johnstone, Australia

- **13:20** WS05.07: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer - PACIFIC Trial  
  Joe Wei, Australia
16:00  WS07.19: Managing Cancer & Living Meaningfully (CALM) - An Australian Nurse Perspective
Mary Duffy, Australia

16:10  WS07.20: Perceptions and Measurements of Dyspnea and Quality of Life Experienced by Malignant Pleural Mesothelioma Patients before and after Lung-Sparing Surgery: A Pilot Mixed Methods Study
Melissa Culligan, USA

16:20  WS07.21: How Do We Integrate Cancer Services?
Anne Fraser, New Zealand

16:30  WS07.22: Breaking Barriers to Facilitate Participation in Pulmonary Rehabilitation in Patients Following Lung Resection for Non-small Cell Lung Cancer: Is It Physical Activity Coaching?
Sarah Haesevoets, Belgium

16:40  WS07.23: Successfully Navigating the WCLC Program, Summary & Close
Morten Quist, Denmark

13:00 - 14:00  PC01: Press Conference
ROOM: 327, LEVEL 3

13:15 – 14:15  Industry Sponsored Symposium
FOR FURTHER INFORMATION, PLEASE SEE PAGE 222.

14:30 – 15:30  Concurrent Industry Sponsored Symposia
FOR FURTHER INFORMATION, PLEASE SEE PAGE 223.

15:30 - 17:00  WS08: LATAM Workshop
ROOM: NICOLL 2, LEVEL 3

15:30 Welcome & Introduction
Ticiana Leal, USA & Clarissa Mathias, Brazil

15:32  WS08.03: How We Can Do Immunotherapy and Targeted Therapy Research in Latin America
Oscar Arrieta, Mexico

15:42  WS08.04: Establishing Lung Cancer Screening and Incidental Pulmonary Nodule Programs in the Region
Lucia Viola, Colombia

15:52  WS08.05: Looking for Equity in Access to Genomic Testing and Targeted Therapy Among Hispanics Living in the US and Latin America
Luis Rhee, USA

16:02  WS08.06: The LungTrust Methodology
Andrés Cardona, Colombia

16:12  WS08.07: Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries
Oscar Arrieta, Mexico
16:22  WS08.08: Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes
Norma Hernandez Pedro, Mexico

16:32  WS08.09: Discussant (WS08.06 - WS08.08)
Andres Cardona, Colombia

16:42  Q&A

15:45 – 16:45  Concurrent Industry Sponsored and CME Satellite Symposia

FOR FURTHER INFORMATION, PLEASE SEE PAGES 224 & 226.

17:00 - 18:00  IASLC Award Ceremony
ROOM: 405B, LEVEL 4

Join us for the IASLC Award Ceremony as we celebrate our early career researchers and award winners.

18:15 - 20:00  PL01: Opening Plenary Session 1 (with IASLC Distinguished Service Award Presentations): Equity and Access to Appropriate Clinical Care in Lung Cancer – Pathway Towards Effective Global Implementation
ROOM: 406, LEVEL 4
Chairs: Jill Feldman, USA & Fiona Hegi-Johnson, Australia

18:15  Welcome Remarks
18:35  IASLC Distinguished Service Award Presentations
18:55  PL01.09: Lung Cancer Treatment Divide - Breathtaking Inequity
Her Royal Highness Princess Dina Mired, Jordan
19:20  PL01.10: The Humanitarian Crisis in Cancer: Challenges and Solutions
Gary Rodin, Canada
19:45  Q&A

20:00 – 21:30  Welcome Reception
ROOM: EXHIBIT HALL, LEVEL 4
WCLC 2023 FULL PROGRAM

Sunday, September 10, 2023

**07:30 - 08:15** MTE01: Lung Cancer Risk Reduction in Asia - People Who Smoke versus Those Who Haven’t

**Track:** Risk Factors, Risk Reduction & Tobacco Control

**ROOM:** 405B, LEVEL 4

07:30 MTE01.01: Lung Cancer in Asians Who Do Not Have a Smoking History: Epidemiology & Biology

Hsiu-Hsi Chen, Taiwan

07:45 MTE01.02: Women, Smoking and Lung Cancer

Emma O’Dowd, UK

08:00 Q&A

**07:30 - 08:15** MTE02: Oncogene Driven Lung Cancer - From Target Identification to Clinic to Community - Open Panel Discussion

**Track:** Tumor Biology – Preclinical Biology

**ROOM:** SUMMIT 1, LEVEL 3

07:30 MTE02.01: From Target Identification to Clinic

Zofia Piotrowska, USA

07:45 MTE02.02: Real World Impact of Targeted Therapy

Lillian Leigh, Australia

08:00 Q&A

**07:30 - 08:15** MTE03: Screening for Lung Cancer in Individuals with No Smoking History

**Track:** Screening and Early Detection

**ROOM:** SUMMIT 2, LEVEL 3

07:30 MTE03.01: How to Implement CT Screening Program for Person Who Does Not Smoke/ With No History of Smoking

Pan-Chyr Yang, Taiwan

07:45 MTE03.02: IASLC Early Detection and Screening Committee View

Elia Kazerouni, USA

08:00 Q&A

**07:30 - 08:15** MTE04: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas

**Track:** Pathology and Biomarkers

**ROOM:** 405C, LEVEL 4

Chair: Daniel Tan, Singapore

07:30 Welcome & Introduction

Daniel Tan, Singapore

07:32 MTE04.02: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas

Wendy Cooper, Australia

07:47 MTE04.03: Molecular Biomarker Testing for Targeted Therapy in Lung Cancer - All You Need to Know in One Atlas

Ming-Sound Tsao, Canada

08:02 Q&A

**07:30 - 08:15** MTE05: Challenges in the Management of Recurrent Brain Metastases Previously Treated with Radiation Therapy in Non-small Cell Lung Cancer

**Track:** Metastatic Non-small Cell Lung Cancer – Local Therapies

**ROOM:** NICOLL 2, LEVEL 3

07:30 MTE05.01: Treatment Approaches for Recurrent Brain Metastases Previously Treated with Radiation Therapy in Non-small Cell Lung Cancer

Nicolaus Andratschke, Switzerland

07:45 MTE05.02: Challenges in the Diagnosis and Management of Radiation Necrosis in the Brain

Wee-Yao Koh, Singapore

08:00 Q&A

**07:30 - 08:15** MTE06: Equity in Lung Cancer Care - Indigenous Health, Digital Health, Access to Treatments/Diagnostics

**Track:** Multidisciplinary Care: Nursing, Allied Health & Palliative Care

**ROOM:** NICOLL 3, LEVEL 3

07:30 MTE06.01: Equity in Indigenous Health

Gail Garvey, Australia

07:45 MTE06.02: Equity in Lung Cancer Care – Access to Approved Therapies and Clinical Trials

Abhijit Pal, Australia

08:00 Q&A
**07:30 - 08:15  MTE07: Biology of Individuals without a Smoking History**

Track: Tumor Biology – Translational Biology  
Room: NICOLL 1, LEVEL 3  
07:30  MTE07.01: Biology of Individuals without a Smoking History  
Charles Swanton, UK  
07:50  Q&A

**08:30 - 10:30  PL02: Plenary Session 2: IASLC Lectureship Award Presentations**

Room: 406, LEVEL 4  
Chairs: Karen Kelly, USA & Heather Wakelee, USA  
08:30  Welcome & Introduction  
Karen Kelly, USA & Heather Wakelee, USA  
08:32  PL02.03: IASLC Lectureship Award for Tobacco Control and Smoking Cessation  
Silvia Novello, Italy  
08:45  PL02.04: Tsuguo Naruke Lectureship Award for Surgery  
Alan Siho, China  
08:58  PL02.05: Daniel C. Ihde Lectureship Award for Medical Oncology  
D. Ross Camidge, USA  
09:11  PL02.06: Robert J. Ginsberg Lectureship Award for Surgery  
Jessica Donington, USA  
09:24  PL02.07: James D. Cox Lectureship Award for Radiation Oncology  
Rafał Dziadziuszko, Poland  
09:37  PL02.08: Heine H. Hansen Lectureship Award for Small Cell Lung Cancer  
Jie Wang, China  
09:50  PL02.09: Fred R. Hirsch Lectureship Award for Translational Research  
Wendy Cooper, Australia  
10:03  PL02.10: IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)  
Melissa Culligan, USA  
10:16  PL02.11: Clifton F. Mountain Lectureship Award for Staging  
Navneet Singh, India  
10:40 - 11:10  IASLC01: IASLC Board Office Hours  
Room: EXHIBIT HALL, COLLABORATIVE MEETING LOUNGE  
Join select IASLC Board Members and ask them anything you want to know about the IASLC and its activities, being a member, being a board or committee member or anything else you have always wanted to know!

**11:15 - 12:15  ES01: Smoking Cessation Is a Necessary Intervention**

Track: Risk Factors, Risk Reduction & Tobacco Control  
Room: NICOLL 1, LEVEL 3  
Chairs: Kwun Fong, Australia & Joelle Fathi, USA  
11:15  Welcome & Introduction  
Kwun Fong, Australia & Joelle Fathi, USA  
11:17  ES01.03: How to Incorporate Smoking Cessation to CT Screening Program  
Rachael Murray, UK  
11:32  ES01.04: How to Introduce Smoking Cessation to Clinic: Pharmacological and Non-pharmacological Aids  
Sita Andarini, Indonesia  
11:47  ES01.05: End of the Lung Cancer Epidemic from Tobacco  
Janet Hoek, New Zealand  
12:02  Q&A


Track: Tumor Biology – Preclinical Biology  
Room: NICOLL 3, LEVEL 3  
Chairs: Eliza Fong, Singapore & Trever Bivona, USA  
11:15  Welcome & Introduction  
Eliza Fong, Singapore & Trever Bivona, USA  
11:17  ES02.03: The Evolution of Tumour Cells and Targeted Therapy Resistance  
Caicun Zhou, China  
11:32  ES02.04: Tumour Immune Microenvironment and Immunotherapy Resistance  
Ping Chih Ho, Switzerland  
11:41  ES02.05: Exploiting the TME For Novel Therapeutic Development  
Katey Enfield, UK  
11:53  ES02.06: Mediators of Radiotherapy Resistance in the TME  
Magnus Dillon, UK  
12:05  Q&A

**10:30 - 11:15  Meet Her Royal Highness Princess Dina Mired, Jordan**

IASLC BOOTH IN THE EXHIBIT HALL

**10:30 - 11:15  Coffee Break**

Room: EXHIBIT HALL, LEVEL 4

**10:35 - 11:30  PC02: Press Conference**

Room: 327, LEVEL 3

**10:40 - 11:10  IASLC01: IASLC Board Office Hours**

Room: EXHIBIT HALL, COLLABORATIVE MEETING LOUNGE  
Join select IASLC Board Members and ask them anything you want to know about the IASLC and its activities, being a member, being a board or committee member or anything else you have always wanted to know!

**11:15 - 12:15  ES01: Smoking Cessation Is a Necessary Intervention**

Track: Risk Factors, Risk Reduction & Tobacco Control  
Room: NICOLL 1, LEVEL 3  
Chairs: Kwun Fong, Australia & Joelle Fathi, USA  
11:15  Welcome & Introduction  
Kwun Fong, Australia & Joelle Fathi, USA  
11:17  ES01.03: How to Incorporate Smoking Cessation to CT Screening Program  
Rachael Murray, UK  
11:32  ES01.04: How to Introduce Smoking Cessation to Clinic: Pharmacological and Non-pharmacological Aids  
Sita Andarini, Indonesia  
11:47  ES01.05: End of the Lung Cancer Epidemic from Tobacco  
Janet Hoek, New Zealand  
12:02  Q&A


Track: Tumor Biology – Preclinical Biology  
Room: NICOLL 3, LEVEL 3  
Chairs: Eliza Fong, Singapore & Trever Bivona, USA  
11:15  Welcome & Introduction  
Eliza Fong, Singapore & Trever Bivona, USA  
11:17  ES02.03: The Evolution of Tumour Cells and Targeted Therapy Resistance  
Caicun Zhou, China  
11:32  ES02.04: Tumour Immune Microenvironment and Immunotherapy Resistance  
Ping Chih Ho, Switzerland  
11:41  ES02.05: Exploiting the TME For Novel Therapeutic Development  
Katey Enfield, UK  
11:53  ES02.06: Mediators of Radiotherapy Resistance in the TME  
Magnus Dillon, UK  
12:05  Q&A
11:15 - 12:15  ES03: Personalising LCS: A Global Perspective of Barriers, Opportunities and Challenges for Improving Equity in Screening

Track: Screening and Early Detection  
ROOM: 405A, LEVEL 4  
Chairs: Christine Argento, USA & WenTao Fang, China

11:15  Welcome & Introduction  
Christine Argento, USA & WenTao Fang, China

11:17  ES03.03: Modelling the Benefits of Screening to Better Include Women and the Underserved  
Rafael Meza, USA

11:29  ES03.04: The Need for Expanding LC Screening in Women: Balance Between Harms and Benefits  
Monica Castro, Argentina

11:41  ES03.05: Improving the Uptake of Screening for Lung Cancer Among Women and Minorities: The Search Continues  
Narjust Florez (Duma), USA

11:53  ES03.06: Early Detection in Indigenous/First Population: Breaking Down Barriers  
Sue Crengle, New Zealand

12:05  Q&A

11:15 - 12:15  ES04: Updates on Staging of Lung Cancer

Track: Pulmonology and Staging  
ROOM: SUMMIT 1, LEVEL 3  
Chairs: Chunxue Bai, China & Tetsuya Mitsudomi, Japan

11:15  Welcome & Introduction  
Chunxue Bai, China & Tetsuya Mitsudomi, Japan

11:17  ES04.03: Pitfalls of Clinical Lung Cancer Staging  
Florian Fintelmann, USA

11:29  ES04.04: CT Deep Learning for Survival Prediction  
Jin Mo Goo, Republic of Korea

11:41  ES04.05: Approach to Multistation Lymph Node Staging and Multifocal NSCLC  
Kazuhiro Yasufuku, Canada

11:53  ES04.06: NO/1 Staging for Limited Resection and Resectable N2 NSCLC  
Kenichi Suda, Japan

12:05  Q&A

11:15 - 12:15  ES05: Improving Outcomes for Lung Cancer Patients

Track: Patient Advocacy  
ROOM: NICOLL 2, LEVEL 3  
Chairs: Christina Sit, Canada & Satoko Yamaoka, Japan

11:15  Welcome & Introduction  
Christina Sit, Canada & Satoko Yamaoka, Japan

11:17  ES05.03: Global State of Lung Cancer Research  
Richard Sullivan, UK

11:29  ES05.04: Lung Cancer Screening. Focus on Information for Participants  
Maureen Rigney, USA

11:41  ES05.05: Global Consumer Polling on Lung Cancer Issues. What Does the General Public Think?  
Carolyn Aldige, USA

11:53  ES05.06: Implementing Lung Cancer Screening - The Challenge for Africa  
Lauren Pretorius, South Africa

12:05  Q&A

11:15 - 12:15  MA01: Holistic Patient Care: Advances in Symptom Management and Supportive Care

Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care  
ROOM: 405C, LEVEL 4  
Chairs: Felicia Zhang, Canada & Mary Duffy, Australia

11:15  Welcome & Introduction  
Felicia Zhang, Canada & Mary Duffy, Australia

11:17  MA01.03: Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies  
Nikolaos Tsoukalas, Greece

11:22  MA01.04: Randomized Phase II Study of Zoledronate Dosing Every 4 Versus 8 Weeks in Patients With Bone Metastasis From Lung Cancer (Hanshin Cancer Group 0312)  
Akito Hata, Japan

11:32  MA01.06: Retrospective Analysis of Intrapleural Administration of Hypotonic Cisplatin for Malignant Pleural Effusions with Non-Expandable Lung  
Wataru Mori, Japan

11:37  Q&A

11:45  MA01.08: Effect of Ayurvedic Rasayan Therapy on Outcome of Quality of Life in Advanced-Stage Geriatric Lung Cancer Patients  
Anandrao Patil, India

11:50  MA01.09: A Novel Advanced Nurse Practitioner Virtual Clinic for Patients with Low Probability of Lung Cancer  
Kirstie Woods, UK

ACCME Accredited By IASLC  
Recommended for Early Career Researchers  
Not for CME Credit
11:15 - 12:15  OA01: Advancing Immunotherapy in ES-SCLC
Track: Small Cell Lung Cancer and Neuroendocrine Tumors  
ROOM: 406, LEVEL 4
Chairs: Michael Boyer, Australia & Chunxia Su, China

11:15  Welcome & Introduction
Michael Boyer, Australia & Chunxia Su, China

11:17  OA01.03: Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
Ying Cheng, China

11:27  OA01.04: Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
Stephen Liu, USA

11:37  OA01.05: Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 in Patients with DLL3+ Tumors: Focus on SCLC
Martin Wermke, Germany

11:47  OA01.06: First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study
Ying Cheng, China

11:57  OA01.07: Discussant
Noemí Reguart, Spain

11:57  Q&A

12:15 - 12:20  Q&A

12:30 - 13:30  ES06: Perioperative Therapies in Early Stage NSCLC
Track: Early-Stage Non-small Cell Lung Cancer
ROOM: 405A, LEVEL 4
Chairs: Jazmin Eckhaus, Australia & Jamie Chaft, USA

12:30  Welcome & Introduction
Jazmin Eckhaus, Australia & Jamie Chaft, USA

12:32  ES06.03: Adjuvant Therapies in Resected NSCLC
Dolores Isla, Spain

12:44  ES06.04: Neoadjuvant Therapies in Resectable NSCLC
Tina Cascone, USA

12:56  ES06.05: Targeted Therapies in Resected NSCLC
Haiquan Chen, China

13:08  ES06.06: Predictive Biomarker Testing in Early Stage NSCLC
Atocha Romero, Spain

13:20  Q&A

12:30 - 13:30  ES07: Challenging Therapeutic Targets in Lung Cancer
Track: Tumor Biology – Translational Biology
ROOM: SUMMIT 1, LEVEL 3
Chairs: Junko Tanizaki, Japan & Jii Bum (Joy) Lee, Republic of Korea

12:30  Welcome & Introduction
Junko Tanizaki, Japan & Jii Bum (Joy) Lee, Republic of Korea

12:32  ES07.03: Targeting DNA Repair Pathways in Lung Cancer
Timothy Yap, USA

12:44  ES07.04: Targeting Drug Tolerant Persisters
Trever Bivona, USA

12:56  ES07.05: Treatment of Clonally Heterogeneous Lung Cancers
Antonio Passaro, Italy

13:08  ES07.06: Exploiting Metabolic Dependencies in Lung Cancer for Therapeutic Interventions
Wai Leong Tam, Singapore

13:20  Q&A
12:30 - 13:30  ES08: Advances in the Management of Bone Metastases in De Novo Oligometastatic Non-small Cell Lung Cancer

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies

**ROOM: NICOLL 2, LEVEL 3**

Chairs: Anil Tibdewal, India & Po Yee Yip, Australia

12:30  Welcome & Introduction
Anil Tibdewal, India & Po Yee Yip, Australia

12:32  ES08.03: Role and Timing of Surgery for Bone Metastases
Mark Puhaindran, Singapore

12:44  ES08.04: Role and Timing of Radiation Therapy for Bone Metastases
Jing Zeng, USA

12:56  ES08.05: Role and Timing of Interventional Radiology Treatments for Bone Metastases
Amgad Moussa, USA

13:08  ES08.06: Integration of Systemic Therapies with Bone Metastases Directed Local Therapies
Yasir Elamin, USA

13:20  Q&A

12:30 - 13:30  ES09: The Role of Biomarkers and Pathology for Optimal Neoadjuvant/Adjuvant Therapy in Early Stage Lung Cancer

Track: Pathology and Biomarkers

**ROOM: SUMMIT 2, LEVEL 3**

Chairs: Sanja Dacic, USA & Sylvie Lantuejoul, France

12:30  Welcome & Introduction
Sanja Dacic, USA & Sylvie Lantuejoul, France

12:32  ES09.03: Neo-Adjuvant Trials in NSCLC? What Does It Mean for Pathological Assessment (CPR/MPR)
Anjali Saqi, USA

12:44  ES09.04: Neo-Adjuvant Trials in NSCLC? What Does It Mean for Biomarker Assessment
Stephen Fox, Australia

12:56  ES09.05: Adjuvant Trials in NSCLC? What Does This Mean for Pathology/Biomarkers
Yasuhi Yatabe, Japan

13:08  ES09.06: Prognostic Factors in NSCLC: Potential Role in Selecting Patients for Neoadj and Adjuvant Therapy Eg Tumour Grade
John Le Quesne, UK

13:20  Q&A

12:30 - 13:30  MA02: Real World Initiatives for Lung Cancer Screening

Track: Screening and Early Detection

**ROOM: 405B, LEVEL 4**

Chairs: John Field, UK & Ella Kazerooni, USA

12:30  Welcome & Introduction
John Field, UK & Ella Kazerooni, USA

12:32  MA02.03: Incidentally-Detected Lung Cancer in Individuals Who Smoked v Never Smoked in a US Cohort
Matthew Smeltzer, USA

12:37  MA02.04: Does the Evidence Support Years-Since-Quit Smoking as a Factor in Lung Cancer Screening Eligibility
Robert Smith, USA

12:42  MA02.05: Long-Term Follow-up of Screening Detected Pure Ground-Glass Nodules Stable for 10 Years
Sang-Won Um, Republic of Korea

12:47  MA02.06: Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening
Jacqueline Aredo, USA

12:52  Q&A

13:00  MA02.08: Pack-Year Smoking History is an Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility
Alexandra Potter, USA

13:05  MA02.09: Effectiveness of Screening with Concurrent Smoking Cessation for the Netherlands
Koen de Nijs, Netherlands

13:10  MA02.10: A Strategic Plan to Accelerate Lung Cancer Screening - An American Cancer Society National Lung Cancer Roundtable Initiative
Lauren Rosenthal, USA

13:15  MA02.11: Population-Based Implementation of Lung Cancer Screening: Coupling Model Parsimony and Performance to Determine Screening Eligibility
Thomas Callender, UK

13:20  Q&A


Track: Risk Factors, Risk Reduction & Tobacco Control

**ROOM: 405C, LEVEL 4**

Chairs: Lawson Eng, Canada & Douglas Arenberg, USA

12:30  Welcome & Introduction
Lawson Eng, Canada & Douglas Arenberg, USA
12:32  MA03.03: Does Smoking Status Affect Survival After Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer?  
Neil Wallace, Australia

12:37  MA03.04: Pre-diagnosis Smoking Cessation and Overall Survival Among Non-small Cell Lung Cancer Patients: Results from a Large Lung Cancer Survivor Cohort  
Xinan Wang, USA

12:42  MA03.05: Factors Associated with Smoking Cessation of Participants in National Lung Cancer Screening Program in Korea  
Na-Young Yoon, Republic of Korea

12:47  MA03.06: Respiratory Tract Malignancy-associated Mortality Attributable to Particulate Matter in South Asia from the Global Burden of Disease  
Karl D’Silva, USA

12:52  Q&A

13:00  MA03.08: Regular Use of Pharmaceutical Opioids and Subsequent Risk of Lung Cancer  
Mahdi Sheikh, France

13:05  MA03.09: Embedding Smoking Cessation into a Potential Lung Cancer Screening Program: Australian Tobacco Control Expert Perspectives  
Nathan Harrison, Australia

13:10  MA03.10: The Interim Analysis of Can-Prevent-Lung Trial: Canakinumab for The Prevention of Lung Cancer  
JianJun Zhang, China

13:15  MA03.11: Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk, Family History of Cancer and Lung Cancer. Results from CLARIFY  
Virginia Calvo, Spain

13:20  Q&A

12:30 - 13:30  OA03: Newer Generation Treatments for EGFR, ALK and ROS1  
Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy  
ROOM: 406, LEVEL 4  
Chairs: Pei Ni Ding, Australia & Fiona Blackhall, UK

12:30  Welcome & Introduction  
Pei Ni Ding, Australia & Fiona Blackhall, UK

12:32  OA03.03: Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study  
Jing Chen, China

12:42  OA03.04: A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions  
Baohui Han, China

12:52  OA03.05: A Randomized, Phase 3 Study of Iruplinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK+ Non-small Cell Lung Cancer (NSCLC)  
Runxiang Yang, China

13:02  OA03.06: Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial  
Byoung Chul Cho, Republic of Korea

13:12  OA03.07: Discussant  
Hiroaki Akamatsu, Japan

13:22  Q&A

12:30 - 13:30  OA04: Lung Cancer Management - Research to Reality  
Track: Global Health, Health Services, and Health Economics  
ROOM: NICOLL 3, LEVEL 3  
Chairs: Marjolein Heuvelmans, Netherlands & Hirotsugu Kenmotsu, Japan

12:30  Welcome & Introduction  
Marjolein Heuvelmans, Netherlands & Hirotsugu Kenmotsu, Japan

12:32  OA04.03: Australian Registry and Biobank of Thoracic Cancers (AURORA) - A Multi-Site Research Platform and Longitudinal Cohort Study  
Jennifer Rogers, Australia

12:42  OA04.04: The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study  
Bin-Chi Liao, Taiwan

12:52  OA04.05: To Treat or Not to Treat: Factors Impacting Treatment Decisions in Octogenarians with Non-Small Cell Lung Cancer (NSCLC)  
Wan Hsiang Chen, USA

13:02  OA04.06: The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 2020  
Jia Wang, China

13:12  OA04.07: Discussant  
Fabio Ynoe de Moraes, Canada

13:22  Q&A

13:45 – 14:45  Lunch Break  
ROOM: EXHIBIT HALL, LEVEL 4  
Lunch Provided

13:45 – 14:45  Concurrent Industry Sponsored and Satellite CME Symposia

FOR FURTHER INFORMATION, PLEASE SEE PAGES 228 & 230.

13:45 - 14:45  GE01: Gender Equity in Thoracic Oncology  
ROOM: NICOLL 1, LEVEL 3  
Chairs: Narjust Florez (Duma), USA & Heather Wakelee, USA

13:45  Welcome & Introduction  
Narjust Florez (Duma), USA & Heather Wakelee, USA

13:47  Listen to Interesting and Inspiring Personal Stories  
Her Royal Highness Princess Dina Mired, Jordan  
Mei Ling Yap, Australia  
Pyng Lee, Singapore  
Paula Ugalde Figueroa, USA
14:27  Panel Discussion
Shalini Vinod, Australia
Helena Linardou, Greece
Karen Kelly, USA
Lucia Viola, Colombia

14:35  Round Table Discussions – What Can IASLC Do to Help Achieve Gender Equity?

15:00 - 16:00  ES10: Optimal Surgical Approaches in Early Stage NSCLC
Track: Early-Stage Non-small Cell Lung Cancer
ROOM: 405A, LEVEL 4
Chairs: Brendon Stiles, USA & Alan Sihoe, China

15:00  Welcome & Introduction
Brendon Stiles, USA & Alan Sihoe, China

15:02  ES10.03: Surgical Techniques: The Global Perspective
Aneez Ahmed Dokeu, Singapore

15:14  ES10.04: When and Why Wedge Resection is Good Enough
Alejandra Romero, Spain

15:26  ES10.05: Lobectomy Reigns Supreme
Eric Lim, UK

15:38  ES10.06: Surgery and Shared Decision Making: The Patient Perspective
Upal Roy, USA

15:50  Q&A

15:00 - 16:00  ES11: Tailored Therapies for KRAS Mutant Lung Cancers
Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy
ROOM: SUMMIT 2, LEVEL 3
Chairs: Julia Rotow, USA & Hiroaki Akamatsu, Japan

15:00  Welcome & Introduction
Julia Rotow, USA & Hiroaki Akamatsu, Japan

15:02 ES11.03: Mechanisms of Resistance to KRAS G12C Inhibitors
Biagio Ricciuti, USA

15:14  ES11.04: New Combinations Therapies and Moving beyond Current KRAS G12C Inhibitors
Pasi Janne, USA

15:26  ES11.05: Novel Therapies for Non G12C KRAS-Mutant Lung Cancers
Kathryn Arbour, USA

15:38  ES11.06: Sequencing Treatments for KRAS-Mutant Lung Cancers and Role for KRAS Inhibitors as First-Line Treatment and Adjuvant Treatment
Enriqueta Felip, Spain

15:50  Q&A

15:00 - 16:00  ES12: Early Palliative Care for Lung Cancer: Where Are We in 2023?
Track: Multidisciplinary Care: Nursing, Allied Health & Palliative Care
ROOM: NICOLL 2, LEVEL 3
Chairs: Michael Franco, Australia & Anne Fraser, New Zealand

15:00  Welcome & Introduction
Michael Franco, Australia & Anne Fraser, New Zealand

15:02 ES12.03: Review of Evidence: Positive Studies
Andreas Charalambous, Cyprus

15:14  ES12.04: Review of Evidence: Negative or Equivocal
Jaclyn Yoong, Australia

15:26  ES12.05: Components of Successful Early Referral/Screening Tools/Who to Refer
David Hui, USA

15:38  ES12.06: Early Lung Cancer Referral: Implementation Challenges/Models of Care
Peter Poon, Australia

15:50  ES12.07: Q&A

15:00 - 16:00  ES13: Pleural Malignancy, Old Problems and New Solutions
Track: Pulmonology and Staging
ROOM: NICOLL 3, LEVEL 3
Chairs: Yvonne Ang, Singapore & Harish Mithiran, Singapore

15:00  Welcome & Introduction
Yvonne Ang, Singapore & Harish Mithiran, Singapore

15:02 ES13.03: Realtime Ultrasound Guided Interventions in Pleural Disease
Christine Argento, USA

15:14  ES13.04: Tumor Markers in Diagnosis & Treatment of Malignant Pleural Effusion
Carla Lamb, USA

15:26  ES13.05: Pleural Effusion Control - Where Have We Come From and Going?
YC Gary Lee, Australia

15:38  ES13.06: Surgical Intervention for Malignant Pleural Disease
Takahiro Nakajima, Japan

15:50  Q&A

15:00 - 16:00  MA04: Novel Targets and Overcoming Drug Resistance
Track: Tumor Biology – Translational Biology
ROOM: 405B, LEVEL 4
Chairs: Jonathan Ostrem, USA & Regina Hoo, Singapore

15:00  Welcome & Introduction
Jonathan Ostrem, USA & Regina Hoo, Singapore

15:02 ES14.03: Realtime Ultrasound Guided Interventions in Pleural Disease
Christine Argento, USA

15:14  ES14.04: Tumor Markers in Diagnosis & Treatment of Malignant Pleural Effusion
Carla Lamb, USA

15:26  ES14.05: Pleural Effusion Control - Where Have We Come From and Going?
YC Gary Lee, Australia

15:38  ES14.06: Surgical Intervention for Malignant Pleural Disease
Takahiro Nakajima, Japan

15:50  Q&A
15:02 MA04.03: Osimertinib-induced Epigenetic and Transcriptional Reprogramming Drives a BRD4-POUF-PDGFRB-YAP-EMT Axis of Resistance in NSCLC
Antja-Voy Hartley, USA

15:07 MA04.04: A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC
Haoyue Guo, China

15:12 MA04.05: Transcriptionic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI
Ming Tsao, Canada

15:17 MA04.06: Epigenomic Drug Effect on Osimertinib-Induced Drug Tolerant Persister in a Lung Cancer Patient-Derived Xenograft Model
Yoshiaki Inoue, Japan

15:22 Q&A

15:30 MA04.08: Identifying Early and Late Hallmarks of Plasticity in Neuroendocrine Transformation of Lung Cancer at Single-Cell Level
Joseph Chan, USA

15:35 MA04.09: The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
Rafael Rossell, Spain

15:40 MA04.10: Molecular Characteristics of Non-Small Cell Lung Cancer with MET Fusions
Chul Kim, USA

15:50 Q&A

15:30 MA05.08: LungMATCH - The Impact of Direct to Patient Clinical Trial Navigation on Engagement In the Lung Cancer Trial Process
Andrew Ciuper, USA

15:35 MA05.09: Neutrophil Count In African American Patients with Lung Cancer: Implications for Inclusion in Clinical Trials
Haiping Cheng, USA

15:40 MA05.10: Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
Kazuo Hasegawa, Japan

15:45 MA05.11: Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with aNSCLC in EMPOWER-Lung 1 and 3
David R. Gandara, USA

15:50 Q&A

15:00 - 16:00 OA05: Antibody Drug Conjugates: The Next Tsunami
Track: Small Cell Lung Cancer and Neuroendocrine Tumors
ROOM: 406, LEVEL 4
Chairs: Melissa Moore, Australia & Aliyah Pabani, USA

15:00 Welcome & Introduction
Melissa Moore, Australia & Aliyah Pabani, USA

15:02 OA05.03: Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Helena Yu, USA

15:12 OA05.04: Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
Byoung Chul Cho, Republic of Korea

15:22 OA05.05: Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study
Melissa Johnson, USA

15:32 OA05.06: Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04
Saiaima Waqar, USA

15:42 OA05.07: Discussant
Helena Linardou, Greece

15:42 Q&A
15:02 OA06.03: An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer  
Ilias Houda, Netherlands

15:12 OA06.04: Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial  
Chris Dickhoff, Netherlands

15:22 OA06.05: Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies  
Mariana Brandao, Netherlands

15:32 OA06.06: A Novel Multiparameter Biomarker of Pathological Response for NSCLC Receiving Neoadjuvant Immunotherapy: A Real-world Study  
Shaowei Wu, China

15:42 OA06.07: Discussant  
Sandip Patel, USA

15:52 Q&A

16:17 ES14.03: Tobacco Moment: Impact of Smoking on Clinical Outcomes in Radiotherapy  
Jacek Jassem, Poland

16:22 ES14.04: Staging for Radiation Therapy in Locally Resectable NSCLC  
Michael MacManus, Australia

16:34 ES14.05: Assessment for Surgery in Locally Resectable NSCLC  
Akif Turna, Turkey

16:46 ES14.06: Assessment for Systemic Therapy in Locally Resectable NSCLC  
Christine Bestvina, USA

16:58 ES14.07: Preparing the Patient for Treatment in Locally Resectable NSCLC  
Mary Duffy, Australia

17:05 Q&A

16:15 - 17:15 ES15: How Are Antibody Drug Conjugates (ADCs) Being Strategized to Revolutionize NSCLC Treatment?  
Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

16:15 Welcome & Introduction  
Egbert Smit, Netherlands & Melissa Johnson, USA

16:17 ES15.03: Pharmacology of ADC Classes  
Pamela Abdayem, France

16:29 ES15.04: Current ADC Development in NSCLC  
William Nassib Williams, Brazil

16:41 ES15.05: Management of ADC Associated Toxicities  
Sun Min Lim, Republic of Korea

16:53 ES15.06: Are Biomarkers Necessary for ADCs?  
Aakash Desai, USA

17:05 Q&A

16:15 - 17:15 ES16: Early Mesothelioma  
Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

16:15 Welcome & Introduction  
Steven Kao, Australia & Shalini Subramaniam, Australia

16:17 ES16.03: Biomarkers for Early Detection  
Haining Yang, USA

Sonja Klebe, Australia

16:41 ES16.05: Surgical Management of Pleural Mesothelioma  
Seiki Hasegawa, Japan

16:53 ES16.06: Radiation as Part of Multimodality Therapy  
Andreas Rimner, USA

17:05 Q&A

16:15 - 17:15 ES17: Hot Topics in Lung Cancer Biomarkers  
Track: Pathology and Biomarkers

16:15 Welcome & Introduction  
Angela Takano, Singapore & Wendy Cooper, Australia

16:17 ES17.03: Biomarkers for Antibody/Drug Conjugates - Lessons from PD-L1  
Mary Beth Beasley, USA

16:29 ES17.04: Liquid vs Tissue? Which and When Is the Issue for Clinical Utility  
Umberto Malapelle, Italy

16:41 ES17.05: Refining Prediction of Response to IO in NSCLC Eg CD8+, Spatial Immune Variability  
Kosuke Tanaka, Japan

16:53 ES17.06: Emerging Biomarkers for IO Therapy in Small Cell Lung Cancer  
Navin Mahadevan, USA

17:05 Q&A
16:15 - 17:15  MA06: Targeted Therapy: KRAS and Beyond
Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ROOM: 405B, LEVEL 4

Chairs: Sukhmani Padda, USA & Thanyanan Baisamut (Reungwetwattana), Thailand

16:15  Welcome & Introduction
Sukhmani Padda, USA & Thanyanan Baisamut (Reungwetwattana), Thailand

16:17  MA06.03: KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
Marcelo Negrao, USA

16:22  MA06.04: KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC
Shirish Gadgeel, USA

16:27  MA06.05: CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC.
Jeffrey Clarke, USA

16:32  MA06.06: A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J
Gary Middleton, UK

16:37  Q&A

16:45  MA06.08: Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC
Dazhi Liu, USA

16:55  MA06.10: Discovery of Potent Degraders of KRASG12D Based on a Novel KRAS Binder
Dongzhou Liu, China

16:50  MA06.11: Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China
Katharine See, Australia

17:00  MA06.10: Co-Design and Implementation of A Digital Care Pathway for Patients with Lung Cancer
Shen Lu, China

17:05  Q&A

16:15 - 17:15  MA07: Barriers and Benefits
Track: Patient Advocacy

ROOM: 405C, LEVEL 4

Chairs: Dave Bjork, USA & Ewelina Szmytke, Poland

16:15  Welcome & Introduction
Dave Bjork, USA & Ewelina Szmytke, Poland

16:17  MA07.03: Analyzing and Understanding the Unmet Needs of Lung Cancer Patients and Their Loved Ones
Britney Nichols, USA

16:22  MA07.04: Barriers to Lung Cancer Care in Europe
Anne-Marie Baird, Ireland

16:37  Q&A

16:45  MA07.08: Patient Involvement in Decision-Making Around Their Treatment and Care: Findings from a Global Patient Experience Survey
Jackie Fenemore, UK

16:50  MA07.09: Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)
Stefania Vallone, Italy

17:00  MA07.11: An International Survey Assessing the Unmet Needs of Family Caregivers of People with Lung Cancer: Preliminary Findings
Heather Law, USA

17:05  Q&A

16:15 - 17:15  OA07: Refining Risk Prediction Models for Lung Cancer Screening
Track: Screening and Early Detection

ROOM: 405A, LEVEL 4

Chairs: Ricardo Sales Santos, Brazil & Lucia Viola, Colombia

16:15  Welcome & Introduction
Ricardo Sales Santos, Brazil & Lucia Viola, Colombia

16:17  OA07.03: Performance of PLCoM2012-Based Screening Eligibility in the Manchester Lung Health Check Pilot Cohort after 6 years
Patrick Goodley, UK

16:27  OA07.04: Effectiveness of NELSON versus PLCoM2012 Lung Cancer Screening Eligibility Criteria: First Results from the German HANSE Study
Jens Vogel-Clausen, Germany

16:37  OA07.05: Pre-Recruitment as a Strategy to Address “Near-Miss” Cases in Risk-Based Lung Cancer Screening Selection: An Analysis of ILST Data
Chellan Kumarasamy, Australia

16:47  OA07.06: Development and Validation of a Protein-Based Lung Cancer Risk Prediction Model - Initial Results from the Lung Cancer Cohort Consortium (LC3)
Hana Zahed, France

17:07  Q&A
16:15 - 17:15  OA08: Thriving not Surviving: Advances in Lung Cancer Rehabilitation and Lung Cancer in Older Adults
Track: Multidisciplinary Care: Nursing, Allied Health & Palliative Care
ROOM: NICOLL 3, LEVEL 3
Chairs: Morten Quist, Denmark & Maria Ftanou, Australia

16:15  Welcome & Introduction
Morten Quist, Denmark & Maria Ftanou, Australia

16:17  OA08.03: Do Enhanced Recovery after Lung Cancer Surgery Programs Risk Putting Primacy of Caring at Stake?
Malene Missel, Denmark

16:27  OA08.04: Exploring Survivorship Care Needs for Low-Income Older Adults with Lung Cancer in a Safety-Net Setting: A Qualitative Study
Ana Velazquez, USA

16:37  OA08.05: Implementation and Evaluation of a Geriatric Oncology Model of Care for Older Patients with Lung Cancer
Shalini Vinod, Australia

16:47  OA08.06: Development of a Lung Cancer Rehabilitation Core Outcome Set: An International Delphi Study (UNITE)
Lara Edbrooke, Australia

16:57  OA08.07: Discussant
David Hui, USA

17:07  Q&A

17:30 – 19:30  Poster Viewing Networking Reception (Poster Session 1: P1) with Presenters in Attendance
ROOM: EXHIBIT HALL, LEVEL 4

18:00 - 18:30  JTO and JTO CRR Editorial Reception (By Invitation Only)
ROOM: CONCOURSE 1/REGISTRATION, LEVEL 3

18:30 – 19:30  Concurrent Industry Sponsored and Satellite CME Symposium
FOR FURTHER INFORMATION, PLEASE SEE PAGES 229 & 230.

20:00 – 23:00  Faculty Dinner (By Invitation Only)
The Journal of Thoracic Oncology 2022 Impact Factor has risen to 20.4

#13 OF 241 ONCOLOGY JOURNALS

#4 OF 65 RESPIRATORY SYSTEM JOURNALS

THE HIGHEST YET!

LUNG CANCER CONSIDERED

with Dr. Stephen Liu and Dr. Narjast Florez
an IASLC Podcast

In 2023, the podcast was ranked in the Top 5% of Global Podcasts by Listen Notes.

2022 w3 Gold Award for Creative Excellence

Join us in listening to our award winning content on your favorite app.

Find new podcast episodes here.

Lung Cancer Considered is funded in part by:
AstraZeneca, Daiichi-Sankyo, Genentech, and Takeda
Monday, September 11, 2023

07:30 - 08:15  HOD01: Highlights of the Day - Sunday Abstracts

ROOM: 405A, LEVEL 4

07:30  HOD01.01: Radiation Oncology
Feng-Ming Kong, Hong Kong

07:40  HOD01.02: Pulmonology
Kwun Fong, Australia

07:50  HOD01.03: Medical Oncology
Rami Manochakian, USA

08:00  Q&A

07:30 - 08:15  MTE08: Liquid Biopsies - Current Technologies and Clinical Applications

Track: Tumor Biology – Translational Biology

ROOM: 405C, LEVEL 4

07:30  MTE08.01: New and Novel Technologies for Liquid Biopsies
Maximilian Diehn, USA

07:45  MTE08.02: Current and Future Clinical Applications of Liquid Biopsies
Se-Hoon Lee, Republic of Korea

08:00  Q&A

07:30 - 08:15  MTE09: Patient Centered Grand Rounds in Local Regional NSCLC: Single Mediastinal Station Stage IIIA

Track: Local-Regional Non-small Cell Lung Cancer

ROOM: SUMMIT 1, LEVEL 3

07:30  MTE09.01: Surgery Perspective
Simon Knight, Australia

07:40  MTE09.02: Rad Onc Perspective
Shalini Vinod, Australia

07:50  MTE09.03: Med Onc Perspective
Jamie Chaft, USA

08:00  MTE09.04: Patient Response
Jill Feldman, USA

08:07  MTE09.05: Patient Response
Seamus Cotter, Ireland

07:30 - 08:15  MTE10: Systemic Therapy Combinations in EGFR-mutated NSCLC

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

ROOM: NICOLL 2, LEVEL 3

07:30  MTE10.01: Chemotherapy after Targeted Therapy - What Is the Best Strategy?
Laura Mezquita, Spain

07:45  MTE10.02: Choosing the Best Chemotherapy Regimen for NSCLC Subpopulations
Rina Hui, Hong Kong

08:00  Q&A

07:30 - 08:15  MTE11: Optimizing First-Line Targeted Therapy Treatment

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ROOM: NICOLL 3, LEVEL 3

07:30  MTE11.01: First Line-Combination Therapies to Eradicate Persister Cells
James Chih-Hsin Yang, Taiwan

07:45  MTE11.02: Risk Adaptive First-Line Treatments: Use of ctDNA, Comutations or Clinical Factors to Risk Stratify
Helena Yu, USA

08:00  Q&A

07:30 - 08:15  MTE12: Debate: Upfront NGS Testing Should Be the Standard of Care in Advanced NSCLC

Track: Global Health, Health Services, and Health Economics

ROOM: SUMMIT 2, LEVEL 3

07:30  MTE12.01: For the Proposition
Natasha Leighl, Canada

07:45  MTE12.02: Against the Proposition
Herbert Loong, Hong Kong

08:00  MTE12.03: Q&A
Luis Raez, USA

07:30 - 08:15  MTE13: Controversy in Staging: Nodes vs Nodule

Track: Pulmonology and Staging

ROOM: NICOLL 1, LEVEL 3

07:30  MTE13.01: Prioritizing Staging vs Nodule Diagnosis. Case Illustration
Douglas Arenberg, USA

07:50  MTE13.02: Robotic Navigational Bronchoscopy and Ablative Therapy
Calvin Ng, Hong Kong

08:10  Q&A
08:30 - 10:00  PL03: Plenary Session 3: Presidential Symposium
ROOM: 406, LEVEL 4  
Chairs: Heather Wakelee, USA & Paul Van Schil, Belgium

08:30  PL03.02: President’s Address
Heather Wakelee, USA

08:36  PL03.03: Incoming President’s Address
Paul Van Schil, Belgium

08:46  PL03.04: The Taiwan National Lung Cancer Screening Program
Chi-Yen Huang, Taiwan

08:53  PL03.05: Discussant
Gerard Silvestri, USA

09:01  Q&A

09:03  PL03.07: Invasion or No Invasion, That’s the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification
Erik Thunnissen, Netherlands

09:10  PL03.08: Discussant
Mari Mino-Kenudson, USA

09:18  Q&A

09:20  PL03.10: MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus No Radical Surgery for Mesothelioma
Eric Lim, UK

09:30  PL03.11: Discussant
Paula Ugalde Figueroa, USA

09:38  Q&A

09:40  PL03.13: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
Pasi Janne, USA

09:50  PL03.14: Discussant
Yi-Long Wu, China

09:58  Q&A

10:00 – 10:45  Meet the IASLC Committees
IASLC MEMBERSHIP LOUNGE IN THE EXHIBIT HALL
IASLC Members - Visit the Committee Corner within the IASLC Membership Lounge for a chance to connect with Committee Members and to learn more about IASLC Committee initiatives.

10:00 – 10:45  Coffee Break
ROOM: EXHIBIT HALL, LEVEL 4  
 Refreshments Provided
### SCIENTIFIC PROGRAM - MONDAY, SEPTEMBER 11, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Venue</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:45</td>
<td>ES20: Defining and Managing Oligoprogression in Metastatic Non-small Cell Lung Cancer</td>
<td>NICOLL 1, LEVEL 3</td>
<td></td>
<td>Mark Berry, USA &amp; Connie Yip, Singapore</td>
</tr>
<tr>
<td>10:47</td>
<td>Welcome &amp; Introduction</td>
<td></td>
<td></td>
<td>Yolande Lievens, Belgium</td>
</tr>
<tr>
<td>10:59</td>
<td>ES20.04: Considerations for Surgery for Oligoprogression</td>
<td></td>
<td></td>
<td>Mara Antonoff, USA</td>
</tr>
<tr>
<td>11:11</td>
<td>ES20.05: Considerations for Radiation Therapy for Oligoprogression</td>
<td></td>
<td></td>
<td>Kevin Chua, Singapore</td>
</tr>
<tr>
<td>11:23</td>
<td>ES20.06: Strategies for Empowering Patients and Personalizing Treatment Recommendations for Oligoprogression: Patient's Perspectives</td>
<td></td>
<td></td>
<td>Fan Yang, Australia</td>
</tr>
<tr>
<td>11:35</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>ES21: Risk Reduction and Tobacco Control</td>
<td>405A, LEVEL 4</td>
<td></td>
<td>Yvonne Ang, Singapore &amp; Feng Ming Kong, Hong Kong</td>
</tr>
<tr>
<td>10:47</td>
<td>Welcome &amp; Introduction</td>
<td></td>
<td></td>
<td>Emily Stone, Australia</td>
</tr>
<tr>
<td>10:52</td>
<td>ES21.04: Air Pollution and Lung Cancer - Public Health Perspectives</td>
<td></td>
<td></td>
<td>Michelle Turner, Spain</td>
</tr>
<tr>
<td>11:07</td>
<td>ES21.05: Pathologic and Molecular Features of Lung Adenocarcinoma in People Who Smoke and People Who Do Not Smoke</td>
<td></td>
<td></td>
<td>Guoping Cai, USA</td>
</tr>
<tr>
<td>11:30</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>MA08: Mediastinal Lumps and Bumps</td>
<td>405C, LEVEL 4</td>
<td></td>
<td>Andrea Bezjak, Canada &amp; Michael Boyer, Australia</td>
</tr>
<tr>
<td>10:47</td>
<td>Welcome &amp; Introduction</td>
<td></td>
<td></td>
<td>Yi-Ting Yen, Taiwan</td>
</tr>
<tr>
<td>10:52</td>
<td>MA08.04: STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials</td>
<td></td>
<td></td>
<td>Anlin Li, China</td>
</tr>
<tr>
<td>10:57</td>
<td>MA08.05: ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors</td>
<td></td>
<td></td>
<td>Chee Lee, Australia</td>
</tr>
<tr>
<td>11:07</td>
<td>MA08.06: A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)</td>
<td></td>
<td></td>
<td>Caiicun Zhou, China</td>
</tr>
<tr>
<td>11:17</td>
<td>MA08.07: Discussant</td>
<td></td>
<td></td>
<td>Justin Gainor, USA</td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td>OA09: Immunotherapy for Advanced NSCLC</td>
<td>406, LEVEL 4</td>
<td></td>
<td>Benjamin Solomon, Australia &amp; Ana Gelatti, Brazil</td>
</tr>
<tr>
<td>10:47</td>
<td>Welcome &amp; Introduction</td>
<td></td>
<td></td>
<td>Benjamin Solomon, Australia &amp; Ana Gelatti, Brazil</td>
</tr>
<tr>
<td>10:52</td>
<td>OA09.03: STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials</td>
<td></td>
<td></td>
<td>Anlin Li, China</td>
</tr>
<tr>
<td>10:57</td>
<td>OA09.04: ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors</td>
<td></td>
<td></td>
<td>Chee Lee, Australia</td>
</tr>
<tr>
<td>11:07</td>
<td>OA09.05: A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)</td>
<td></td>
<td></td>
<td>Caiicun Zhou, China</td>
</tr>
<tr>
<td>11:17</td>
<td>OA09.07: Discussant</td>
<td></td>
<td></td>
<td>Justin Gainor, USA</td>
</tr>
</tbody>
</table>

ACCME Accredited By IASLC
Live-Streamed
Recommended for Early Career Researchers
Not for CME Credit
SCIENTIFIC PROGRAM - MONDAY, SEPTEMBER 11, 2023

10:45 - 11:45  OA10: Precision Language in Thoracic Oncology

Track: Patient Advocacy

ROOM: SUMMIT 2, LEVEL 3

Chairs: Upal Basu Roy, USA & Cecilia Pompili, Italy

10:45  Welcome & Introduction
Upal Basu Roy, USA & Cecilia Pompili, Italy

10:47  OA10.03: Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective
Eric Singhi, USA

10:57  OA10.04: A Systems Approach to Improving Clinical Trial Informed Consent Forms in Lung Cancer Clinical Trials
Bellinda King-Kallimanis, USA

11:07  OA10.05: Patient-Facing Biomarker Testing Reports: Views and Preferences of People with Lung Cancer and Caregivers
Andrew Ciupek, USA

11:17  OA10.06: Recognizing Early Adopters of Non Stigmatizing Language at IASLC WCLC 2022
Jill Feldman, USA

11:27  OA10.07: Discussant
Lawrence Feldman, USA

11:37  Q&A

12:00 - 13:00  ES22: Pushing the Limit- Novel Solutions to Challenges Related to Pulmonary Malignancy

Track: Pulmonology and Staging

ROOM: NICOLL 3, LEVEL 3

Chairs: Navneet Singh, India & John Tam, Singapore

12:00  Welcome & Introduction
Navneet Singh, India & John Tam, Singapore

12:02  ES22.03: Virtual Image-Based Biopsy of Lung Metastases: Promise of Radiomics
Ritu Gill, USA

12:14  ES22.04: Therapeutic Bronchoscopic Interventions for Modification of Primary Tumor and Nodal Microenvironment
Daniel Sterman, USA

12:26  ES22.05: Bronchoscopy for Malignant Central Airway Obstruction and Fistula
Anne Hsu, Singapore

12:38  ES22.06: Robotic Surgery for Locally Advanced and Oligometastatic NSCLC
Seong-Yong Park, Republic of Korea

12:50  Q&A

12:00 - 13:00  ES23: Supporting Smoking Cessation in the Clinic - The Complete Toolbox for Doctors

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

ROOM: SUMMIT 2, LEVEL 3

Chairs: Emily Stone, Australia & Alvin Lo, Singapore

12:00  Welcome & Introduction
Emily Stone, Australia & Alvin Lo, Singapore

12:02  ES23.03: The Effect of Smoking on Survival in NSCLC - Is It Too Late to Quit?
Matthew Steliga, USA

12:14  ES23.04: Smoking Cessation in Different Patient Groups - Is There a Personalised Strategy?
Magdalena Cedzynska, Poland

12:26  ES23.05: Building Trust and Supporting Quitting - What Not to Do
Matthew Evison, USA

12:38  ES23.06: Taking the Pain out of Discussing Quitting in the Clinic - An Effective Approach
Henry Marshall, Australia

12:50  Q&A

12:00 - 13:00  ES24: Forward Progress in Oncogene-Addicted NSCLC

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ROOM: 405A, LEVEL 4

Chairs: Byoung Chul Cho, Republic of Korea & Jhanelle Gray, USA

12:00  Welcome & Introduction
Byoung Chul Cho, Republic of Korea & Jhanelle Gray, USA

12:02  ES24.03: The Effect of Smoking on Survival in NSCLC - Is It Too Late to Quit?
Matthew Steliga, USA

12:14  ES24.04: Smoking Cessation in Different Patient Groups - Is There a Personalised Strategy?
Magdalena Cedzynska, Poland

12:26  ES24.05: Building Trust and Supporting Quitting - What Not to Do
Matthew Evison, USA

12:38  ES24.06: Taking the Pain out of Discussing Quitting in the Clinic - An Effective Approach
Henry Marshall, Australia

12:50  Q&A
ES24.03: How to Incorporate Liquid Biopsies into Treatment beyond Diagnosis - Consider Role in Early Stage Setting, Minimal Residual Disease and in the Resistance Setting Prior to Radiographic Changes  
Jordi Remon, France

ES24.04: Mechanisms of Resistance to Targeted Therapy - Common Themes and Treatments to Target  
Sanjay Popat, UK

ES24.05: Addressing the Problem of CNS Mets  
Yu Yang Soon, Singapore

ES24.06: Second Line and beyond Treatments for Advanced/Metastatic EGFR-Mutant NSCLC  
Tae Min Kim, Republic of Korea

ES25.03: Grading of Lung Cancers and the Clinical Significance - ADC, SCC Prognostic Factors Being Considered for Grading Scheme  
Mari Mino-Kenudson, USA

ES25.04: Assessment of Invasion in Lung Adenocarcinoma  
Akihiko Yoshizawa, Japan

ES25.05: Lessons from Challenging Lung Cases  
Edwina Duhig, Australia

ES25.06: AI Applications in Lung Cancer Pathology - Diagnosis, Classification, MPR Assessment  
Jan von der Thusen, Netherlands

ES25.08: Single-cell Analysis Revealed an Immunosuppressive Subtype of Senescent Tumor Cells in Lung Adenocarcinoma  
Guangyu Fan, China

ES25.09: CASPASE1 Modulates CD8+ T Cell Infiltration through IL-18 Secretion in Tumor Immune Microenvironment of EGFR-TKI-Resistant NSCLC  
Yajie Cheng, China

ES25.10: Paired Specimens Elucidate the Role of Tumor Microenvironment Reprogramming in the Efficacy of Neoadjuvant Chemoimmunotherapy in NSCLC  
Yang Xia, China

ES25.11: Acetaminophen Reduces Neoadjuvant Chemo-immunotherapy Efficacy in NSCLC Patients by Promoting Neutrophil Extracellular Traps Formation  
Junqi Wu, China

MA09.04: Genome-wide Analysis Identifies Nuclear Factor IC as a Novel Transcription Factor and Potential Therapeutic Target in SCLC  
Haitao Wang, USA

MA09.05: Tumoral ATF4-Mediated Fatty Acid Metabolism Disorder Fuels MDSC Reprogramming in LKB1-Mutant Lung Cancer  
Zeqin Guo, China

MA09.06: NSCLC Oncogenotypes as Biomarkers and Regulators of Cachexia Development  
Puneeth Iyengar, USA

MA09.08: Single-cell Analysis Revealed an Immunosuppressive Subtype of Senescent Tumor Cells in Lung Adenocarcinoma  
Guangyu Fan, China

MA09.10: Paired Specimens Elucidate the Role of Tumor Microenvironment Reprogramming in the Efficacy of Neoadjuvant Chemoimmunotherapy in NSCLC  
Yang Xia, China

MA09.11: Acetaminophen Reduces Neoadjuvant Chemo-immunotherapy Efficacy in NSCLC Patients by Promoting Neutrophil Extracellular Traps Formation  
Junqi Wu, China

MA10.03: A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)  
Yvonne Ang, Singapore

MA10.04: Evaluation of a Risk-Sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries  
Oscar Arrieta, Mexico

MA10.05: Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review  
Kelly Needham, UK

MA10.06: CARMA-BROS: Cancers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study  
Faisal Al Agha, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>MA10.08: The Disparate Burden of COVID-19 Lung Cancer Patients During Periods of High Transmission of SARS-CoV-2</td>
<td>Priyanka Senthil, USA</td>
<td>NICOLL 1, LEVEL 3</td>
</tr>
<tr>
<td>12:40</td>
<td>MA10.10: A Review of the Routes into the Lung Cancer Pathway for Patients Diagnosed with Lung Cancer in Wales</td>
<td>Lydia Guhaniyogi, UK</td>
<td>NICOLL 1, LEVEL 3</td>
</tr>
<tr>
<td>12:45</td>
<td>MA10.11: Exploration of Side Effects and Patient-Reported Outcomes in First Line Compared to Late Line Chemotherapy and Targeted Therapies</td>
<td>Upal Basu Roy, USA</td>
<td>NICOLL 1, LEVEL 3</td>
</tr>
<tr>
<td>13:00</td>
<td>Welcome &amp; Introduction</td>
<td>Tina Cascone, USA &amp; Gavin Wright, Australia</td>
<td>NICOLL 1, LEVEL 3</td>
</tr>
<tr>
<td>13:02</td>
<td>OA12.03: An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC</td>
<td>Thomas Stinchcombe, USA</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:12</td>
<td>OA12.04: Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial</td>
<td>Joe Chang, USA</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:22</td>
<td>OA12.05: Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)</td>
<td>Tetsuya Mitsudomi, Japan</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:32</td>
<td>OA12.06: Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)</td>
<td>David Harpole, USA</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:42</td>
<td>OA12.07: Discussant</td>
<td>Solange Peters, Switzerland</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:52</td>
<td>Q&amp;A</td>
<td></td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:15</td>
<td>Welcome &amp; Introduction</td>
<td>Renelle Myers, Canada &amp; William Evans, Canada</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:20</td>
<td>HW01.02: Expanding the Wellness Paradigm: Beyond Personal Resilience to Building a Comprehensive Academic Center Wellness Program</td>
<td>Anne Tsao, USA</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:35</td>
<td>HW01.03: Empowering Self-Care: Nurturing Wellness and Personal Growth in Everyday Life</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>13:50</td>
<td>Q&amp;A</td>
<td></td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>14:00</td>
<td>Welcome &amp; Introduction</td>
<td>Carlos Gil Ferreira, Brazil</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>14:20</td>
<td>HW01.04: Advancing the Wellness Paradigm: Community Involvement in Wellness Programs</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>14:30</td>
<td>HW01.05: Engaging in Community Wellness Programs: Implementing the Wellness Paradigm</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>14:50</td>
<td>HW01.06: Enhancing the Wellness Paradigm: Creating a Culture of Wellness</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>15:00</td>
<td>Q&amp;A</td>
<td></td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>15:15</td>
<td>Welcome &amp; Introduction</td>
<td>Renelle Myers, Canada &amp; William Evans, Canada</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>15:20</td>
<td>HW01.07: Enhancing the Wellness Paradigm: The Role of Wellness Coaches</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>15:35</td>
<td>HW01.08: Advancing the Wellness Paradigm: Integrating Wellness with Existing Healthcare Programs</td>
<td>Maria Ftanou, Australia</td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
<tr>
<td>15:50</td>
<td>Q&amp;A</td>
<td></td>
<td>SUMMIT 1, LEVEL 3</td>
</tr>
</tbody>
</table>
14:30 - 15:30  ES26: Rethinking the Scope of LCS: What Will Screening Look Like in 20 Years?

Track: Screening and Early Detection  
ROOM: SUMMIT 2, LEVEL 3

Chairs: Kirsty Lee, Hong Kong & Edith Marom, Israel

14:30  Welcome & Introduction
Kirsty Lee, Hong Kong & Edith Marom, Israel

14:32  ES26.03: Incorporating Biomarkers into Lung Cancer Screening: Who Benefits?
Hillary Robbins, France

14:44  ES26.04: Artificial Intelligence in Lung Cancer Screening: Current and Future Perspectives
Lecia Sequist, USA

14:56  ES26.05: To Screen or Not to Screen: Decisions at the Patient Level
David Baldwin, UK

15:08  ES26.06: Quality Criteria for Future Initiatives on LCS
Monica Perez-Rios, Spain

15:20  Q&A

14:30 - 15:30  ES27: Disrupting the Landscape in Oncogene-Addicted NSCLC

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy  
ROOM: NICOLL 1, LEVEL 3

Chairs: Caicun Zhou, China & Mark Kris, USA

14:30  Welcome & Introduction
Caicun Zhou, China & Mark Kris, USA

14:32  ES27.03: EGFR TKI-Based Combination Therapies and Novel Targeted Therapies After Initial EGFR TKI
Sehhoon Park, Republic of Korea

Joop de Langen, Netherlands

14:56  ES27.05: New Data from ALK, ROS1 and RET
Jessica Lin, USA

15:08  ES27.06: New Data for MET and HER2
Xiuning Le, USA

15:20  Q&A

14:30 - 15:30  ES28: State-of-the-Art Management of LR NSCLC

Track: Local-Regional Non-small Cell Lung Cancer  
ROOM: SUMMIT 1, LEVEL 3

Chairs: Stephanie Saw, Singapore & Gerard Hanna, UK

14:30  Welcome & Introduction
Stephanie Saw, Singapore & Gerard Hanna, UK

14:32  ES28.03: State of the Art in LR NSCLC: Systemic Therapy
Tom John, Australia

14:44  ES28.04: State of the Art in NSCLC: Radiation Therapy
Kristin Higgins, USA

14:56  ES28.05: State of the Art in LR NSCLC: Surgery
Isabelle Opitz, Switzerland

15:08  ES28.06: State of the Art: Supportive Care
Paul Glare, Australia

15:20  Q&A
14:47  MA11.06: Results from a Phase II trial of a Tumor-Activated Fluorescent Molecule for the Intra-Operative Identification of Lung Cancer
Gavin Wright, Australia

15:00  MA11.08: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
Enriqueta Felip, Spain

15:05  MA11.09: SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis
Patrick Dorn, Switzerland

15:10  MA11.10: Intravenous Indocyanine Green Administration Provides Sufficient Margins in Pulmonary Segmentectomy
Takahiro Ochi, Japan

15:15  MA11.11: Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA)
Jii Bum Lee, Republic of Korea

14:30 - 15:30  MA12: Big Data & New Technologies
Track: Tumor Biology – Translational Biology
ROOM: 405B, LEVEL 4
Chairs: Vamsidhar Velcheti, USA & Harriet Gee, Australia

14:30  Welcome & Introduction
Vamsidhar Velcheti, USA & Harriet Gee, Australia

14:32  MA12.03: New Data from the LungNENomics Project Provide Insights on the Supra-Carcinoid Emerging Variant of Lung Neuroendocrine Tumors
Lynnette Fernandez-Cuesta, France

14:37  MA12.04: Evolutionary Proteogenomic Landscape from Pre-invasive to Invasive Lung Adenocarcinoma
Yang Zhang, China

14:42  MA12.05: The Patterns & Prognostic Value of Clonal Seeding in Lung Cancer Metastasis
Chao Zhang, China

14:47  MA12.06: Integrative Multi-Omics Analyses Reveal Molecular Subtypes with Distinct Prognosis of Early-Stage High-Grade Lung Adenocarcinoma
Nan Wu, China

15:10  MA12.10: Three Subsets of Lung Cancer-associated Fibroblasts Define Tumor Progression, Therapy Resistance and Patient Prognosis
Xu Weijiao, China

15:15  MA12.11: A Novel 89Zr-anti-PD1 immunoPET-CT May Predict Response to PD-1 Inhibitors in a Lung Cancer Murine Model Receiving Immunotherapy
Ignacio Gil-Bazo, Spain

14:30 - 15:30  OA14: Immune Checkpoint Therapy: Long Term Follow Up
Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy
ROOM: 405A, LEVEL 4
Chairs: Puey Ling Chia, Singapore & Elizabeth Dudnik, Israel

14:30  Welcome & Introduction
Puey Ling Chia, Singapore & Elizabeth Dudnik, Israel

14:32  OA14.03: Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
Solange Peters, Switzerland

14:42  OA14.04: Three-Year Outcomes with First-Line Pembrolizumab, in Patients with Non-small Cell Lung Cancer and A PD-L1 Tumor Proportion Score >90%
Biagio Ricciuti, USA

14:52  OA14.05: 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC with PD-L1 Tumor Proportion Score <1%
Shirish Gadgeel, USA

15:02  OA14.06: Reported Cardiovascular Events in Lung Cancer Patients After Immune-Checkpoint Inhibitor Therapy
Sai-Ching Yeung, USA

15:12  OA14.07: Discussant
Ferdinandos Skoulidis, USA

14:30 - 15:30  OA15: Pathological Biomarkers for Immunotherapy
Track: Pathology and Biomarkers
ROOM: NICOLL 2, LEVEL 3
Chairs: Deepali Jain, India & Dongmei Lin, China

14:30  Welcome & Introduction
Deepali Jain, India & Dongmei Lin, China

14:32  OA15.03: Evaluation of Pathological Tumor and Nodal Responses Following Neoadjuvant Chemoimmunotherapy in NSCLC Patients
Shujie Huang, China

14:42  OA15.04: Comparison of Digital Vs Manual PD-L1 Tumor Cell Scoring on SP263-Stained Whole Imaging Slides from IMPower110
Roy S. Herbst, USA
14:52 OA15.05: Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC
Matthieu Roulleaux Dugage, France

15:02 OA15.06: Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L)
Jumpei Kashima, Japan

15:12 OA15.07: Discussant
Annikka Weissferdt, USA

15:22 Q&A

15:45 - 16:45 ES30: Non-invasive Approaches for Early Stage NSCLC

Track: Early-Stage Non-small Cell Lung Cancer

ROOM: NICOLL 2, LEVEL 3

Chairs: Jane Ludbrook, Australia & Kristin Higgins, USA

15:45 Welcome & Introduction
Jane Ludbrook, Australia & Kristin Higgins, USA

15:47 ES30.03: SBRT and IO Combinations
Harriet Gee, Australia

15:59 ES30.04: SBRT in the Operable Patient
Megan Daly, USA

16:11 ES30.05: High-Risk SBRT Scenarios
Delphine Antoni, France

16:23 ES30.06: Tobacco Moment: The Role of the Surgeon in a Patient's Smoking Cessation
Matthew Steliga, USA

16:35 Q&A

15:45 - 16:45 ES31: The Future of Biomarkers in Immunotherapy

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

ROOM: NICOLL 1, LEVEL 3

Chairs: Clarissa Baldotto, Brazil & Yasushi Yatabe, Japan

15:45 Welcome & Introduction
Clarissa Baldotto, Brazil & Yasushi Yatabe, Japan

15:47 ES31.03: Tumor Biomarkers
Biagio Ricciuti, USA

15:59 ES31.04: ctDNA for Checkpoint Inhibitor Monitoring
Christian Rolfo, USA

16:11 ES31.05: Biomarkers Beyond PDL1
Yoon La Choi, Republic of Korea

16:23 ES31.06: Integration of Biomarkers with Artificial Intelligence
Arsela Prelaj, Italy

16:35 Q&A

15:45 - 16:45 ES32: Limited-Stage SCLC & Thoracic NETs

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

ROOM: SUMMIT 1, LEVEL 3

Chairs: Sukhmani Padda, USA & Aaron Tan, Singapore

15:45 Welcome & Introduction
Sukhmani Padda, USA & Aaron Tan, Singapore

15:47 ES32.03: Recent Insights into the Biology of Lung Neuroendocrine Neoplasms
Lynette Fernandez Cuesta,

15:59 ES32.04: Surgical Management of Thoracic NETs
Leanne Ashrafi, UK

16:11 ES32.05: Optimising the Use of Radiation Therapy in LS-SCLC
Bjorn Henning Gronberg, Norway

16:23 ES32.06: Systemic Therapy for Thoracic Carcinoids
Nick Pavlakis, Australia

16:35 Q&A

15:45 - 16:45 ES33: Access to Lung Cancer Care for All

Track: Patient Advocacy

ROOM: NICOLL 3, LEVEL 3

Chairs: Ewelina Szymtke, Poland & Angeline Low, Australia

15:45 Welcome & Introduction
Ewelina Szymtke, Poland & Angeline Low, Australia

15:47 ES33.03: Empowering Underserved Communities in Lung Cancer Screening and Treatment
Monica Baskin, USA

15:59 ES33.04: Lung Cancer Experiences: A Pathway for Improvement in Europe
Maria Calibo Sales, Australia

16:11 ES33.05: Gendered Lenses in Lung Cancer Screening and Treatment
Angeline Low, Australia

16:23 ES33.06: Gendered Lenses in Lung Cancer Screening and Treatment
Angeline Low, Australia

16:35 Q&A

15:45 - 16:45 MA13: Targeted Therapy: EGFR and HER2

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ROOM: 405B, LEVEL 4

Chairs: David R. Gandara, USA & Marina Garassino, USA

15:45 Welcome & Introduction
David R. Gandara, USA & Marina Garassino, USA

15:45 Welcome & Introduction
David R. Gandara, USA & Marina Garassino, USA
15:47 MA13.03: BBT-176, a 4th Generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: Updated Report from a Phase 1 Study
Sun Min Lim, Republic of Korea
15:52 MA13.04: Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09)
Jang Ho Cho, Republic of Korea
15:57 MA13.05: Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
Min Yu, China
16:02 MA13.06: Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
Se-Hoon Lee, Republic of Korea
16:07 MA13.07: Q&A
16:15 MA13.08: Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
Noboru Yamamoto, Japan
16:20 MA13.09: Targetable Driver Alterations in Non-adenocarcinoma NSCLC: Population-Based Prevalence Data from the National Swedish Lung Cancer Registry
Johan Isaksson, Sweden
16:25 MA13.10: Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC
Sehhoon Park, Republic of Korea
16:30 MA13.11: Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
Milena Cavic, Serbia
16:35 MA13.12: Q&A

15:45 - 16:45 MA14: Genetic Biomarkers for NSCLC
Track: Pathology and Biomarkers
ROOM: 405C, LEVEL 4
Chairs: Kurt Schalper, USA & Angela Takano, Singapore
15:45 Welcome & Introduction
Kurt Schalper, USA & Angela Takano, Singapore
15:47 MA14.03: Targetable Driver Alterations in Non-adenocarcinoma NSCLC: Population-Based Prevalence Data from the National Swedish Lung Cancer Registry
Johan Isaksson, Sweden
15:52 MA14.04: Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC
Melina Marmarelis, USA
15:57 MA14.05: Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib
Mengzhao Wang, China
16:02 MA14.06: Clinicopathologic Characteristics of Stage IV NRG1 Fusion-Positive Lung Cancer
Hyo Sup Shim, Republic of Korea
16:07 Q&A
16:15 MA14.07: Pathogenic Germline Variants in Patients with Non-small Cell Lung Cancer (NSCLC) Detected by Tissue Comprehensive Genomic Profiling
Laura Mezquita, Spain
16:20 MA14.08: Development of a Clinico-Proteo-Metagenomic Classifier for Risk Stratification of Incidentally-Detected Pulmonary Nodules
Yijun Song, China
16:25 MA14.09: Genomic Mutational Discordances and Heterogeneous PD-L1 Expression and Immune Infiltrates of Non-small Cell Lung Cancer Metastasis
Jianghua Wu, China
16:30 MA14.10: Q&A

15:45 - 16:45 OA16: Expanding the Scope of Lung Cancer Screening Initiatives Worldwide
Track: Screening and Early Detection
ROOM: 405A, LEVEL 4
Chairs: Raymond Osarogiagbon, USA & Witold Rzyman, Poland
15:45 Welcome & Introduction
Raymond Osarogiagbon, USA & Witold Rzyman, Poland
15:47 OA16.03: Taking A Health Systems Approach to Low-Dose CT Lung Cancer Screening: A Bespoke Framework to Support Implementation
Stephen C. Lam, Canada
15:57 OA16.04: Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS)
Elaine Shum, USA
16:07 OA16.05: Assessing the Impact of Increasing Lung Screening Eligibility by Relaxing the Maximum Years Since Quit Threshold. A Simulation Modeling Study
Rafael Meza, USA
16:17 OA16.06: Trends of Positive Rates of Initial Screening And Repeated Screening in National Organized Population-Based Lung Cancer Screening in Korea
Nayoung Lee, Republic of Korea
16:27 OA16.07: Discussant
Milena Cavic, Serbia
16:27 Q&A
**15:45 - 16:45 OA17: Next Steps in Locally Advanced NSCLC: Optimizing Techniques and Choosing Populations That Benefit**

Track: Local-Regional Non-small Cell Lung Cancer

**ROOM: SUMMIT 2, LEVEL 3**

Chairs: Christine Bestvina, USA & Elisangela Carvalho, Brazil

15:45 Welcome & Introduction

Christine Bestvina, USA & Elisangela Carvalho, Brazil

15:47 OA17.03: Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)

Solange Peters, Switzerland

15:57 OA17.04: Long-Term Outcomes by Radiation Technique for Locally-Advanced Non-small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years

Stephen Chun, USA

16:07 OA17.05: Association Between Pre-Treatment Circulating Immune Biomarkers and Survival in Stage III NSCLC: A Translational Analysis From NRG-RTOG 0617

Mitchell Machtay, USA

16:17 OA17.06: The Predictive Value of PD-L1 levels on Circulating Stromal Cells in Unresectable Stage 3 NSCLC Treated with Chemoradiation

Steven Lin, USA

16:27 OA17.07: Discussant

Matthew Hatton, UK

16:37 Q&A

---

**17:00 - 18:00 PL04: Special Plenary Session 4: TNM for Lung, Mesothelioma and Thymic Cancers - Update on the Proposals for the 9th Edition of TNM Staging**

**ROOM: 406, LEVEL 4**

Chairs: Ramon Rami-Porta, Spain & Paul van Schil, Belgium

17:00 Welcome & Introduction

Ramon Rami-Porta, Spain & Paul van Schil, Belgium

17:02 PL04.03: 9th Edition TNM Staging Classification: Lung Cancer

Hisao Asamura, Japan

17:32 PL04.04: 9th Edition TNM Staging Classification: Mesothelioma

Valerie Rusch, USA

17:42 PL04.05: 9th Edition TNM Staging Classification: Thymic

Enrico Ruffini, Italy

17:52 Q&A

---

**18:00 – 20:00 Poster Viewing Networking Reception (Poster Session 2: P2) with Presenters in Attendance**

**ROOM: EXHIBIT HALL, LEVEL 4**

**19:00 – 20:00 Concurrent Industry Sponsored and Satellite CME Symposia**

**FOR FURTHER INFORMATION, PLEASE SEE PAGES 233 & 234.**

**20:30 – 24:00 IASLC Benefit Supporting Early Career Researchers**
Editor-in-Chief: Emily Stone, MBBS, PhD, FRACP, St. Vincent’s Hospital, Sydney and School of Clinical Medicine, UNSW, Sydney, Australia.

**JTO Clinical and Research Reports** is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing of the following article types in particular:

- Phase I trials
- Well-performed single-arm phase II trials
- Small to moderate-sized randomized phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports

Now indexed in PubMed Central!
07:00  HOD02.04: Medical Oncology  
Kirsty Lee, Hong Kong

08:10  Q&A

07:30 - 08:15  MTE14: Real World Challenges in Integrating Immunotherapy in Our Clinical Practice  
Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

ROOM: 405C, LEVEL 4  
07:30  MTE14.01: What Is the Role of Immune Checkpoint Inhibition in a Patient with an Autoimmune Disease?  
Yuko Oya, Japan

07:45  MTE14.02: IO Use in Patient with Active Infection Such as COVID-19, TB, HIV  
Lizza Hendriks, Netherlands

08:00  Q&A

07:30 - 08:15  MTE15: Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Chemo-Immunotherapy  
Track: Small Cell Lung Cancer and Neuroendocrine Tumors

ROOM: SUMMIT 2, LEVEL 3

07:30  MTE15.01: What Is the Role for PCI and Thoracic RT in ES-SCLC?  
Suresh Senan, Netherlands

07:45  MTE15.02: How Do We Select Second-Line Systemic Therapy in ES-SCLC?  
Ticiana Leal, USA

08:00  Q&A
08:30 - 10:00  PL05: Plenary Session 5: Transforming Discovery into Treatments in Lower Middle Income Regions

ROOM: 406, LEVEL 4  
Chairs: Daniel Tan, Singapore & Pyng Lee, Singapore

08:30  Welcome & Introduction  
Daniel Tan, Singapore & Pyng Lee, Singapore

08:32  PL05.03: Insights into Lung Cancer Evolution from the TRACERx and PEACE Studies  
Mariam Jamal-Hanjani, UK

08:47  PL05.04: State of the Art Management of Early Stage Disease  
Alan Sihoe, China

09:02  PL05.05: Precision Management of Oligometastatic Disease  
Jai Prakash Agarwal, India

09:17  PL05.06: Access to Novel Treatments and Clinical Trials  
Ross Soo, Singapore

09:32  Q&A

10:00 – 10:45  Coffee Break

ROOM: EXHIBIT HALL, LEVEL 4  
Refreshments Provided

10:00 - 10:45  IASLC Business Meeting

ROOM: NICOLL 2, LEVEL 3  
Not for CME Credit  
Refreshments Provided

10:05 - 11:00  PC04: Press Conference

ROOM: 327, LEVEL 3  
Not for CME Credit

10:45 - 11:45  ES34: Implementing Lung Cancer Screening in Asia Unique Challenges and Opportunities

Track: Screening and Early Detection  
ACCME Accredited By IASLC

ROOM: 406, LEVEL 4  
Chairs: Claudia Henschke, USA & Pan-Chyr Yang, Taiwan

10:45  Welcome & Introduction  
Claudia Henschke, USA & Pan-Chyr Yang, Taiwan

10:47  ES34.03: The First Million Screens in U.S.: What Does It Tell Us  
Gerard Silvestri, USA

10:59  ES34.04: Lung Cancer Screening in Europe: What Have We Learnt?  
John Field, UK

11:11  ES34.05: Implementing Screening in Australia: The Challenges of a Diverse Landscape  
Annette McWilliams, Australia

11:23  ES34.06: Lung Cancer Screening in Asia Unique Challenges and Opportunities  
Pyng Lee, Singapore

11:35  Q&A

10:45 - 11:45  ES35: Who, When and How to Give Chemotherapy in the Era of Immunotherapy for NSCLC All-Comers?

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy  
ACCME Accredited By IASLC

ROOM: 405C, LEVEL 4  
Chairs: Fiona McDonald, UK & Nandini Menon, India

10:45  Welcome & Introduction  
Fiona McDonald, UK & Nandini Menon, India

10:47  ES35.03: The Case for Combination Chemo-Immunotherapy Over Sequential Treatment in Advanced NSCLC  
Cheryl Ho, Canada

10:59  ES35.04: The Case for Immunotherapy First Followed by Chemotherapy in Advanced NSCLC  
Myung-Ju Ahn, Republic of Korea

11:11  ES35.05: Chemotherapy After Immunotherapy Failure - What is the Best Strategy?  
Clarissa Baldotto, Brazil

11:23  ES35.06: Integrating Radiotherapy with Chemotherapy in Metastatic NSCLC  
Alexander Louie, Canada

11:35  Q&A

10:45 - 11:45  ES36: Extensive-Stage SCLC

Track: Small Cell Lung Cancer and Neuroendocrine Tumors  
ACCME Accredited By IASLC

ROOM: 405B, LEVEL 4  
Chairs: Stephen Liu, USA & Hidehito Horinouchi, Japan

10:45  Welcome & Introduction  
Stephen Liu, USA & Hidehito Horinouchi, Japan

10:47  ES36.03: Latest Updates for Upfront Systemic Therapy in ES-SCLC  
Misty Shields, USA

10:59  ES36.04: Smoking Cessation Data in Oncology Clinical Trials - What Are We Missing?  
Bill Evans, Canada

11:11  ES36.05: State of the Art in Novel Agents for SCLC  
Byoung Chul Cho, Republic of Korea

11:23  ES36.06: Applying Emerging Biomarkers in SCLC  
Triparna Sen, USA

11:35  Q&A
10:45 - 11:45  ES37: Actions Towards Equity
Track: Patient Advocacy  
ROOM: NICOLL 3, LEVEL 3  
Chairs: Lillian Leigh, Australia & Stefania Vallone, Italy

10:45  Welcome & Introduction  
Lillian Leigh, Australia & Stefania Vallone, Italy

10:47  ES37.03: Tobacco Moment: The Role of the Oncologist in a Cancer Patient’s Smoking Cessation  
Lawson Eng, Canada

10:52  ES37.04: Actions from Africa in Addressing Unmet Needs in Lung Cancer  
Caleb Egwuenu, Nigeria

11:04  ES37.05: Actions from Latin America in Addressing Unmet Needs in Lung Cancer  
Luis Corrales, Costa Rica

11:16  ES37.06: Improving Radiotherapy Access in Countries with Limited Resources  
Shekinah Elmore, USA

11:28  ES37.07: Importance of Implementation Science to Promote Health Equity in Lung Cancer Screening  
Nicole Rankin, Australia

11:40  Q&A

10:45 - 11:45  MA15: Bringing New Discoveries into Early Phase Clinical Trials
Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy  
ROOM: 405A, LEVEL 4  
Chairs: Junko Tanizaki, Japan & Roy S. Herbst, USA

10:45  Welcome & Introduction  
Junko Tanizaki, Japan & Roy S. Herbst, USA

10:47  MA15.03: Harnessing Cornification and Tumor Microenvironment for Evaluation of Immunotherapy Efficacy in Squamous Cell Lung Carcinoma  
Minlin Jiang, China

10:52  MA15.04: Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer  
Adam Grippin, USA

11:02  MA15.06: Association of Pathomics-based MHC-II Assessment with NSCLC Immunotherapy Efficacy  
Jaeding Liu, China

11:07  Q&A

11:10  MA15.07: NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC  
Roy Herbst, USA

11:15  MA15.08: Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naive Metastatic NSCLC  
Adam Schoenfeld, USA

11:20  MA15.09: Ph 2 Trial of IO102-10103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma  
Jonathan Riess, USA

11:25  MA15.10: Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for Advanced NSCLC with Untreated Brain Metastases: Nike Trial (LOGIK2004)  
Yuko Tsuchiya-Kawano, Japan

11:30  MA15.11: A Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies: Phase II Results Updates  
Meiqi Shi, China

11:35  Q&A

10:45 - 11:45  MA16: Innovations in the Treatment of Stage III NSCLC
Track: Local-Regional Non-small Cell Lung Cancer  
ROOM: SUMMIT 1, LEVEL 3  
Chairs: Christine Bestvina, USA & Sue Yom, USA

10:45  Welcome & Introduction  
Christine Bestvina, USA & Sue Yom, USA

10:47  MA16.03: Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial  
Michiel Smeenk, Netherlands

10:52  MA16.04: Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used  
Roberto Serna Blasco, Spain

10:57  MA16.05: Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC  
Juan Li, China

11:02  MA16.06: Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study  
Cheryl Ho, Canada

11:07  Q&A

11:16  MA16.08: The Efficacy of MR-Guided Hypo-Fractionated Radiotherapy and Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer  
Pengxin Zhang, China

11:21  MA16.09: Evaluation of the Diagnostic Performance of AI Accompanied by CT Images in the Differentiation of Malignant or Benign MLN in NSCLC  
Yusuf Kahya, Turkey

11:26  MA16.10: An Update 5 Years of Randomized Phase 2 Study (PRot-BM Trial)  
Oscar Arrieta, Mexico

11:31  MA16.11: Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI) vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC  
Amin Nassar, USA

11:36  Q&A
10:45 - 11:45  MA17: Current Standards and Future Directions in Mesothelioma

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ROOM: NICOLL 1, LEVEL 3

Chairs: Joachim Aerts, Netherlands & Wendy Cooper, Australia

10:45  Welcome & Introduction

Joachim Aerts, Netherlands & Wendy Cooper, Australia

10:47  MA17.03: Determining the Clinical Utility of a Breath Test to Screen Asbestos-Exposed Persons for Pleural Mesothelioma.

Kevin Lamote, Belgium


Andrea Wolf, USA

10:57  MA17.05: Real World Outcomes of Immunotherapy (IO) for Pleural MES0thelioma in Australia - RIOMeso

Nicholas McNamee, Australia

11:02  MA17.06: Surgical Results of EORTC 1205, a Randomized Phase II Study of Surgery for Mesothelioma Preceded or Followed by Chemotherapy

Paul Van Schil, Belgium

11:07  Q&A

11:07  MA17.08: Whole-Genome CRISPR Screening Reveals Genetic Vulnerabilities and Therapeutic Targets in Malignant Pleural Mesothelioma

Duo Xu, China

11:12  MA17.09: BAPI Deficiency Inflames the TME & is a Candidate Biomarker for Improved Immunotherapy in Malignant Pleural Mesothelioma

Yongqian Shu, Switzerland

11:17  MA17.10: miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors

Farhad Kosari, USA

11:22  MA17.11: Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT Axis That is Reversible via PRX3 Inhibition

Dean Fennell, UK

11:35  Q&A

10:45 - 11:45  OA18: Targeting Molecular Drivers of Tumour Immunity

Track: Tumor Biology – Preclinical Biology

ROOM: SUMMIT 2, LEVEL 3

Chairs: Nir Peled, Israel & Arutha Kulasinghe, Australia

10:45  Welcome & Introduction

Nir Peled, Israel & Arutha Kulasinghe, Australia

10:47  OA18.03: Surfaceome of TP53-Mutant NSCLC Reveals a Distinct Subtype with Immunotherapy Vulnerability, Characterized by Co-occurring PTPRD Mutant

Xiaoting Cai, China

12:00 - 13:00  ES38: Cost and Accessibility of Oncology Treatments for Lung Cancer

Track: Global Health, Health Services, and Health Economics

ROOM: NICOLL 3, LEVEL 3

Chairs: Yiqing Huang, Singapore & Wee-Yao Koh, Singapore

12:00  Welcome & Introduction

Yiqing Huang, Singapore & Wee-Yao Koh, Singapore

12:02  ES38.03: Access to Radiotherapy in the Management of Lung Cancer

Mei-Ling Yap, Australia

12:14  ES38.04: The Development of Fast Followers for Cancer Care: Opportunities & Challenges

Gilberto Lopes, USA

12:26  ES38.05: Access to Systemic Therapies in Developing Nations - Challenges and Opportunities

Nandini Menon, India

12:38  ES38.06: Cost-Effectiveness of Immunotherapy in NSCLC

Pedro Aguiar, Brazil

12:50  Q&A

12:00 - 13:00  ES39: Next Generation Immunotherapies: Are We There Yet?

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

ROOM: 406, LEVEL 4

Chairs: Tom John, Australia & Julie Brahmer, USA

12:00  ES39.01: Chair

Tom John, Australia & Julie Brahmer, USA

12:02  ES39.03: Emerging Strategies Eg Combinations with Newer Immune Checkpoint Targets-TIGIT, LAG3, TIM3

Puey Ling Chia, Singapore
12:14  ES39.04: Immunotherapy Beyond Immune Checkpoints (Vaccines, Cytokines Etc)
Edward Garon, USA

12:26  ES39.05: Cellular Therapy in NSCLC: Challenges and Opportunities
Melissa Johnson, USA

12:38  ES39.06: Integrating RT into the Immunotherapy Treatment Paradigm in Advanced Disease
Fiona McDonald, UK

12:50  Q&A

12:00 - 13:00  ES40: Unresectable Mesothelioma
Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ROOM: 405C, LEVEL 4
Chairs: Aaron Mansfield, USA & Yukari Tsubata, Japan

12:00  Welcome & Introduction
Aaron Mansfield, USA & Yukari Tsubata, Japan

12:02  ES40.03: Current Systemic Therapy Options
Maria Disselhorst, Netherlands

12:14  ES40.04: Future Biomarker Driven Treatment
Dean Fennell, UK

12:26  ES40.05: Role of Radiation in Mesothelioma
Nicholas Bucknell, Australia

12:38  ES40.06: Supportive Care during Treatment
Rachel Thomas, UK

12:50  Q&A

12:00 - 13:00  ES41: Joint IASLC-ESTRO Session

ROOM: NICOLL 2, LEVEL 3
Chairs: Nicolaus Andratschke, Switzerland & Andrea Bezjak, Canada

12:00  Welcome & Introduction
Nicolaus Andratschke, Switzerland & Andrea Bezjak, Canada

12:02  ES41.03: New Neoadjuvant/Adjuvant Strategies for Resectable Disease
Malinda Itchins, Australia

12:14  ES41.04: New Strategies for Unresectable Disease
Ken Harada, Japan

12:26  ES41.05: The Challenge of Equipoise When Comparing Surgical vs. Non-surgical Strategies in Stage III NSCLC
Erin Gillaspie, USA

12:32  ES41.06: The Challenge of Equipoise When Comparing Surgical vs. Non-surgical Strategies in Stage III NSCLC
Alexander Louie, Canada

12:38  ES41.07: Biomarkers for Patient Selection and Monitoring
Gerard Hanna, UK

12:50  Q&A

12:00 - 13:00  MA18: Refining Practice and Redefining Standards in SCLC
Track: Small Cell Lung Cancer and Neuroendocrine Tumors

ROOM: 405A, LEVEL 4
Chairs: Margot Lehman, Australia & Bin-Chi Liao, Taiwan

12:00  Welcome & Introduction
Margot Lehman, Australia & Bin-Chi Liao, Taiwan

12:02  MA18.03: Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated Versus Conventional Fractionated Concurrent Chemoradiation for LS-SCLC
Nan Bi, China

Michael Farris, USA

12:12  MA18.05: Biomarkers for Brain Metastases Risk and Survival Benefit of Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer
Li Li, China

12:17  MA18.06: Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503
Chinmay Haridas, USA

12:22  Q&A

12:30  MA18.08: A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis
Yoko Agemi, Japan

12:35  MA18.09: Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - G0IRC-01-2019 CeLEBrATE Trial
Giuseppe Lamberti, Italy

12:40  MA18.10: Phase 2 Multicohort Study of CC-90011, a LSD1 Inhibitor, in Combination with Nivolumab in Patients with Advanced Lung Cancer
Enric Carcereny, USA

12:45  MA18.11: A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients
Min Hee Hong, Republic of Korea

12:50  Q&A

12:00 - 13:00  MA19: Emerging Technologies in Lung Cancer Screening
Track: Screening and Early Detection

ROOM: SUMMIT 1, LEVEL 3
Chairs: Helmut Prosch, Austria & Claudia Henschke, USA

12:00  Welcome & Introduction
Helmut Prosch, Austria & Claudia Henschke, USA

12:02  MA19.03: Sex Differences in the Prediction of Future Lung Cancer Risk Based on a Single Low-Dose Chest Computed Tomography Scan
Florian Fintelmann, USA
**12:00 - 13:00 OA19: Novel Targets and Biomarkers**

**Track:** Tumor Biology - Translational Biology

**ROOM:** 405B, LEVEL 4

**Chairs:** Kenneth O’Byrne, Australia & Esra Akbay, USA

12:00 **Welcome & Introduction**
Kenneth O’Byrne, Australia & Esra Akbay, USA

12:02 **OA19.03:** Exportin 1 Inhibition Constraints Lineage Plasticity and Histological Transformation through Downregulation of SOX2
Alvaro Quintanal-Villalonga, USA

12:12 **OA19.04:** MEF2Dhigh Pericytes Orchestrate an Immunosuppressive Perivascular Niche and Curtail Immunotherapy Efficacy of Lung Cancer
Bai Xue, China

12:22 **OA19.05:** Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
Seshiru Nakazawa, USA

12:32 **OA19.06:** CRTAM Acts as a Checkpoint of Immune-related Adverse Events Uncoupling Efficacy and Toxicity During Immunotherapy
Si-Cong Ma, China

12:42 **OA19.07:** Discussant
Dominic Rothwell, UK

12:52 **Q&A**

---

**13:15 – 14:15** Lunch Break

**ROOM:** EXHIBIT HALL, LEVEL 4

**Lunch Provided**

---

**14:30 - 15:30 ES42: Models to Improve Lung Cancer Care**

**Track:** Global Health, Health Services, and Health Economics

**ROOM:** NICOLL 3, LEVEL 3

**Chairs:** Shalini Vinod, Australia & Melody Qu, Canada

14:30 **Welcome & Introduction**
Shalini Vinod, Australia & Melody Qu, Canada

14:32 **ES42.03:** Quality Models to Improve Cancer Care and Find Value-Based Propositions for High/Middle/Low Income Countries
Vedner Guerrier, USA

14:44 **ES42.04:** Diversity in Clinical Trials - How Do We Ensure a Safe Space and Access
Anne-Marie Baird, Ireland

14:56 **ES42.05:** Real World Data and Value Driven Outcomes - Opportunities and Limitations
Susan Harden, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Track/Room/Level</th>
<th>Chairs</th>
<th>Lecture/Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:08</td>
<td>ES42.06: Models of Nursing Care in Lung Cancer</td>
<td>Room: 405A, LEVEL 4</td>
<td>Chairs: Malinda Itchens, Australia &amp; Jordi Remon, France</td>
<td>Anne Fraser, New Zealand</td>
</tr>
<tr>
<td>15:20</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>ES43: Integrating Immunotherapy in Metastatic NSCLC Patients</td>
<td>Room: 405B, LEVEL 4</td>
<td>Chairs: Malinda Itchens, Australia &amp; Jordi Remon, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ES43.03: Checkpoint Inhibition for Concogene-Addicted Disease (EGFR, ALK, ROS1)</td>
<td></td>
<td></td>
<td>Hidetoshi Hayashi, Japan</td>
</tr>
<tr>
<td></td>
<td>ES43.04: Best Sequencing Strategies for Patients with KRAS Mutations - When to Use Chemo IO vs KRAS Inhibitors</td>
<td></td>
<td></td>
<td>Pilar Garrido, Spain</td>
</tr>
<tr>
<td></td>
<td>ES43.05: Selecting a Patient for CTLA4 Inhibition</td>
<td></td>
<td></td>
<td>Maurice Perol, France</td>
</tr>
<tr>
<td></td>
<td>ES43.06: Duration of Immune Checkpoint Inhibitor: Stop or Continue After 2 Years?</td>
<td></td>
<td></td>
<td>Marina Garassino, USA</td>
</tr>
<tr>
<td>15:20</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>ES44: Thymic Epithelial Tumour</td>
<td>Room: SUMMIT 2, LEVEL 3</td>
<td>Chairs: Yuki Katsuya, Japan &amp; Bin-Chi Liao, Taiwan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ES44.03: From Diagnosis to Surgery</td>
<td></td>
<td></td>
<td>Harish Mithiran, Singapore</td>
</tr>
<tr>
<td></td>
<td>ES44.04: Developments and Challenges in the Pathology of Thymic Epithelial Tumors</td>
<td></td>
<td></td>
<td>Anja Roden, USA</td>
</tr>
<tr>
<td></td>
<td>ES44.05: The Role of Radiation Therapy in Localized Thymic Epithelial Tumours</td>
<td></td>
<td></td>
<td>Annemarie Shepherd, USA</td>
</tr>
<tr>
<td></td>
<td>ES44.06: Systemic Therapy for Advanced Thymic Epithelial Tumors</td>
<td></td>
<td></td>
<td>Yusuke Okuma, Japan</td>
</tr>
<tr>
<td>15:20</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
14:30 - 15:30  MA21: The Continuous Reshaping of Lung Cancer Staging

**Track: Pulmonology and Staging**

**ROOM: NICOLL 2, LEVEL 3**

Chairs: John Tam, Singapore & Jazmin Eckhaus, Australia

14:30  Welcome & Introduction
John Tam, Singapore & Jazmin Eckhaus, Australia

14:32  MA21.03: Preoperative Assessment of N2 Mediastinal Lymph Nodes in Non-small Cell Lung Cancer Using Ga-68 FAPI PET/CT: A Prospective Pilot Study
Kwon Joong Na, Republic of Korea

14:37  MA21.04: Novel Classification with Number or Zones of Involved Lymph Nodal Stations in Patients with Resected Non-Small Cell Lung Cancer
Atsushi Kamigaichi, Japan

14:42  MA21.05: What Is the Proper T Category for the Tumor with Additional Nodules in Different Lobes of Ipsilateral Lung?
Jing-Sheng Cai, China

14:47  Q&A

14:47  MA21.07: Validation of The Proposal in the IASLC R Classification to Upgrade Extracapsular Extension of Tumor in Nodes from RO to Incomplete Resection
Chenyang Dai, China

14:52  MA21.08: Usefulness of Bronchoscopic Cytology Pellets for Next Generation Sequencing
Chihiro Mimura, Japan

14:57  MA21.09: More Accurate Staging of Stage IV Lung Cancer Through EUS B of the Left Adrenal Gland
Filiz Oezkan, Germany

15:15  Q&A

14:30 - 15:30  OA21: MET Matters in NSCLC

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

**ROOM: 406, LEVEL 4**

Chairs: Nandini Menon, India & Rafael Rosell, Spain

14:30  Welcome & Introduction
Nandini Menon, India & Rafael Rosell, Spain

14:32  OA21.03: A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation
Shun Lu, China

14:42  OA21.04: Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
Natasha Leighl, Canada

14:52  OA21.05: Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Tae Min Kim, UK

15:02  OA21.06: ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
Xiuning Le, UK

15:12  OA21.07: Discussant
Alexander Drilon, USA

15:22  Q&A

14:30 - 15:30  OA22: Integration of Local Therapies with Modern Immune Checkpoint Inhibitors and Targeted Therapies in Metastatic NSCLC: When and How?

**Track: Metastatic Non-small Cell Lung Cancer – Local Therapies**

**ROOM: 405A, LEVEL 4**

Chairs: Nan Bi, China & Steven Kao, Australia

14:30  Welcome & Introduction
Nan Bi, China & Steven Kao, Australia

14:32  OA22.03: The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial
Aditya Juloori, USA

14:42  OA22.04: BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC
Yasir Elamin, USA

14:52  OA22.05: TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study
Ticiana Leal, USA

15:02  OA22.06: Changes in Cognition after Osimertinib, with or without SRS, in EGFRm NSCLC with Brain Metastases: a Pooled Analysis of RCTs
Yu Yang Soon, Singapore

15:12  OA22.07: Discussant
Daniel Gomez, USA

15:22  Q&A
15:45 - 16:45  PL06: Closing Plenary Session 6: Advances in Lung Cancer Pathology

ROOM: 406, LEVEL 4

Chairs: Chee Lee, Australia & Ignacio Wistuba, USA

15:45  Welcome & Introduction
Chee Lee, Australia & Ignacio Wistuba, USA

15:47  PL06.03: NeoPathology? The Role of Pathology in the Setting of Neoadjuvant Treatment for NSCLC
Keith Kerr, UK

16:07  PL06.04: Assessment of Pathological Response to Neoadjuvant Therapy? Results of the IASLC Interobserver Study
Sanja Dacic, USA

16:27  Q&A

16:30  Closing Remarks and Invitation to WCLC 2024 San Diego, USA

On Demand  HOD03: Highlights of the Day - Tuesday Abstracts

HOD03.01: Radiation Oncology
Ken Harada, Japan

HOD03.02: Medical Oncology
Deborah Zhou, Australia

HOD03.03: Medical Oncology
Aaron Tan, Singapore

Recommended for Early Career Researchers

ACCME Accredited By IASLC

Live-Streamed

Recommended for Early Career Researchers

ACCME Accredited By IASLC
Now Available!
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer.

The IASLC’s latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results, from both a diagnostic and clinical perspective.

The IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer is a useful reference for anyone involved in treating lung cancer patients, from allied health professionals to surgeons. All pathologists and medical oncologists should have access to these best practices.

Visit the IASLC booth for a free hard copy or scan the QR code to order online.
**P1.01 Track: Risk Factors, Risk Reduction & Tobacco Control**

- **P1.01-01** Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)
  - Ernest Nadal, Spain

- **P1.01-02** Diabetes as Prognostic and Predictive Factors in Resected Non-small Cell Lung Cancer, from a Large Chinese Cohort
  - Yifan Guo, China

- **P1.01-03** Novel Anoikis-Related Prognostic Signatures of NSCLC Based on mRNA-lncRNA Analysis and Primary Validation in CRISPR Screening
  - Anlin Li, China

- **P1.01-04** Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients
  - Cristina Candal-Pedreira, Spain

- **P1.01-05** A Predictive Model for Postoperative Recurrence of Lung Cancer Based on Multi-omic Machine Learning
  - Zhihao Chen, China

- **P1.01-06** A Phase IB Trial Of Nivolumab for Immunoprevention of Bronchial Dysplasia Progression in High-risk Current and Former Smokers
  - Hui Yu, USA

- **P1.01-07** Asbestos Exposure and Small Cell Lung Cancer. Systematic Review and Meta-Analysis
  - Julia Rey Brandariz, Spain

- **P1.01-08** A Content Analysis E-cigarette Retailer Websites and Nicotine Addiction Among E-cigarette Users - Mixed Methods Study from Malaysia
  - Chandrashekhar Steeramareddy, Malaysia

- **P1.01-09** Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis
  - Zeyi Liu, China

- **P1.01-10** Peptic Ulcer and Long-Term Risk of Lung Cancer: A Prospective Cohort Study from UK Biobank
  - Zhuangzhuang Liu, China

- **P1.01-11** Lung Cancer Risk Prediction Model Incorporating Liver Function Markers: a Prospective Cohort Study from the UK Biobank
  - Xiang Yu Sun, China

- **P1.01-12** “A Core Part of the Whole Thing…”: Stakeholder Views on Offering Smoking Cessation Support in Lung Cancer Screening
  - Nathan Harrison, Australia

- **P1.01-13** Amelioration of the Toll of Air Pollution on Lung Cancer
  - Renelle Myers, Canada

---

**P1.02 Track: Tumor Biology – Preclinical Biology - Molecular Therapeutic Targets**

- **P1.02-01** HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window
  - Yunan Tian, China

- **P1.02-02** Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib for KRAS-Mutant NSCLC
  - Baohui Han, China

- **P1.02-03** Identifying Biomarkers of Response to Ensartinib, Lorlatinib, and Alectinib in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)
  - Christopher Bulow, USA

- **P1.02-04** Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD
  - Zeyi Liu, China

- **P1.02-05** METTL3-mediated m6A Modification of SRPK1 Promotes Lung Adenocarcinoma Through Aerobic Glycolysis
  - Zeyi Liu, China

- **P1.02-06** Glucose Deprivation Promotes Pseudo-Hypoxia and De-differentiation in Lung Adenocarcinoma
  - Claudio Scaglìo, USA

---

**P1.03 Track: Tumor Biology – Preclinical Biology – Omics Approaches**

- **P1.03-01** Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio
  - Zhen-bin Qiu, China

- **P1.03-02** Combination of Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment
  - Yuanliu Nie, China

---

**P1.04 Track: Tumor Biology – Preclinical Biology - Radiobiology**

- **P1.04-01** CDK4/6 Inhibitor Improves Radioimmunotherapy Efficacy via Inducing PD-L1 Transcription through Increased c-Jun Activation in NSCLC
  - Yan Gong, China

- **P1.04-02** Ablative Radiation Induces Distinct Sequential Waves of Mitotic and Innate Immune Death Regulated through DNA Repair Pathways
  - Harriet Gee, Australia

---

**P1.05 Track: Tumor Biology – Preclinical Biology – Regulatory Mechanisms**

- **P1.05-01** Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis
  - Yvan Guo, China

---

**P1.06 Track: Tumor Biology – Preclinical Biology – Tumor Immunity**

- **P1.06-01** NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation
  - Haiyu Zhou, China
P1.06-02 Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer Through ID1 Downregulation
Ignacio Gil-Bazo, Spain

P1.06-03 Effect and Mechanism of ASNS Remodeling the Metastatic Lymph Node Immune Microenvironment in Lung Cancer
Min Li, China

P1.06-04 Phenotype Mapping of Patient-Derived Small Cell Lung Cancer Organoids Illuminate Subtype-Specific Therapeutic Vulnerability
Takahiro Fukushima, Japan

P1.07 Track: Tumor Biology – Translational Biology – Disease Modeling
P1.07-01 Collective Lung Cancer Migration Using a 3D Model
Helmut Popper, Austria

P1.08 Track: Tumor Biology – Translational Biology - Drug Resistance
P1.08-01 CoxMoE: A Deep Learning Model Predicts Survival and Response in T790M Positive NSCLC Patients Treated with Third-Generation EGFR-TKI
Ning Lou, China

P1.09 Track: Tumor Biology – Translational Biology - IO
P1.09-01 Anti-Cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-small Cell Lung Cancer
Kanishtha Rangamunwa, Australia

P1.10 Track: Tumor Biology – Translational Biology – Novel Targets
P1.10-01 Enrichment of FA/HR Aberrations in ATM/ATR-mutated NSCLC was Accompanied by Distinct Molecular Features and Poor Prognosis
Yang Shao, China

P1.11 Track: Tumor Biology – Translational Biology - Omics and New Technologies
P1.11-01 Utility of ctDNA Monitoring During Surveillance in Surgically Resected NSCLC Patients
Shuta Ohara, Japan

P1.12 Track: Tumor Biology – Translational Biology - Translational Therapeutics
P1.12-01 CD66c Activates EGFR Signalling Pathway and Promotes EMT in Lung Adenocarcinoma
Yushi Li, Hong Kong

P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC
Yang-Si Li, China

P1.09-03 Clinical Relevance of Serum Lipids in Increasing NK Cell Anti-tumor Activity Within NSCLC Tumor Microenvironment
Yang Yang, China

P1.09-04 Characterization of the Immunosuppressive Function of UPPhigh Tumor Cells in Lung Adenocarcinoma and Its Association with Immunotherapy
Yin Li, China

P1.09-05 SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche
Zhang Yanpei, China

P1.09-06 SRSF9 Fuels PD-L1+ Regulatory T Cells and Cancer Oncogenic Pathway to Drive Hyperprogression Under Immunotherapy
Zhong-Hi Dong, China

P1.09-07 Obesity Promotes Lung Carcinogenesis Through T-cell Immune Dysfunction
Sai Yendamuri, USA

P1.09-08 Characterization of the Expression of BTN1A1 Exclusive to PD-L1/PD-1 Axis in Small Cell Lung Cancer Using Spatial Biology Approach
Stephen Yoo, USA

P1.09-09 DCBLD2 Impacts Tumor Immune-Vascular Microenvironment of Lung Cancer by Inducing Pro-angiogenic Macrophages
Bai Xue, China

P1.09-10 SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche
Zhang Yanpei, China

P1.09-11 SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche
Zhang Yanpei, China

P1.09-12 Emboldened Tumor metabolism under metabolic imaging
Yu Bai, China
P1.12-03 LP-184, a Tumor Site Activated Small Molecule Acylfulvene, is Effective Preclinically in Subsets of Lung Cancer
Reginald Ewesuedo, USA

P1.12-04 In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models
Lara McGrath, USA

P1.12-05 Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy May Improve Treatment Outcomes in SqNSCLC
Dipti Thakkar, Singapore

P1.12-06 BiFeO₃@PANI Sensitizes LKB1-Deficient LUAD to Radiotherapy via Induction of Tumoral Lipid Oxidation and Ferroptosis
Zeqin Guo, China

P1.12-07 Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer
Ke Xu, China

P1.12-08 Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-small Cell Lung Cancer (NSCLC)
So Yeon Kim, USA

P1.12-09 APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer
Emily Lin, Taiwan

P1.12-10 Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway
Moshe Giladi, Israel

P1.12-01 A Proteomics-Annotated Risk Model to Predict Recurrence in Stage I Non-small Cell Lung Cancer
Ying Huang, China

P1.12-02 Deep Multi-omic Blood-Based Biomarker Discovery in People with Smoking History Demonstrates High Early Detection of Nsclc
Brian Koh, USA

P1.12-03 Proof-of-mechanism for a Diagnostic Probe Generating D5-Ethanol Asan On-Breath Reporter Molecule for Lung Cancer - Evolution Phase 1.
Marc Schee, UK

P1.12-04 The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial
Marc Schee, UK

P1.12-05 Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma
Claudio Scafoglio, USA

P1.12-06 Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer
Yee Fang Hum, Singapore

P1.12-07 A Novel Blood-Based DNA Methylation Panel for Detection of Lung Cancer at Very Early Stage
Rongxi Yang, China

P1.14-01 Strengthening the Screening of Lung Cancer in Europe (SOLACE) Project
Hans-Ulrich Kauczor, Germany

P1.14-02 Validation of Lung Cancer Risk Prediction Models in an Asbestos Exposed Population
Chellan Kumarasamy, Australia

P1.14-03 How Do Patients with Screening-Detected Pulmonary Nodules, Experience and React to Being under Surveillance?
Evangelos Katsampouris, UK

P1.14-04 European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial
Matthijs Oudkerk, Netherlands

P1.15-01 Optimised Lung Cancer Screening to Prevent Cardiovascular and Pulmonary Diseases Coupled with Primary Prevention: Results of the Baseline Round
Piergiorgio Muriana, Italy

P1.15-02 Cardiovascular Implications of Lung Cancer Screening Program: The Smokers Health Multiple Actions (SMAC) study
Piergiorgio Muriana, Italy

P1.15-03 Dedicated Cardiovascular Screening in Lung Cancer Screening: Preliminary Results from the European 4-IN-THE-LUNG-RUN Trial
Matthijs Oudkerk, Netherlands

P1.15-04 Awareness, Understanding, and Follow Up of Women with Dense Breasts Identified on Low-Dose CT Screening for Lung Cancer
Rowena Yip, USA

P1.16-01 Artificial Intelligence-Assisted Quantitative CT parameters in Predicting the Degree of Risk of Solitary Pulmonary Nodules
Long Jiang, China

P1.16-02 Three Dimensional Volumetric Analysis Is Useful to Improve Diagnostic Accuracy in Early-Stage Lung Adenocarcinoma.
Shinji Kaneda, Japan

P1.16-03 Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer
Jung Seop Eom, Republic of Korea

P1.16-04 Differences in Incidentally Detected Versus Screening Detected Stage I Lung Cancer Surgery Patients
Shubham Gulati, USA
P1.16-05 Quality Initiative to Improve Timeliness of Care in a Rapid Assessment Lung Cancer Clinic
Shakti Dabholkar, Australia

P1.17 Track: Screening and Early Detection - Program Design

P1.17-01 Lung Cancer Screening in Low- and Middle-income Countries - Report on Status, Challenges and Perspectives from WCLC2022 and LALCA2023
Milena Cavic, Serbia

P1.17-02 Interval of Computed Tomography after Lung Cancer Surgery Follow-Ups Did Not Affect Survival
Natsumi Maru, Japan

P1.17-03 Cost-effectiveness of Low-dose Computerized Tomography Lung Cancer Screening in High-risk Non-smokers and Smokers in Hong Kong
Herbert Loong, Hong Kong

P1.17-04 Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy
Pierluigi Novellis, Italy

P1.17-05 Cost-Effectiveness of LDCT Screening in Never Smokers at High Lung-Cancer Risk
Szu-Chun Yang, Taiwan

P1.17-06 Integrated TB and Lung Cancer Screening in Viet Nam
Thang Dao, Viet Nam

P1.17-07 Impact of Lung Cancer Screening with Low-Dose Chest Computed Tomography Scan in an Elderly Population: A Retrospective Cohort Study
Hyeong-Jun Noh, Republic of Korea

P1.17-08 Program Factors Associated with the Psychosocial Outcomes of Lung Cancer Screening: A Systematic Review
Kathleen McFadden, Australia

P1.18 Track: Screening and Early Detection - Recruitment + Screening Uptake

P1.18-01 Association between Cognitive Impairment & Lung Cancer Screening Use among People with Significant Smoking History: Population-Based Study
Hermine Poghosyan, USA

P1.18-02 Coordinating Lung Cancer Screening with Screening Mammography: The CALM Study
Robert Smith, USA

P1.18-03 Patients with Smoking-Associated Atherosclerotic Cardiovascular Diseases: Does Prevalung Refines Eligibility for Screening?
David Boulware, France

P1.18-04 First Annual Lung Cancer Screening Day in the United States Saturday November 12 2022
Elia Kazerooni, USA

P1.18-05 Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening
Kate Parker, New Zealand

P1.18-06 Barriers to Completing Low Dose CT Scan for Lung Cancer Screening
Lye-Yeng Wong, USA

P1.19 Track: Pulmonology and Staging

P1.19-01 Pleural Invasion of Primary Lung Cancer Withinterstitial Lung Disease Treated by Surgical Resection
Takahisa Koizumi, Japan

P1.19-02 Results of Comparing Seven Lymph Node Staging Systems in Completely Resected Non-small Cell Lung Cancer Patients
Jing-Sheng Cai, China

P1.19-03 External Validation of the T Category for the Patients with Bronchus Involvements: A Population-Based Study
Jing-Sheng Cai, China

P1.19-04 The Prognosis of the T2N0M0 Non-small Cell Lung Cancer with Visceral Pleural Invasion Is Dependent on Tumor Size
Jing-Sheng Cai, China

P1.20 Track: Pathology and Biomarkers - Artificial Intelligence in Pathology

P1.20-01 Computed Tomography-based Deep Learning Model for Spread Through Air Spaces Prediction in Ground-Glass Predominant Lung Adenocarcinoma
Meng-Wei Lin, Taiwan

P1.20-02 Improved Diagnosis of Lung Neuroendocrine Tumors: Role of Proliferative Activity and Deep Learning
Sylvie Lantuejoul, France

P1.20-03 Solute Carrier Transporter-based Machine Learning Model Predicts Efficacy of Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer
Mengting Shi, China

P1.20-04 Predictability of Actionable Mutations in NSCLC using Attention-Based Multiple-Instance Learning on H&E Images
Pierre Murchan, Ireland

P1.20-05 Leveraging NLP to Identify Biomarker-Eligible Patients
John Ruckdeschel, USA

P1.20-06 Mapping the Histopathological Landscape of Lung Adenocarcinoma Using Self-Supervised Learning Artificial Intelligence
John Le Quesne, UK

P1.21 Track: Pathology and Biomarkers - Biomarkers for Immuno-oncology

P1.21-01 Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement
Sungjin Kim, Republic of Korea

P1.21-02 Genetic Susceptibility to Immune Checkpoints Blockade Resistance
Jose Benitez, Spain

P1.21-03 Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC
Hui Kang Xie, China
P1.21-04  Role of HLA-I as a Molecular Prognostic Factor for Long Term Responders in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Enric Carcereny, Spain

P1.21-05  The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity
Xuequan Wang, China

P1.21-06  Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
Diego de Miguel Perez, USA

P1.21-07  Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer
Javier Baena, Spain

P1.21-08  Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC)
Joe Wei, Australia

P1.21-09  Radiomic Signature of Identities Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC)
Nathaniel Braman, USA

P1.21-10  PD-1 and Interleukin-10-Receptor Expression by T Lymphocytes in Malignant and Benign Pleural Effusions
Berta Mosleh, Austria

P1.21-11  Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS:50%
Jennifer Suga, USA

P1.21-12  Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation
Soo-Ryum Yang, USA

P1.21-13  Genomic Correlates of Response to PD-1 Blockade Plus Chemotherapy in Patients with Untreated Advanced NSCLC
Tao Jiang, China

P1.21-14  LIPi-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS:50%
Elizabeth Dudnik, Israel

P1.21-15  Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab
Mingjia Li, USA

P1.21-16  NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy
Dhruv Bansal, USA

P1.21-17  DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-small Cell Lung Cancer
Yang Shao, China

P1.21-18  Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy
Young Kwang Chae, USA

P1.21-19  Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI
Young Kwang Chae, USA

P1.22-01  Clinical Characteristics and Biomarkers in Lung Cancer: A Comparison Between Screened and Non-Screened Cohorts
Mary Pasquinelli, USA

P1.22-02  Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer
Yoon-La Choi, Republic of Korea

P1.22-03  Ventana ALK (DSF3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC
Li-Xu Yan, China

P1.22-04  Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study
Natasha Leighl, Canada

P1.22-05  Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases
Faran Polani, USA

P1.22-06  Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey
Jackie Fenemore, UK

P1.22-07  Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer
Petra Rietschel, USA

P1.22-08  Biomarker Testing Trends from a Global Patient-Reported Outcomes Registry
Heather Law, USA

P1.22-09  Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma
Yang Shao, China

P1.22-10  RET Fusion (RETfus+) Driven Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study with Histologic Correlation
Alina Basnet, USA

P1.22-11  Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study
Xue Lin, China

P1.22-12  Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia
Edwin Njoto, Indonesia

P1.22-13  Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes
Oscar Arrieta, Mexico
<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.22-14</td>
<td>A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC Kei Morikawa, Japan</td>
</tr>
<tr>
<td>P1.22-15</td>
<td>Identification of MIF as a Multiple Primary Lung Cancer Related Gene Based on RNA Sequencing Technology and Study of Its Function Haoshuai Yang, China</td>
</tr>
<tr>
<td>P1.22-16</td>
<td>ERBB3 and BRAF Mutations as Potential Biomarkers in Non-small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments Lucía Robado de Lope, Spain</td>
</tr>
<tr>
<td>P1.22-17</td>
<td>Addressing Lung Cancer Biomarker Testing Through the ECHO Model - Results from a 3-State Pilot in the United States Lauren Rosenthal, USA</td>
</tr>
<tr>
<td>P1.22-18</td>
<td>Immediate Biomarkers Profiling of Actionable NSCLC Panel from a Digitized H&amp;E Biopsy Image Nurit Paz-Yaacov, Israel</td>
</tr>
<tr>
<td>P1.22-19</td>
<td>Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions Mihaela Aldea, France</td>
</tr>
<tr>
<td>P1.22-20</td>
<td>High Incidence of Ischemic Stroke in Patients with Non-small Cell Lung Cancer and RET Fusions Wei-Hsun Hsu, Taiwan</td>
</tr>
<tr>
<td>P1.22-21</td>
<td>Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations Wei-Hsun Hsu, Taiwan</td>
</tr>
<tr>
<td>P1.23-01</td>
<td>ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC Sampurna Chatterjee, USA</td>
</tr>
<tr>
<td>P1.23-02</td>
<td>Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC Ullas Batra, India</td>
</tr>
<tr>
<td>P1.23-03</td>
<td>Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer Richa Dawar, USA</td>
</tr>
<tr>
<td>P1.23-04</td>
<td>Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC Kenneth O'Byrne, Australia</td>
</tr>
<tr>
<td>P1.23-05</td>
<td>Clinical Utility of Plasma-Based Comprehensive Genomic Profiling in Korean Non-small Cell Lung Cancer Patients Jiwon Lee, Republic of Korea</td>
</tr>
<tr>
<td>P1.23-06</td>
<td>Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer Laura Bonanno, Italy</td>
</tr>
<tr>
<td>P1.23-07</td>
<td>Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study Marco Tagliamento, France</td>
</tr>
<tr>
<td>P1.24-01</td>
<td>Is It Possible to Predict STAS before Surgery in Non-small Cell Lung Cancer? Yusuf Kahya, Turkey</td>
</tr>
<tr>
<td>P1.24-02</td>
<td>Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer Edwin Ostrin, USA</td>
</tr>
<tr>
<td>P1.24-03</td>
<td>TAT3 Predicts Favourable Prognosis in Advanced Non small Cell Lung Cancer Xuequan Wang, China</td>
</tr>
<tr>
<td>P1.24-04</td>
<td>A Comparative Analysis of Secreted MiRNAs Reveals Candidate Biomarkers for Pleural Mesothelioma Detection Agniszka Kraft, Switzerland</td>
</tr>
<tr>
<td>P1.24-05</td>
<td>The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients Hanie Abolfathi, Canada</td>
</tr>
<tr>
<td>P1.24-06</td>
<td>Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer Luning Mao, China</td>
</tr>
<tr>
<td>P1.24-07</td>
<td>Association between Whole Blood ACTB methylation and Lung Cancer: A Case-Control Study Rongxi Yang, China</td>
</tr>
<tr>
<td>P1.24-08</td>
<td>Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer Chen-Guang Liu, China</td>
</tr>
<tr>
<td>P1.24-09</td>
<td>Spatially Defined Immune Response Signatures in 5μm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome Ping Yang, USA</td>
</tr>
<tr>
<td>P1.24-10</td>
<td>Clinical Implication of Karyopherin a 2, Which Is a Nuclear Export Protein in Lung Adenocarcinoma Seoree Kim, Republic of Korea</td>
</tr>
<tr>
<td>P1.24-11</td>
<td>Single-Cell Profiling Reveals the Trajectory of FOLR2+TAMs to Tregs in the Progression of Lung Adenocarcinoma Yuchen Han, China</td>
</tr>
<tr>
<td>P1.24-12</td>
<td>Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoradiotherapy Fangjie Liu, China</td>
</tr>
<tr>
<td>P1.24-13</td>
<td>Role of EVs-miR-200b-5p Mediating TGF-β Signaling Pathway in Radiation Pneumonia Wei Feng, China</td>
</tr>
<tr>
<td>P1.24-14</td>
<td>Clinicopathological Characteristics of Pulmonary Squamous Cell Carcinoma with KDM5D Copy Number Loss Takuo Hayashi, Japan</td>
</tr>
<tr>
<td>P1.24-15</td>
<td>Prognostic Molecular and Genetic Factors in Early Stage Non-small Cell Lung Cancer Gizem Özçibik Isik, Turkey</td>
</tr>
</tbody>
</table>
P1.24-16  Discovery of Novel Biomarkers of Small Cell Lung Cancer Using Highly Sensitive Quantitative Proteomic Analysis
Seung Hyeun Lee, Republic of Korea

P1.24-17  The Paradoxical Behavior of Kappa When Quantifying Agreement in Histological Subtype Classification Among Thoracic Pathologists
Kay See Tan, USA

P1.25  Track: Early-Stage Non-small Cell Lung Cancer - Pushing the Boundaries: Changing Paradigms and Outcomes

P1.25-01  Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study)
Shinya Katsumata, Japan

P1.25-02  Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis
Jacobi Hines, USA

P1.25-03  Comparing Timeliness of Treatment for Surgery vs Radiation for Early-Stage Lung Cancer
Jeffrey Zhu, USA

P1.25-04  Days Alive and Out of Hospital After Thoracoscopic Surgery and Exploratory Study the Correlation on the PRO of First Discharge Day
 Wenwu Liu, China

P1.25-05  Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimist Multi-Country Analysis
Melinda Daumont, Belgium

P1.25-06  Real-world Primary Treatment Patterns in Stages I-III Non-small Cell Lung Cancer
Jessica Donington, USA

P1.25-07  Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of Early-EGFR
Tu Dao, Viet Nam

P1.25-08  Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2cm or Smaller
Jung-Jyh Hung, Taiwan

P1.25-09  TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIIB NSCLC
Ross Soo, Singapore

P1.25-10  Delays to Early-Stage Lung Cancer Surgery: Patient and Surgeon Perspectives
Sydney Kantor, USA

P1.25-11  Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC
Haoran Xia, China

P1.25-12  Adequacy of Mediastinal Lymph Node Dissection in the Setting of New NCCN Guidelines: Simplified Method From A Rural Hospital
Kevin Kennedy, USA

P1.25-13  Enhanced Assessment of Recurrence Risk of Stage I NSCLC By Combined Adenocarcinoma Grading System and Serum Proteomic Testing
Harvey Pass, USA

P1.25-14  Delayed Recovery Time of Percutaneous Oxygen Saturation After Stair-climbing as a Predictor of Postoperative Complications
Kensuke Takei, Japan

P1.25-15  Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT
Estelamari Rodriguez, USA

P1.25-16  Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study
Carolyn Presley, USA

P1.25-17  Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life
Julie Ahn, Australia

P1.25-18  Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation
Tao Chen, China

P1.25-19  Patient-Reported Outcomes and Exercise Capacity in a Real-Life Setting in Non-small Cell Lung Cancer Patients Undergoing Radiotherapy
Yolande Lievens, Belgium

P1.26  Track: Early-Stage Non-small Cell Lung Cancer - Getting Smaller: More Minimally Invasive Approaches

P1.26-01  A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy Versus Lobectomy for Early-Stage Lung Cancer
Yang Chen, China

P1.26-02  Random Matrix Based Multiple Scattering Component Extraction Can Significantly Shorten the Time of Lung Segmentectomy
Hua Liu, China

P1.26-03  Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer
Hong-Ji Li, China

P1.26-04  Increased Risk of Death from Other Causes After Lobectomy Compared with Sublobar Resection in Lung Cancer Patients
Masayuki Nakao, Japan

P1.26-05  Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule
Sebron Harrison, USA

P1.26-06  Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study
Masahiro Adachi, Japan

P1.26-07  Trisegmentectomy is Indicated for Non-Small Cell Lung Cancer in the Left Upper Division
Paula Ugade Figueroa, USA

P1.26-08  Usefulness and Safety of Chest Tube Removal Regardless of Drainage Volume of Pleural Effusion in Patients Who Underwent Pulmonary Resection
Tomohiro Haruki, Japan

P1.26-09  Wedge Resection vs. Segmentectomy for NSCLC Size ≤2 CM, Consolidation Tumor Ratio >0.25, cNO: A Multicenter Propensity-Score Matching Analysis
Tetsuya Isaka, Japan
P1.26-10 Is Mediastinal Lymph Node Dissection Necessary in Segmentectomy for Peripheral Stage IA (≤2 CM) Non-small-Cell Lung Cancer? Hiroyuki Adachi, Japan

P1.27 Track: Early-Stage Non-small Cell Lung Cancer - Innovation and New Technology

P1.27-01 Comparison of Physical and Mental Load Between VATS and RATS Based on NASA-Task Load Index: A Prospective Cohort Study Weijie Zhan, China

P1.27-02 Artificial Intelligence Analysis Predicts Highly Malignant Potential in Small-Sized Lung Adenocarcinoma Yujin Kudo, Japan

P1.27-03 Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis Chao Zhang, China

P1.27-04 Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung Yong Kwang Chae, USA

P1.27-05 Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More Meng-Min Wang, China

P1.27-06 Construction of Postoperative Prediction Model Based on the New IASLC Grading System for Early Stage Lung Adenocarcinoma Hong Jiang, China

P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy Lucia Robado de Lope, Spain

P1.27-08 Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials Ben Ponvilawan, USA

P1.27-09 Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) Baohui Han, China

P1.27-10 NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma Fang-Liang Lu, China

P1.28 Track: Local-Regional Non-small Cell Lung Cancer

P1.28-01 Adherence to Post-treatment Surveillance Guidelines in Non-small Cell Lung Cancer - A Veteran’s Health Administration Cohort Ryan Randle, USA

P1.28-02 EVs-miRNAs-Based Models in Predicting Radiosensitive Patients with Local Advanced-NSCLC Who Can Benefit from Adaptive Radiotherapy Haihua Yang, China

P1.28-03 Adjuvant CCRT Does Not Improve Survival Outcomes in Patients with ECE Positive Pathologic Stage III-N2 NSCLC After Upfront Surgery Jeonga Son S, Republic of Korea

P1.28-04 Should Older Patients with Stage III Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy? Neil Wallace, Australia

P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT Doses During ChemoRT for NSCLC Correlates with Lymphocyte Decline Michael MacManus, Australia

P1.28-06 Treatment Strategies for Locally-advanced NSCLC with Invasive T4 Tumors: A SEER Analysis in the Era of Precision Medicine Min Wang, China

P1.28-07 Dose-Response Relationship Between Radiotherapy and Loss in Lung Perfusion Determined From DECT and PET/CT in NSCLC Mathieu Gaudreauit, Australia

P1.28-08 Definition of Resectable Stage III Non-small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group Eleni Xenophontos, Belgium

P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel Mariana Brandao, Belgium

P1.28-10 Differential Kinetics of Blood and Immune Subpopulations for Cisplatin vs. Sensitizing Paclitaxel Radiotherapy in Locally Advanced Lung Cancer Yuhchyau Chen, USA

P1.28-11 Recurrence Dynamics for Pathological N2 Non-small Cell Lung Cancer Depending on the IASLC Residual Tumor Descriptor In Ha Kim, Republic of Korea

P1.28-12 Korean Real-world Data on Unresectable Stage III Non-small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy Hyung-Joo Oh, Republic of Korea
**WCLC 2023 POSTER SESSIONS**

**POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023**

**Display Time:** Monday, September 11, 2023 – 10:00 – 20:00

**Presenters in Attendance:** Monday, September 11, 2023 – 18:00 – 20:00

---

**P2.01 Track: Local-Regional Non-small Cell Lung Cancer - Novel Therapies and Trials**

**P2.01-01** Initial Result of the ImmunoPET Phase I Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr-Durvalumab (MEDI4736) PET/CT

Fiona Hegi-Johnson, Australia

**P2.01-02** Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer

Nan Wu, China

**P2.01-03** Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC

Kewei Ma, China

**P2.01-04** An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC

Ashley Horne, UK

**P2.01-05** The Safety and Efficacy of Induction Chemomunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC

Min Tang, China

**P2.01-06** NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC

Jay Lee, USA

**P2.01-07** Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE)

Steven Lin, USA

---

**P2.02 Track: Local-Regional Non-small Cell Lung Cancer - Toxicities of Multimodality Therapy**

**P2.02-01** PROphylactic Pirenidonefor Prevention of Radiation Induced Pneumonitis in Patients with Lung Cancer (PROPeR study)

Naveen Mummudi, India

**P2.02-02** Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer

Nikhil Yegya-Raman, USA

**P2.02-03** Association of irAEs with the Efficacy of PACIFIC Regimen in Patients with Unresectable Stage III NSCLC: WJOG11518L/SUBMARINE

Yukihiro Toi, Japan

---

**P2.03 Track: Metastatic Non-small Cell Lung Cancer – Local Therapies**

**P2.03-01** Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients

Rui Zhou, China

**P2.03-02** Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients

Ren Luo, China

**P2.03-03** Upfront or Delayed Cranial RT in Oncogene Mutated NSCLC with Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial

Anil Tibdewal, India

**P2.03-04** Predicting Risk of Distant Brain Failure with Radiosurgery and Systemic Therapy in a Diverse NSCLC Brain Metastasis Population

Rupesh Kotecha, USA

**P2.03-05** Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer

Rui Fu, China

**P2.03-06** Treatment-related Pneumonitis in Non-small Cell Lung Cancer Treated with Thoracic RT Plus TKI: A Systematic Review and Meta-Analysis

Yinnan Meng, China

---

**P2.04 Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

**P2.04-01** HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade Plus Chemotherapy in Untreated Advanced NSCLC

Tao Jiang, China

**P2.04-02** AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC

Terufumi Kato, Japan

**P2.04-03** EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours

Sally Lau, USA

---

**P2.05 Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Biomarker**

**P2.05-01** Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study

Yuki Katayama, Japan

**P2.05-02** MAPKi/MAPK5 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

Gabriele Minuti, Italy
P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort
Sarah Cook, Canada

P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Petra Rietschel, USA

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC
Yiqing Huang, Singapore

P2.05-06 An Artificial Neural Network System to Predict the Immune-related Adverse Events Based on the RNA Data of ORIENT-3 Study
Tongji Xia, China

P2.05-07 Immunotherapy Prognostication with Thoracic CT Contrastive Self-Supervised Learning in Patients with Non-Small Cell Lung Cancer
Tafadzwa Chaunzwa, USA

P2.05-08 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome
Anlin Li, China

P2.05-09 SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab
Samantha Low, UK

P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome
Anlin Li, China

P2.05-11 Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolic Analysis Based on Two Cohorts
Yun Fan, China

P2.05-12 Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance
Chuxia Su, China

P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1
Daniel Tan, Singapore

P2.05-14 Understanding Genomic and Social Determinants of Cancer Immunotherapy Outcome Across Ancestry
Jian Carrot-Zhang, USA

P2.05-15 Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPULAR and OAK Trials
Yanguo Liu, China

P2.05-16 Immune Suppressve Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy
Jia-Yi Deng, China

P2.05-17 A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PDI Combined With Chemotherapy
Liyuan Dai, China

P2.05-18 A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape
Zhong Lin, China

P2.05-19 Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC
Xinghao Ai, China

P2.06-03 Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
Banzhou Pan, China

P2.06-04 First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN
Xue Hou, China

P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of Patients with PFS ≥12 months in POSEIDON
Byoung Chul Cho, Republic of Korea

P2.06-06 Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC
Byoung Chul Cho, Republic of Korea

P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1801)
Si-Yang Liu, China

P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab
Angel Qin, USA

P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in CTONG1901
Julie Brahmer, USA

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPower-Lung 1
Mahmut Gümiss, Turkey

P2.06-11 Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial
Jinliang Wang, China

P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2
Khwaramze Shaverdashvili, USA

P2.07-01 Development of Postoperative Bronchopleural Fistula after Neoadjuvant Immunochemistry in Non-small Cell Lung Cancer: Case Reports
Kewei Ma, China
P2.07-02 Association between OS and Subsequent ICI in Control Arm Patients of First Line ICI-based RCTs of Advanced/Metastatic NSCLC: FDA Analysis
Oladimeji Akinboro, USA

P2.07-03 Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer
Biagio Ricciuti, USA

P2.07-04 Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO)
Joseph Bador, USA

P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry
Jordi Remon Masip, France

P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
Wallace Akerley, USA

P2.07-07 Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors
Lei Deng, USA

P2.07-08 Checkpoint Inhibitor Pneumonitis Model for NSCLC based on Preexisting Lung Ground Glass Opacities: Development and Validation
Xinyue Wang, China

P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?
Jair Bar, Israel

P2.08 Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy - TIPs

P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
Caicun Zhou, China

P2.08-02 STAR-121: Phase 3 Study of DOM and ZIM plus Chemotherapy in NSCLC with No Actionable Gene Alterations
Delvys Rodriguez-Abreu, Spain

P2.08-03 A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab
Edwin Yau, USA

P2.08-04 A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurutamab Vedotin (BA3021) Alone in Combination with Nivolumab
 Mariam Alexander, USA

P2.08-05 IMRPrinter: A Phase 1/1b Trial of IMU-201 (PDI-Vaxx) as Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC
Michal M. Boyer, Australia

P2.08-06 A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model
Jorge Nieva, USA

P2.08-07 EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC
Lei Deng, USA

POSTER SESSION 2: P2 - MONDAY, SEPTEMBER 11, 2023

P2.09 Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy - EGFR/HER2

P2.09-01 A Large Asian Real-World EGFR exon 20 Insertion Mutated NSCLC Dataset with Deep Genomic Characterization
Aaron Tan, Singapore

P2.09-02 Impact of Co-mutations on the Prognosis of Targeted Therapy in EGFR-Mutant Advanced NSCLC: A Result of Real-World Study
Sisi Pan, China

P2.09-03 Lazertinib vs Gefitinib in Treatment-Naive Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
Thanyanan Reungwetwattana, Thailand

P2.09-04 Treatment Adherence Disparities and Clinical Outcomes of Osimertinib Among Ethnic-Minority Patients with EGFR-Mutated NSCLC
Matthew Lee, USA

P2.09-05 Identification of Co-existing Genetic Alterations in Advanced Stage EGFR mutated NSCLC at Baseline and Disease Progression
Amber Rathi, India

P2.09-06 Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer
Jieran Long, China

P2.09-07 Safety and Efficacy of Aumolertinib in Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
Wei Fang, China

P2.09-08 Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial
Yoonsil Jang, Republic Of Korea

P2.09-09 A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A04 in Patients with EGFR Mutant Advanced NSCLC
Sun Min Lim, Republic of Korea

P2.09-10 Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment
Jin Kang, China

P2.09-11 JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC
Mi Ra Yu, Republic of Korea

P2.09-12 Real World Analysis Of Atezolizumab and Pemetrexed as First Line Treatment Patients with Advanced Stage NSCLC: A Randomized Clinical Trial in a U.S Veterans Affairs Medical Center
Katherine Zhou, USA

P2.09-13 CT-2016: Combination of Atezolizumab with Bevacizumab for First Line Treatment of Advanced NSCLC
Katherine Zhou, USA

P2.09-14 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Katherine Zhou, USA
P2.09-16 Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Wei Wang, China

P2.09-17 OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small-Cell Lung Cancer
Daniel Tan, Singapore

P2.09-18 FURVENT, Phase 3 Trial Testing Fumonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
Alexander Spira, USA

P2.09-19 Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression
Jun Li, China

P2.09-20 Updated Data of Osimertinib Rechallenge after Pneumonitis; A Multicenter Retrospective Cohort Study
Mihoko Imaji, Japan

P2.09-21 VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations
Sunghwan Kim, Republic of Korea

P2.09-22 Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs
Cheng Han, China

P2.09-23 A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)
Kageaki Watanabe, Japan

P2.09-24 Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD
Molly Li, Hong Kong

P2.09-25 Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR
Yohei Matsui, Japan

P2.09-26 Trials in Progress: Phase 1a/b study of ELVN-002, in Solid Tumors with HER2 Mutations, Amplification or Overexpression
Samantha Bowyer, Australia

P2.09-27 Effect of TPS3 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)
Jamie Feng, Canada

P2.09-28 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)
Laura Mezquita, Spain

P2.09-29 Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models
Sampurna Chatterjee, USA

P2.09-30 Intracranial Efficacy of Alatinib as First-line Treatment in Common/Uncommon EGFR-Mutant Advanced Non-small Cell Lung Cancer Patients
Ying Liang, China

P2.09-31 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)
Hua Lin Chen, China

P2.09-32 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Richeng Jiang, China

P2.09-33 Design, Synthesis and Assessment of Novel Molecule Against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC
Vikas Kumar, India

P2.09-34 Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China
Shun Lu, China

P2.09-35 Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases
Xixi Zheng, China

P2.09-36 MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases
Xin Tang, China

P2.09-37 Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers
Shirish Gadgeel, USA

P2.09-38 Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR-ex20ins+ NSCLC PDX Models
Sampurna Chatterjee, USA

P2.10 Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy - FUSIONS

P2.10-01 ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance
Malinda Itchins, Australia

P2.10-02 Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma A-LK-positive Cohort (A-Liquid)
Yuki Nakatani, Japan

P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study
Aaron Tan, Singapore

P2.10-04 Real-World Outcome of Metastatic ALK-Positive Non-small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Per Hydbring, Sweden

P2.10-05 Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK
Hannah Le, USA
P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers
Jane Sui, USA

P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC
Patients with Leptomeningeal Metastases
Tijmen van der Wel, Netherlands

P2.10-08 A New Prognostic Tool for Predicting the Overall Survival of ALK Positive Non-small Cell Lung Cancer with Brain Metastasis
Wei Feng, China

P2.10-09 Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study
Oscar Arrieta, Mexico

P2.10-10 Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer
Oscar Arrieta, Mexico

P2.10-11 Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer
Daniel Tan, Singapore

P2.10-12 Loss of EPHA2 Induces Primary Lorlatinib Resistance Through Sustained MAPK Activation
Anlin Li, China

P2.10-13 Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice
Oscar Arrieta, Mexico

P2.11 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - KRAS/MET

P2.11-01 A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer
Yaewon Yang, Republic of Korea

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION
Myung-Ju Ahn, Republic of Korea

P2.11-03 Synergistic Co-Targeting Of MYC And KRAS In Lung Cancer By Novel Ligand-Directed Inverted Chimeric RNAi Molecules
Yogitha Chareddy, USA

P2.11-04 A Phase IB Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations
Mariam Alexander, USA

P2.11-05 SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation
Chee Lee, Australia

P2.12 Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - Other

P2.12-01 Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer
Xinyu Song, China

P2.12-02 Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to “False” Decreases in Renal Function
Monica Chen, USA

P2.12-03 COVALENT-102: A Phase 1/ib Study of BMF-219, A Menin Inhibitor in Patients with Unresectable, Metastatic NSCLC, PDAC, and CRC
Sandip Patel, USA

P2.12-04 Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer
Jianing Chen, China

P2.12-05 Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan
Takaaki Tokito, Japan

P2.12-06 Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
Sarah Goldberg, USA

P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression
Joseph Treat, USA

P2.12-08 Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations
Guang-Ling Jie, China

P2.12-09 Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients With and Without Cardiac Comorbidities
Ping Yang, USA

P2.13 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Biomarkers and Radiomics

P2.13-01 Spatially Resolved Transcriptomics deciphers Inter- and Intra-Tumor Heterogeneity of Small Cell Lung Cancer
Xuie Sun, China

P2.13-02 Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity
Arkaadipta Mukherjee, India

P2.13-03 Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients
Ayman Ullah, USA

P2.13-04 Pathological Images Machine Learning Predicts Long Term Effects for Immunotherapy in Small-Cell Lung Cancer
Ryota Shibaki, Japan

P2.13-05 Spatiotemporal Heterogeneity of Transcription Factor-Based Subtype Assignment in Small Cell Lung Carcinoma
Mari Mino-Kenudson, USA
P2.13-06 A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer
Yu Ito, Japan

P2.13-07 Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC
Xinghao Ai, China

P2.13-08 Integrated Clinical and Radiomics Approach to Assess the Treatment Outcome of Combined Chemoimmunotherapy in Extensive-Stage SCLC
Yang Xia, China

P2.14 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - First Line Therapy

P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
Manuel Domíne Gómez, Spain

P2.14-02 First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study
Shengjie Sun, China

P2.14-03 Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study
Yuhei Harutani, Japan

P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
Rosario García-Campelo, Spain

P2.14-05 A Phase II Study of Sintilimab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer:SINC-E-01 Trial
Wei Huang, China

P2.14-06 A Phase II Trial Assessing the Safety and Efficacy of Tislelizumab Combined with Chemotherapy and Autologous NK Cells in Patients with ES-SCLC
Mingfang Zhao, China

P2.14-07 Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial
Shengxiang Ren, China

P2.15 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Preclinical

P2.15-01 Priming SCLC Vasculature to Facilitate NK Cell Attack
Navin Mahadevan, USA

P2.15-02 Distinct Tumor Microenvironment in SCLC as compared with NSCLC by Single Cell Analysis
Xuanhe Wang, China

P2.16 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Trials in Progress

P2.16-01 Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC
Mengxing Xie, China

P2.16-02 Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial
Noemi Reguart Aranyay, Spain

P2.16-03 RY2101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer
Claire Mulvey, USA

P2.16-04 Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil
Mauro Zukin, Brazil

P2.16-05 Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): A Pilot Phase II study
Elizabeth Dudnik, Israel

P2.16-06 A Phase 2 Study of ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC
Melissa Johnson, USA

P2.17 Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Relapse and Salvage Therapy

P2.17-01 Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer
Hossein Borghaei, USA

P2.17-02 Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study
Apar Kishor Ganti, USA

P2.17-03 CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer
Ying Cheng, China

P2.17-04 Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC
Hui Zhu, China

P2.17-05 Characterizing Mechanisms of Treatment Resistance in SCLC
Siddhartha Devarakonda, USA

P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial
Jose Antonio Lopez-Vilariño, Spain

P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis
Balazs Halmos, USA
### P2.18 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Clinical

**P2.18-02 Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma**  
Dean Fennell, UK

**P2.18-03 Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma**  
Logan Roof, USA

**P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmuNoMeso)**  
Edgar Aguirre, Argentina

**P2.18-05 Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis**  
Florence Wu, Canada

**P2.18-06 Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry**  
Dani Samankula, Australia

### P2.19 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Clinical Trial in Progress

**P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma**  
Timothy Yap, USA

**P2.19-02 [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers**  
Young Kwang Chae, USA

### P2.20 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Thymic Malignancy

**P2.20-01 A Precision Medicine Approach by Performing Comprehensive Cancer Genome Profiling of Thymomas and Recurrent Thymomas**  
Jessica Evangelista, Italy

**P2.20-02 Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review**  
Anna McGuire, Canada

**P2.20-03 Clinical Outcome of Patients with Thymic Carcinoma Treated with Preoperative Induction Therapy Followed by Surgical Resection**  
Osamu Noritake, Japan

**P2.20-04 Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas**  
Anja Roden, USA

**P2.20-05 The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors**  
Lye-Yeng Wong, USA

**P2.20-06 Does Radical Thymectomy Influence the Neurological Outcome in Patients Aged over 65 with Thymoma and Myasthenia Gravis?**  
Filippo Lococo, Italy

### P2.21 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Translational

**P2.21-01 Inflammatory Biomarkers as Prognostic Factors for Malignant Pleural Mesothelioma**  
Keval Yerigeri, USA

**P2.21-02 A Combination of PD-1 and TIGIT Checkpoint Blockade Elicits a Strong Antitumor Response in the Patient and Mouse Pleural Mesothelioma Model**  
Huaikai Shi, Australia

**P2.21-03 Novel microRNAs are Associated with Presence of Pleural Mesothelioma and Response to Chemotherapy**  
Michaela Kirschner, Switzerland

**P2.21-04 The Significance of BAP1 and MTAP/CDKN2A Expression in Well-Differentiated Papillary Mesothelial Tumours: A Series of 21 Cases**  
Sarita Prabhakaran, Australia

**P2.21-05 Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma**  
Andrea Bille, UK

**P2.21-06 Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry**  
Dani Samankula, Australia

**P2.21-07 Is the Modified Frailty Index (mFI) a Reliable Predictor of Complications after Cardiac Surgery?**  
Sabita Jiwnani, India

**P2.21-08 Novel microRNAs are Associated with Presence of Pleural Mesothelioma and Response to Chemotherapy**  
Michaela Kirschner, Switzerland

**P2.21-09 Long-term Survival in Patients with Primitive Neuroectodermal Tumors of Thorax: Does Size Matter?**  
Akif Turna, Turkey

**P2.21-10 Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma**  
Andrea Bille, UK

**P2.21-11 A Novel Proteomic Technique Uncovers New Diagnostic Biomarkers for Malignant Pleural Mesothelioma**  
Kevin Lamote, Belgium

**P2.21-12 Mutant NF2-Driven De Novo Pyrimidine Synthesis is a Metabolic Vulnerability in Malignant Pleural Mesothelioma**  
Duo Xu, China

**P2.21-13 Single-Cell Dissection Reveals Mesothelial Heterogeneity and Dysfunctional Immunity in Malignant Pleural Mesothelioma**  
Duo Xu, China

### P2.22 Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Other Thoracic Malignancy

**P2.22-01 Single-nuclei RNA Sequencing Reveals Heterogeneity and Malignancy in Pulmonary Sarcomatoid Carcinoma**  
Fei Zhou, China

**P2.22-02 Long-term Survival in Patients with Primitive Neuroectodermal Tumors of Thorax: Does Size Matter?**  
Akif Turna, Turkey

**P2.22-03 NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer**  
Maria Virginia Sanchez-Becerra, France

**P2.22-04 Is the Modified Frailty Index (mFI) a Reliable Predictor of Complications after Thoracic Esophagectomy?**  
Sabita Jiwnani, India

**P2.22-05 Unique Genomic Features of Malignant Pleural Mesothelioma**  
Sarita Prabhakaran, Australia

**P2.22-06 Does Radical Thymectomy Influence the Neurological Outcome in Patients Aged over 65 with Thymoma and Myasthenia Gravis?**  
Filippo Lococo, Italy
P2.23 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Nursing and Allied Health

P2.23-01 An Untold Story About Living with Low Muscle Mass and its Impact Throughout Curative Radiotherapy Treatment for Lung Cancer
Nicole Kiss, Australia

P2.23-02 Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A)
Naoki Furuya, Japan

P2.23-03 The Role of The Mesothelioma UK Nurse Increases the Number of Patients Accessing Legal Representation, Financial Entitlement.
Louise Gilham, UK

P2.23-04 Changes in Physical Activity, Fatigue, and Six-Minute Walk Distance Among Lung Cancer Patients Before and After Chemotherapy
P-Hua Chang, Taiwan

P2.23-05 Counseling & Rehabilitation of Lung-Cancer Sufferers by Nursing Personnel
S Pal, India

P2.23-06 Evaluation/Analysis of Opinions of Oncology Nurses. What We Need to Do?
S Pal, India

P2.23-07 Crucial, Complex, Caring: A Professional Development Framework for Lung Cancer Nurse Specialists
Jackie Fenemore, UK

P2.23-08 Determination of the Best Cut-off Point To Establish the Performance of a Mexican Cohort with Non-small Cell Lung Cancer in the 6-Minute Walk Test
Oscar Arrieta, Mexico

P2.25 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Supportive Care

P2.25-01 Geriatric Assessment in Lung Cancer Surgery Patients and Caregivers
Jae Kim, USA

P2.25-02 Resiliency among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Novel Pilot Supportive Care Intervention Study
Carolyn Presley, USA

P2.25-03 Functional Independence of Older Adults after Lung Cancer Surgery: Final Analysis of a Prospective Observational Study
Tomonari Mizutani, Japan

P2.25-04 Unmet Social Needs and Spiritual Well-Being of Lung Cancer Surgery Patients and Family Caregivers from the United States
Dede Teteh, USA

P2.26 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Symptom Management

P2.26-01 Managing Pain Lung Cancer Patients -- Contribution of Oncology Nurses
S Pal, India

P2.26-02 Patient-Reported Symptom Monitoring Improves 1-Year Quality of Life in Lung Cancer Patients: the SYMPRO-Lung Trial
Annemarie Becker-Commissaris, Netherlands

P2.27 Track: Patient Advocacy

P2.27-01 Does Patient Experience with Robotic Thoracic Surgery Influence Their Willingness to Pay for It?
Yogita S. Patel, Canada

P2.27-02 Stigma-Reducing Interventions for Lung Cancer and Other Smoking-Related Respiratory Diseases: A Systematic Review
Nathan Harrison, Australia

P2.27-03 Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins
Jun Zhang, USA

P2.27-04 Advocates Unite to Increase Lung Cancer Research Funding
Dusty Donaldson, USA

P2.27-05 Everywhere Is Local: Applying Lessons from the Community to Areas across the Globe
Maureen Rigney, USA

P2.28 Track: Global Health, Health Services, and Health Economics - COVID 19

P2.28-01 Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic
Jean Henri Maselli-Schoueri, Brazil

P2.28-02 Impact of the Covid-19 Pandemic on Lung Cancer Diagnosis in a German Comprehensive Cancer Center. Are we Still Paying the Debt?
Jane Winantea, Germany

P2.28-03 Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis
Fred R. Hirsch, USA

P2.29 Track: Global Health, Health Services, and Health Economics - Digital Solutions

P2.29-01 Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain
Edurne Arriola Aperribay, Spain

P2.29-02 The LungTrust Methodology
Andrés Cardona, Colombia

P2.30 Track: Global Health, Health Services, and Health Economics - Health Economics

P2.30-01 Cost Estimation of Radiotherapy for Local Control and Overall Survival Benefit of Lung Cancer in the Australian Population
Shalinith Vinod, Australia

P2.30-02 Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer
Yong Yuan, USA
P2.31 Track: Global Health, Health Services, and Health Economics - Real World Data

P2.31-01 Characterization of Survival Disparities among Asian Pacific Islander (API) Subgroups in Stage IV NSCLC in California
Robert Hsu, USA

P2.31-02 Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution
Robert Hsu, USA

P2.31-03 Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data
David Morrell, USA

P2.31-04 Implementation of a Novel Chart Rounds Application to Facilitate Lung Radiotherapy Plan Peer-Review in a Virtual Environment
Naba Ali, USA

P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data
Melina Marmarelis, USA

P2.31-06 Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
Shivani Mhatre, USA

P2.31-07 Incidence and Survival Outcomes of Lung Cancer Post-Double Lung Transplant and its Association with Graft Rejection
Hye Sung Kim, USA

P2.31-08 Disparities in Representation of Older Adults, Women, Racial/Ethnic Minorities in Lung Cancer Clinical Trials: Meta-analysis
Kaushal Parikh, USA

P2.31-09 Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service
Pedro Aguiar Jr, Brazil

P2.31-10 Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy
Jyoti Patel, USA

P2.31-11 Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia
Sanuki Tissera, Australia

P2.31-12 Sexual Dysfunction on Patients with Lung Cancer: Results from the CLARIFY Project
Aylen Ospina Serrano, Spain
GET SOCIAL

Remember to use the official hashtag: #WCLC23

@IASLC
facebook.com/IASLC
@iaslungcancer
linkedin.com/IASLC
IASLC
IASLC

JOIN THE CONVERSATION

Official Journal of the International Association for the Study of Lung Cancer

Editor-in-Chief: Alex A. Adjei, MD, PhD, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

jto.org
<table>
<thead>
<tr>
<th>EP01</th>
<th>Track: Risk Factors, Risk Reduction &amp; Tobacco Control</th>
</tr>
</thead>
</table>
| EP01.01-01 | Adenocarcinoma and Small Cell Lung Cancer Risk Associated with Occupation in Women  
Alberto Ruano Ravina, Spain |
| EP01.01-02 | Prognostic Analysis and Nomogram Establishment of Synchronous Dual Primary Lung Cancer: Based on Multicenter Data  
Haoshuai Yang, China |
| EP01.01-03 | Postoperative Course of Completion Pneumonectomy May Be Better than Predicted  
Kana Kinjo, Japan |
| EP01.01-04 | Postoperative Course of Surgically Resected Lung Cancer Patients in Preserved Ratio Impaired Spirometry  
Hayato Konno, Japan |
| EP01.01-05 | Poor Sleep Quality in Lung Cancer Patients  
Andika Putra, Indonesia |
| EP01.01-06 | Casual Effects of Some Chronic Respiratory Diseases on Squamous Cell Lung Cancer: A Mendelian Randomization Study  
Xiaoxue Cheng, China |
| EP01.01-07 | Sex Difference Indicate Survival Disparity in Resected NSCLC, from a Large Chinese Cohort  
Yifen Guo, China |
| EP01.01-08 | Histopathological Risk Factors Correlation in Patients with Non-small Cell Lung Cancer  
Aldiesa Pritami, Indonesia |
| EP01.01-09 | Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule  
Yuichi Saito, Japan |
| EP01.01-10 | Long-term Surivals Associated with High Levels of Na⁺ and Ca²⁺ in the Blood of Patients with Stage IV Lung Cancer  
Feng-Ming (Spring) Kong, China |
| EP01.01-11 | Familial Aggregation in Non-small Cell Lung Cancer  
Sindhura Durga Chitikela, India |
| EP01.01-12 | Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program  
Daniela Bafunno, Italy |
| EP01.01-13 | Awareness and Perceptions of Compliance with the Nigerian Tobacco Control Law Among Young Adults in Lagos, Nigeria  
Adebusayo Sipe, Nigeria |

<table>
<thead>
<tr>
<th>EP02.01</th>
<th>Track: Tumor Biology – Preclinical Biology – Molecular Therapeutic Targets</th>
</tr>
</thead>
</table>
| EP02.01-01 | Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines  
Madeleine Berry, New Zealand |
| EP02.01-02 | Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer  
Daniel Kottmann, UK |
| EP02.01-03 | Suppression of Telomerase RNA Component Induces Autophagy and Ferroptosis in Lung Cancer via Regulation of AMP-activated Protein Kinase  
Wenmei Su, China |
EP02.01-04  Androgen Receptor Suppresses Lung Cancer Invasion and Cisplatin Resistance via Decreasing TPDS2 Expression  
Shiqing Liu, China

EP02.01-05  Using Siliibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases  
Yaxian Yang, China

EP02.01-06  TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer  
Hironori Hinokuma, Japan

EP02.01-07  DEPDC1 Expression and Mechanisms in Lung Adenocarcinoma: Insights into Proliferation and KIF2C Regulation  
Sisi He, China

EP02.01-08  SOX2 Deregulated Squamous Carcinomas Are Vulnerable to AKT3 Inhibition  
Wenrui Guo, UK

EP02.01-09  TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer  
Masaoki Ito, Japan

EP02.01-10  Dysfunction of FBXL5-mediated Ferrous Iron Homeostasis Suppresses Lung Cancer Growth  
Jun Lu, China

EP02.01-11  CSNK1D and CSNK1E Inhibition Regulates Autophagy by Promoting Autophagic Flux in Lung Cancer  
Wenmei Su, China

EP02.02  Track: Tumor Biology – Preclinical Biology – Omics Approaches

EP02.02-01  Genomic Correlates with Ancestry in Lung Squamous Cell Carcinoma  
Alison Taylor, USA

EP02.02-02  Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types  
Moshe Giladi, Israel

EP02.02-03  Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer  
Wuyan Xia, China

EP02.02-04  Lysimachia Capillipes Capilliposide C Modulates the Irradiation-Sensitivity of Lung Cancer through Regulation of STAT3-ERRFI1 Axis in Vivo  
Lucheng Zhu, China

EP02.02-05  Microbiome in Lung Cancer: Culture-Based Analysis Using Transtrhoracic Needle Biopsy (TTNB)  
KUAN-LI WU, Taiwan

EP02.02-06  Radiation-Induced SERPINE2 Expression Inhibit Abscopal Effect in Non-small Cell Lung Cancer via Exosomes  
Maria Isabel Idolor, Philippines

EP02.02-07  Machine Learning for Multi-Omics Data Identifies Vulnerabilities in a Subset of Squamous Cell Lung Cancers  
Duk Ki Kim, Republic of Korea

EP02.02-08  Identification of COL5A2+ Cancer-Associated Fibroblast in Solid Subtype of LUAD by Integrated Analysis of WGCNA and Single Cell RNA-seq  
Zhaoxuan Wang, China
EP02.04-07 Metformin Enhances Immune Checkpoint Inhibitor Efficacy in an Obesity-Specific Manner
Sai Yendamuri, USA

EP03.01 Track: Tumor Biology – Translational Biology - Disease Modeling
EP03.01-01 Genetic Alterations as Independent Prognostic Factors to Predict Organ-Metastases of Lung Cancer
Ann Valter, Estonia
EP03.01-02 Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants
Vanya Aggarwal, USA
EP03.01-03 Differences in Glucose and Energy Metabolism between Lung Squamous Cell and Lung Adenocarcinoma
Shanshan Xiao, China
EP03.01-04 The Role of Microenvironmental Biomechanics in Lung Cancer Development and Metastasis
Jian Gao, China

EP03.02 Track: Tumor Biology – Translational Biology - Drug Resistance
EP03.02-01 EGFR T790M Detection Differences by Original Mutation Types and Detection Samples
Jian Ni, China
EP03.02-02 mir-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in NSCLC Cells by Targeting USP37
Sei-hoon Yang, Republic of Korea
EP03.02-03 High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer
Hongfang Zhang, China

EP03.03 Track: Tumor Biology – Translational Biology - IO
EP03.03-01 IS1160 Transposon Mycobacterium Tuberculosis Detection in Lung Cancer - A Preliminary Study
Hana Faisal, Indonesia
EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer
Sanad Alhushki, Jordan
EP03.03-03 Comprehensive Analysis of Primary Immunotherapy-resistant Genes with Regard Immune Infiltration and Prognosis in Lung Adenocarcinoma
Jianxiong Deng, China
EP03.03-04 Decoding the Immune Dysfunction of Cancer Cachexia in Lung Cancer Patients
Laila Roisman, Israel
EP03.03-05 Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes
Xiaoshen Zhang, China
EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma
Dawei Yang, China

EP03.04 Track: Tumor Biology – Translational Biology - Novel Targets
EP03.04-01 Detection of Possible Targets in Aggressive Lung Cancer Using Molecular Abundances and Catalytic Action of Serine Hydrolases
Sven Hillinger, Switzerland
EP03.04-02 Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays
Fatemeh Ardeshir Larijani, USA

EP03.05 Track: Tumor Biology – Translational Biology - Omics and New Technologies
EP03.05-01 Aberrant Methylation of ZNFS77 As a Potential Prognostic Biomarker for Lung Adenocarcinoma
Batkhishig Munkhjargal, Japan
EP03.05-02 Genomic Landscape Features of Minimally Invasive Adenocarcinoma and Invasive Lung Adenocarcinoma
Bo Liu, China
EP03.05-03 Hollow-MnO2 Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment
Yu-fang Zhang, China
EP03.05-04 RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer
Nicolette Yun, USA
EP03.05-05 Non-Small Cell Lung Cancer: Artificial Intelligence, Complex System Analysis and Computer Simulation for Best Management.
Oleg Kshivets, Russian Federation
EP03.05-06 Identification of Oncogenic Non-coding Regions Inducing the ANKZF1 Expression in Lung Cancer by a Multi-omics Website Omsics3D
Chen Lian, China

EP03.06 Track: Tumor Biology – Translational Biology - Translational Therapeutics
EP03.06-01 Differential Anticancer Compound Response of Filipino Patient-derived Lung Adenocarcinoma Cells (GLO1) Against A549 Cell Line
Kim Claudette Fernandez, Philippines
EP03.06-02 Novel HDAC Inhibitor CG200745 Inhibit EMT and Induce Apoptosis in Lung Cancer Cells
Hak-Ryul Kim, Republic of Korea
EP03.06-03 The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients  
Zhenliang Shi, China

EP03.06-04 Development of an Inhibitor for the Treatment of Lung Cancer  
Amila Suraweera, Australia

EP03.06-05 Synthetic Lethality Targeting Programmed Cell Death Reverses the Osimertinib Resistance Induced by ARID1A Deficiency in LUAD  
Dantong Sun, China

EP03.06-06 KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil  
Pedro De Marchi, Brazil

EP04.01 Track: Screening and Early Detection - Biomarkers/Imaging Technology

EP04.01-01 The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum  
Michael Meyer, USA

EP04.01-02 Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer: A Screening-Based Study in High-Risk Participants  
Annamaria Catino, Italy

EP04.01-03 Advancing Malignancy Risk Stratification for Early-Stage Cancers in Lung Nodules by Combined Imaging and Electrical Impedance Analysis  
Dawei Yang, China

EP04.01-04 Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-small Cell Lung Cancer Using Digital Droplet PCR  
Caeli Zahra, Australia

EP04.01-05 True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer  
Michael Meyer, USA

EP04.01-06 Double Blind Evaluation of Circulating Cancer Associated Macrophage Like (CAML) Cells for Detection of Cancer in Pulmonary Nodules  
Martin Edelman, USA

EP04.01-07 Optimal Predictors for Lung Cancer Using High-Resolution CT  
Hirotugu Notsuda, Japan

EP04.01-08 Users’ Satisfaction and Usefulness of Cloud-based Computer Aided Quality Control System Using in Korean National Lung Cancer Screening Program  
Yeeol Kim, Republic of Korea

EP04.01-09 The Combination of a Seven-Autoantibody Panel with Computed Tomography Scanning Can Enhance the Diagnostic Efficiency of Lung Cancer  
Tianyu He, China

EP04.01-10 Metabolomic Biomarkers for Lung Cancer: A Systematic Review  
Zhangyan Lyu, China

EP04.01-11 AI-based Detection on Low-Dose CT: A Focus on Augmenting Model Performance  
Soo-Youn Ham, Republic of Korea

EP04.01-12 METTL7A Inhibits Cell Proliferation and M2-Like Polarisation of Tumor-Associated Macrophage in Lung Adenocarcinoma  
Junfan Pan, China

EP04.02 Track: Screening and Early Detection - Implementation

EP04.02-01 Impact of an Urban Based Lung Cancer Screening Program: Seven Year Follow-up  
Mary Pasquinelli, USA

EP04.02-02 Implementation of an Integrated Lung Cancer Screening Program at a Large Academic Community Health System in the U.S.  
Jannifer Stromberg, USA

EP04.02-03 Cost-Effectiveness Analysis of Artificial Intelligence Assisted Image Reading in Lung Cancer Screening  
Harriet Lancaster, Netherlands

EP04.02-04 Screening Success: A Review of Outcomes from Lehigh Valley Health Network’s Multi-Disciplinary Lung Cancer Screening Program  
Timothy Johnson, USA

EP04.04 Track: Screening and Early Detection - Nodule Management

EP04.04-01 Delay in Lung Cancer Diagnosis as a result of being Diagnosed as Pulmonary Tuberculosis in Riau Province  
Ananda Aulia, Indonesia

EP04.04-02 Incidental Lung Nodule Identification and Subsequent Diagnosis of Lung Cancer in a University Hospital in Hong Kong  
Lynn Yim-Wah Shong, China

EP04.04-03 Impact of a Lung Nodule Program in a Tertiary Care Academic Center in the United States  
Hari Keshava, USA

EP04.04-04 Relevance of AI (qCT) In Automated Progression Monitoring of Pulmonary Nodules in Follow-up Lung CT Scans  
Rohitashva Agrawal, India

EP04.04-05 Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis  
Yuki Misumi, Japan

EP04.04-06 Low-Dose CT Iterative Reconstructions can Impact Lung Nodule Measurements and Type Classification  
Harriet Lancaster, Netherlands

EP04.04-07 The Frequency of Incidental Lung Cancer Detected in Thorax CT During the COVID-19 Pandemic Process in Turkey  
Berna Komurcuoglu, Turkey

EP04.05 Track: Screening and Early Detection - Program Design

EP04.05-01 Comparison of Two Enrolment Criteria in Lung Cancer Screening Pilot Project in Estonia  
Tanel Laisaar, Estonia

EP04.05-02 Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening  
Raymond Osarogiagbon, USA

EP04.05-03 Perspectives of Potentially Eligible Indigenous Māori on a Lung Cancer Screening Programme - A Qualitative Study  
Kate Parker, New Zealand
EP04.05-04  Impact of Magnitude of Lung Cancer Screening Benefit on Uptake
  David Yankelevitz, USA

EP04.05-05  Singapore Lung Cancer Screening through Integrating CT with Other Biomarkers (SOLSTICE), A Single Arm Lung Cancer Screening Study
  Gillianne Lai, Singapore

EP04.05-06  Centralized Shared Decision Making in Lung Cancer Screening: Unexpected Consequences
  David Yankelevitz, USA

EP04.05-07  Improved Efficiency with Lungflag vs Opportunistic Selection in a Theoretical East Asian Lung Cancer Screening Program
  Eran Netanel Choman, Israel

EP04.06  Track: Screening and Early Detection - Recruitment + Screening Uptake

EP04.06-01  Compliance with Lung Cancer Screening Guidelines Among At-Risk Patients at a Rural Teaching Hospital in West Texas
  Kavya Bharathidasan, USA

EP04.06-02  Multimodal Intervention Strategies to Improve Lung Cancer Screening for Women Undergoing Breast Screening
  Lye-Yeng Wong, USA

EP04.06-03  Qualitative Study Using Focus-Group Interviews on Cognition of Lung Cancer Screening and Symptom
  Minji Seo, Republic of Korea

EP04.06-04  Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population
  Hina Khan, USA

EP04.07  Track: Screening and Early Detection - Others

EP04.07-01  Message from the Patients: What If I Wasn’t COVID 19
  Cengiz Gebitekin, Turkey

EP05.01  Track: Pulmonology and Staging

EP05.01-01  An Analysis of Lymph Node Metastasis Patterns in Surgical Cases of Non-small-Cell Lung Cancer
  Miyuki Abe, Japan

EP05.01-02  Cryobiopsy for Peripheral Pulmonary Lesions Using a 1.1 mm Cryoprobe and Guide Sheath without Fluoroscopy: The Initial 400 Cases
  Dongil Park, Republic of Korea

EP05.01-03  Efficacy of Artificial Intelligence and Deep Learning Predicting N0 Status
  Gizem Özçibik Isik, Turkey

EP05.01-04  A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer
  Zentaro Saito, Japan

EP05.01-05  Predictive Factors for Hemoptysis Following CT-guided PCNB: The Role of Post-procedure CT Findings and Cough after Biopsy
  Green Hong, Republic Of Korea

EP05.01-06  Stepwise Progression of Invasive Mucinous Adenocarcinoma Based on the Radiological and Biological Characteristics
  Eisuke Goto, Japan

EP05.01-07  Projective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer
  Teresa Garcia Mannique, Spain

EP05.01-08  Observation of Peripheral Airways Using Ultra-Thin Fiberscope
  Tonomari Kinoshita, Japan

EP05.01-09  Lung Cancer in Combined Pulmonary Fibrosis and Emphysema Syndrome Patients. A Complication or a Comorbidity?
  Jolanda Nikolla, Albania

EP05.01-10  Multi-scale Generator with Channel-wise Mask Attention to Generate Synthetic Contrast-enhanced Chest Computed Tomography
  Yun-Gyoo Lee, Republic of Korea

EP05.01-11  Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore
  Mamta Ruparel, Singapore

EP05.01-12  A Retrospective Audit of Lung Nodules with Validation of the Brock Tool in a Singaporean Cohort
  Mamta Ruparel, Singapore

EP05.01-13  Time to Lung Cancer Diagnosis and Treatment in the Era of the COVID-19 Pandemic
  Melinda Hsu, USA

EP05.01-14  Survival in Patients with Malignant Pleural Effusion Treated with a Tunneled Pleural Catheter Compared to the Lent Prognostic Score Scale
  Rafael Lopez-Castro, Spain

EP05.01-15  Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System
  Toshimasa Okazaki, Japan

EP05.01-16  Re Evaluation of a Larger Sample: Anatomical Variation Analysis of Left Upper Pulmonary Based on 3Dreconstruction of Chest CT
  Youjun Deng, China

EP06.01  Track: Pathology and Biomarkers - Artificial Intelligence for Pathology

EP06.01-01  Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC
  Hye Sung Kim, USA

EP06.01-02  A Circulating Tumor Cell-based Artificial Neural Network of Patients with Advanced Non-Small Cell Lung Cancer
  Xuyu Gu, China

EP06.01-03  Evaluation of Unstained Cytology Slides for Artificial Intelligence Rapid On-Site Evaluation
  Eric Flenaugh, USA

EP06.01-04  Deep Learning Based Quality Assessment of DAPI Stained Nuclei Images Obtained from Routine FISH Test for Lung Cancer
  Tae-Jung Kim, Republic of Korea
EP06.02  Track: Pathology and Biomarkers - Biomarkers for Immuno-oncology

EP06.02-01  Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: A Real-World Australian Perspective
Sarita Prabhakaran, Australia

EP06.02-02  Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Muhammad Awidi, USA

EP06.02-03  PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings
Naoko Shigeta, Japan

EP06.02-04  The Relationship between Pathologic and Molecular Characteristics and PD-L1 Expression in Surgically Resected Non-small Cell Lung Cancer
Atsushi Ito, Japan

EP06.02-05  Agreement Among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer
Tomohito Saito, Japan

EP06.02-06  Pan-cancer Analyses Reveal Immune Infiltration and Clinical Outcomes of IL7R
Jiafeng Liang, China

EP06.02-07  Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoinmunotherapy in Resectable NSCLC
Xinying Xue, China

EP06.03  Track: Pathology and Biomarkers - Genetic Biomarkers

EP06.03-01  Genetic Characterization of Driving Metastasis in TP53-Mutant Non-small Cell Lung Cancer Patients
Jun Lu, China

EP06.03-02  Elucidating Tumor Heterogeneity from Spatially Resolved Transcriptomics in ALK-Rearranged Non-small Cell Lung Cancer
JungHan Oh, Republic of Korea

EP06.03-03  Oncogenic Drivers of Pulmonary Invasive Mucinous Adenocarcinoma, Detected by Trusight Oncology 500
Kanako Shinada, Japan

EP06.03-04  Molecular Alterations in Non-Small Cell Lung Cancer Arising in Emphysematous and Fibrotic Lungs
Yinghan Hsu, Canada

EP06.03-05  EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy
Jieun Park, Republic of Korea

EP06.03-06  Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma
Jiahao Jiang, USA

EP06.03-07  Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience
Emmanouil Panagiotou, Greece

EP06.03-08  Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma
Francisco Heralde, Philippines

EP06.03-09  Characteristics of Insufficient Samples for EGFR Mutation Testing at the Lung Center of the Philippines
Francisco Heralde, III, Philippines

EP06.03-10  HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics
Ross Soo, Singapore

EP06.03-11  Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center
Danielle Dressler, USA

EP06.03-12  Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)
Amanda Gibson, Canada

EP06.03-13  HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer
Madhu Nagaraj, India

EP06.03-14  Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital
Qamruzzaman Chowdhury, Bangladesh

EP06.03-15  Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis
Ghassen Soussi, France

EP06.03-16  Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations
Ebaa Al-Obeidi, USA

EP06.03-17  The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III
Shota Nakamura, Japan

EP06.03-18  Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients
Umberto Malapelle, Italy

EP06.03-19  Genomic Landscape of Non-Small Cell Lung Cancer in the Republic of Ireland
Rachel Keogh, Ireland

EP06.03-20  Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement
Gooyeon Hong, Republic Of Korea

EP06.03-21  Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China
Pei Yuan, China

EP06.03-22  Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla
Iván Romarico González-Espinoza, Mexico
EP06.04  Track: Pathology and Biomarkers - Liquid Based Biomarkers

EP06.04-01  Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device
Hitoshi Dejima, Japan

EP06.04-02  FLUIDIndia: Liquid “First” Approach is a “Solid” Solution in NSCLC
Ullas Batra, India

EP06.05  Track: Pathology and Biomarkers - Pathology

EP06.05-01  Molecular, Clinicopathological Characteristics of Thoracic SMARCA4-deficient Undifferentiated Malignant Tumor - 5 Cases Review
Yu-Deok Choi, Republic of Korea

EP06.05-02  Accuracy of Postoperative Thoracic Malignancy Diagnosis in National Respiratory Center Persahabatan Hospital
Evi Ha, Indonesia

EP06.05-03  Subpleural Cystic Mesenchymal Neoplasm with Endometrioid-type Stromal Proliferation: A Report of 3 Cases
Peter Ileil, USA

EP06.05-04  SMARCA4/BRG1 Deficient Thoracic Neoplasms: Spectrum Encompassing Carcinomas to Undifferentiated Tumors
Arshi Tandon, India

EP06.05-05  Molecular Characteristics of Lung Signet Ring Cell Carcinoma in the Chinese Population
Shirong Zhang, China

EP06.05-06  Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients
Anna Cecilia Bettini, Italy

EP06.05-07  Non Small Cell Lung Cancer Associated to Dipnych: A Clinico-Pathological Analysis of 32 Cases
Filippo Lococo, Italy

EP06.05-08  Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma
Seijy Ohntani, Japan

EP06.05-09  Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC
Simon Christ, Germany

EP06.05-10  Clinical Value of Baseline Plasma Epstein-Barr Virus DNA in Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma
Ying Li, China

EP06.05-11  Immunohistochemical Features in Tissue Microarray in Pleomorphic Carcinoma of the Lungs
Won-II Choi, Republic of Korea

EP06.05-12  Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis
Hidaka Oeda, Japan

EP06.05-13  Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center
Kisuung Park, Republic of Korea

EP06.06  Track: Pathology and Biomarkers - Prognostic Biomarkers

EP06.06-01  Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy
Xuequan Wang, China

EP06.06-02  Correlation Between Vitamin C and CRP Serum Levels in Non Small Cell Lung Cancer Patient Among Sumatera Utara Population
Elizabeth Napitupulu, Indonesia

EP06.06-03  The Expression of MIR-320B in Extracellular Vesicles as a Prognostic factor for Non-small Cell Lung Carcinoma
Willy Ariawan, Indonesia

EP06.06-04  The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma
Willy Ariawan, Indonesia

EP06.06-05  Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion
Ragha Taleb, Egypt

EP06.06-06  Plasma Extracellular Vesicle miR-10b-5p as a Biomarker for Progressivity, Survivorship and Treatment Response in NSCLC Patients
Jaka Pradipta, Indonesia

EP06.06-07  Surveying for Lung Cancer after Idiopathic Pulmonary Fibrosis at Pham Ngoc Thach Hospital - Viet Nam in 5 year (2017 - 2021)
Nguyen Lam, Viet Nam

EP06.06-08  Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma
Andras Khoo, USA

EP06.06-09  Clinical Significance of the Presence of MECA-79-Positive Tumor Cells in Pathological Stage IA Invasive Adenocarcinoma of the Lung
Tomohito Saito, Japan

EP06.06-10  Cancer-Associated Fibroblasts and Estrogen Receptor Beta in Lung Cancer with Idiopathic Pulmonary Fibrosis
Eiji Nakajima, Japan

EP06.06-11  Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy
Mariska Pangaribuan, Indonesia

EP06.06-12  EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC
Anna Mclean, Australia

EP06.06-13  Fibronectin Promotes Tumor Angiogenesis and Progression of Non-small-Cell Lung Cancer
Guanghui Gao, China
EP06.06-14  High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients
Mir Alireza Hoda, Austria

EP06.06-15  Epigenetic Silencing of MYO1E in a US Veterans Cohort with Lung Adenocarcinoma and the Effect on Overall Survival
Kathleen Kennedy, USA

EP07.01-01  Track: Early-Stage Non-small Cell Lung Cancer - Best Practice

EP07.01-01-01  Nomogram for Predicting Prognosis and Adjuvant Chemotherapy Benefits in Early-stage Invasive Mucinous Lung Adenocarcinoma
Hua He, China

EP07.01-01-02  Gender Differences in Postoperative Symptoms of Lung Cancer and its Influencing Factors
Jia Liao, China

EP07.01-01-03  Perioperative Outcomes and Strategies for Pleomorphic Carcinoma in Lung
Aki Kobayashi, Japan

EP07.01-01-04  Factors Affecting Survival in YPTINOIMO Non Small Cell Lung Cancer Patients
Gizem Özçibik Isik, Turkey

EP07.01-01-05  A Study of the Characteristics of Lung Cancer Surgery Cases in the Elderly and the Usefulness of the Japanese NCD Risk Calculator
Teruhisa Kawaguchi, Japan

EP07.01-01-06  Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care
Raymond Osarogiabgon, USA

EP07.01-01-07  Comparison of Surveillance with Contrast Chest CT and Non-contrast Chest CT Among who Survived 2 Years after Curative Resection for Lung Cancer
Bubse Na, Republic of Korea

EP07.01-01-08  Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer
Konstantinos Leventakos, USA

EP07.01-01-09  Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients?
Sara Ricciardi, Italy

EP07.01-01-10  Risk Assessment of Severe Pulmonary Complications Leading to Death or Oxygen Therapy After Lung Resection in Patients with Primary Lung Cancer
Shinji Otani, Japan

EP07.01-01-11  Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients with Interstitial Lung Disease: A Multicenter Retrospective Cohort Study
Florian Fintelmann, USA

EP07.01-01-12  A Retrospective Study on the Methods of Covering Bronchial Stump/ Anastomotic Site to Avoid the Bronchopleural Fistula after Lung Cancer Surgery
Tomohiro Habu, Japan

EP07.01-01-13  Definitive Chemoradiation versus Radiation Alone for Stage II Non-Small Cell Lung Cancer. A National Cancer Database Analysis
Janakiraman Subramanian, USA

EP07.01-14  Assessing Morphometric Complexity in Lung Parenchyma of NSCLC Patients with IPF Undergoing Radiotherapy
Jeongeon Hwang, Republic of Korea

EP07.01-15  Utility of Bronchus-First Right Upper Lobectomy as a Routine Technique
Takahiro Utsumi, Japan

EP07.01-16  The Relationship of FDG PET-SUVm and Glucose Metabolism and Contribution to Early-Stage Non-Small Cell Lung Cancer Survival
Kemp Kernstine, USA

EP07.01-17  Identification of the Inter Segmental Area by Indocyanine Green Fluorescence Navigated Method During Thoracoscopic Segmentectomy
Fumio Watanabe, Japan

EP07.01-18  Adjuvant Chemotherapy is Less Effective in Non Small Cell Lung Cancer Patients Rated Undernourished by CONUT Score
Ken Onodera, Japan

EP07.01-19  Factors Affecting Postoperative Nausea and Vomiting in Surgical Patients with Non-Small Cell Lung Cancer
Satoru Imamura, Japan

EP07.01-20  Perioperative and Long-Term Outcomes of Fissureless Fissure-Last Lobectomy in Patients with Non-small Cell Lung Cancer
Hayato Nanami, Japan

EP07.01-21  A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer
Yoshito Imamura, Japan

EP07.01-22  Identifying the Optimal Number of Lymph Node Stations for Improving Survival in Resections for Non-small Cell Lung Cancer
Matthew Smeltzer, USA

EP07.01-23  Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable
Luan Pham, Viet Nam

EP07.01-24  Surgical Treatment of Lung Cancer in Patients Over the Age of 75 Years: Single Cancer Centre Experience
Oleg Pikin, Russian Federation

EP07.01-25  Implementation and Safety of a Same-day Discharge Program for Minimally-invasive Pulmonary Resection
Patrick Villeneuve, Canada

EP07.01-26  Is Chemical Venous Thromboembolism Prophylaxis Necessary After Lung Cancer Resection? A 10-year T-ERAS Experience
Ju Ae Park, USA

EP07.01-27  The Impact of Comorbidities on Exercise Level after Treatment for Early-Stage Lung Cancer Patients
Jiafang Zhang, USA

EP07.01-28  Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors
Serap Akyürek, Turkey

EP07.01-29  What is a Risk Factor for Postoperative Home Oxygen Therapy in Primary Lung Cancer Patients?
Takahiro Yamanaka, Japan
POSTER SESSIONS - ELECTRONIC POSTERS

EP07.01-30 Predictors of Poor Quality of Life Following Lung Cancer Surgery
Anna McGuire, Canada

EP07.01-31 Preoperative Respiratory Assessment Predicts Post-Operative Survival in Stage IA Non-small Cell Lung Cancer
Mototsugu Watanabe, Japan

EP07.01-32 Long Term Outcomes beyond Five Years after Pulmonary Resection for Non-small Cell Lung Cancer
Tetsuya Mizuno, Japan

EP07.01-33 Recurrence Patterns and Prognostic Factors for Relapse in Operated Lung Cancers
Berna Komurcuoglu, Turkey

EP07.02 Track: Early-Stage Non-small Cell Lung Cancer - New Technology and Innovations

EP07.02-01 Evaluation of the Efficacy of Oral Bacterial Lysates in Patients with High-risk Lung Nodules Detected by CT Screening
Dawei Yang, China

EP07.02-02 Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer: A Multi-center Survey of Current Practice from China
Han Wu, China

EP07.02-03 High-Dose Rate Endobronchial Brachytherapy with Palliative and Definitive Intent at a Tertiary Care Hospital
Meng Welliver, USA

EP07.02-04 The Prediction of Pathological Pleural Invasion of Lung Cancer by Artificial Intelligence Image Analysis
Wakako Nagase, Japan

EP07.02-05 A Three-Dimensional Computed Tomography Analysis of Residual Lung Volume Changes after Segmentectomy for Non-small Cell Lung Cancer
Miyuki Abe, Japan

EP07.02-06 MDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients
Karim Vermaelen, Belgium

EP07.02-07 Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer
Soheil Kooraki, USA

EP07.02-08 Comparison of ICG and Methylene Blue in Preoperative Dye Marking Localization of Pulmonary Nodules Under the Guidance of ENB
Yong-Bin Lin, China

EP07.02-09 Hypofractionated Radiation Therapy vs Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumors
Rui Song, USA

EP07.02-10 Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer
Yamato Motooka, Japan

EP07.02-11 Navigational Bronchoscopy: Driving to the Nodule Drives Your Patients to Earlier Stage
Patrick Ross, USA

EP07.02-12 The Role of Online MR-guided Multi-Fraction Stereotactic Ablative Radiotherapy in Lung Tumors
Chukwuka Eze, Germany

EP07.02-13 Utilization of Real-time MRI-guided Stereotactic Ablative Body Radiotherapy in NSCLC, One Step Forward Precise Targeting in Radiotherapy
Yoo Kang Kwak, Republic of Korea

EP07.02-14 Image-Guided Thermal Ablation of Early-Stage Non-small Cell Lung Cancer; Five-Year Outcome
Soheil Kooraki, USA

EP07.02-15 Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers
Jamie Feng, Canada

Deog Gon Cho, Republic of Korea

EP07.02-17 The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer
Bolin Wang, China

EP07.03 Track: Early-Stage Non-small Cell Lung Cancer - Limited Resections and Minimally Invasive Approaches

EP07.03-01 Meeting the Quality Metric for Minimum Lymph Node Harvest for Robotic Lobectomy for Lung Cancer
Jobelle Joyce Anne Baldonado, USA

EP07.03-02 Pulmonary Ligament Approach for Robot-Assisted S8 or S9 and 10 Segmentectomy
Mariko Fukui, Japan

EP07.03-03 Unportal Video-Assisted Thoracoscopic Surgery Simple Segmentectomy Versus Complex Segmentectomy in Lung Cancer Patients
Youngkyu Moon, Republic of Korea

Andrea Bille, UK

EP07.03-05 Oncological Outcomes After Unportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients
Wei Dai, China

EP07.03-06 Challenges in Robotic Lobectomy of the Lung Through the Anterior Approach
Atsushi Osoegawa, Japan

EP07.03-07 Negative Impacts of Mediastinal Lymph Node Dissection Forstage I Ground Glass Opacity Pulmonary Lesions
Jimin Lee, Republic of Korea

EP07.03-08 Impact of Tumor Location on Surgical Margin in Segmentectomy and Wedge Resection
Atsushi Kosuge, Japan
EP07.03-09  A Minimally Invasive Open Surgery Approach Is Superior to VATS with Respect to Intraoperative Outcomes during Lung Cancer Surgery
Satoshi Shiono, Japan

EP07.03-10  Effects of Preoperative Diabetes Mellitus on Postoperative Outcomes After Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy
Eric Toloza, USA

EP07.03-11  Effects of Intraoperative Trainees on Outcomes after Robotic-Assisted Pulmonary Lobectomy
Eric Toloza, USA

EP07.03-12  Early PROs After Uniportal Thoracoscopic Lobectomy vs Da Vinci Robotic-assisted Thoracoscopic Lobectomy
Kaixin Zhang, China

EP07.03-13  Comparison Of Patient-Reported Outcomes for Early-Stage Lung Cancer Patients Underwent Thoracoscopic Segmentectomy Versus Lobectomy
Xin Gao, China

EP07.03-14  Effect of Lymph Node Dissection on Recurrence and Survival Following Thoracoscopic Segmentectomy for Early-Stage Non-small Cell Lung Cancer
René Petersen, Denmark

EP07.03-15  Nodal Upstaging in Uniportal VATS Lobectomy for Early-Stage Lung Cancer: Is It Fair?
Riccardo Orlandi, Italy

EP07.03-16  Early PROs After Thoracoscopic Segmentectomy Versus Wedge Resection for Small-sized Peripheral NSCLC
Yingzhi Zhao, China

EP07.03-17  Robotic Lung Cancer Program: Initial Experience and Results
Daniel Brandao, Brazil

EP07.04  Track: Early-Stage Non-small Cell Lung Cancer - Progress in Pathology

EP07.04-01  Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results
Paola Ulivi, Italy

EP07.04-02  Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC
Ji Hyung Hong, Republic of Korea

EP07.04-03  Analyze Gene Changes Characteristics of MSLAs in Genomic Study
Kewei Ma, China

EP07.04-04  High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma
Cameron Fick, USA

Virginia Calvo de Juan, Spain

EP07.04-06  ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging
Filippo Tommaso Gallina, Italy

EP07.04-07  Early-Stage Low Malignant Potential Adenocarcinomas: A Histological Category with a Significantly Better Prognosis
Filippo Lococo, Italy

EP07.04-08  Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC)
Laura Sellmer, Germany

EP07.04-09  Pleural CEA and SUVmax as Predictors of Visceral Pleural Invasion in Clinical TINOM0 Lung Adenocarcinoma
GaYoung Yoo, Republic of Korea

EP07.04-10  Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center
Joseph Fuchs, USA

EP07.04-11  Clinicopathological Features and Postoperative Prognosis of Bubble-like Appearance Type Lung Adenocarcinoma
Kotaro Murakami, Japan

EP07.04-12  Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-small Cell Lung Cancer
Nicholas Wells, USA

EP07.04-13  Long-term Prognostic Impact of EGFR Mutations on Resected Early-stage Lung Cancer
Takahiro Suzuki, Japan

EP07.04-14  Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces
Eunjue Yi, Republic of Korea

EP07.04-15  Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-small Cell Lung Cancer (NSCLC) in China
Shun Lu, China

EP07.04-16  Occult Lymph Node Metastasis Is Not a Favorable Factor for Resected NSCLC Patients
Jing-Sheng Cai, China

EP07.04-17  Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma
Dawei Yang, China

EP07.04-18  Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data
Jeong Uk Lim, Republic of Korea

EP07.04-19  Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing After Radical Resection
Pietro Bertoglio, Italy

EP07.04-20  Identification of Tumor Microenvironment and Prognosis Risk Prediction Through Proteomics Analysis in Stage I Lung Adenocarcinoma
Hsuan-Yu Chen, Taiwan

EP07.04-21  Lymphatic Vascular Invasion: Diagnostic Variability and Overall Survival Impact on Patients Undergoing Surgical Resection of NSCLC
Kemnasom Nwanwene, USA

EP07.04-22  Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US
Matthew Smeltzer, USA
EP07.04-23  Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer  
Kazuaki Hoshi, Japan

EP07.04-24  Histopathologic Fate of Resected Pulmonary Pure Ground Glass Nodule: A Systematic Review and Meta-Analysis  
Jimin Lee, Republic of Korea

Wenhua Liang, China

Jay Lee, USA

EP07.04-27  Prevalence of Driver Gene Mutation Testing in Resected Early-stage Lung Adenocarcinomas (LUAD): Implications for Perioperative Therapy  
Wei Wang, China

EP07.04-28  Low O-GlcNacase Expression Is Associated with Poor Prognosis in Surgically Resected Early-stage Lung Adenocarcinoma  
Wei Wang, China

EP07.04-29  Hyperspectral Multiplex Immunohistochemistry and Recurrence in Resected Early Stage Non-small Cell Lung Cancer  
Anna McGuire, Canada

EP07.04-30  Analysis of Radiologic-pathologic Correlation for Subsolid Lung Adenocarcinoma Using the Whole-mount Section Technique: A Prospective Study  
Chaoqiang Deng, China

EP07.05  Track: Early-stage Non-small Cell Lung Cancer - Pushing the Boundaries

EP07.05-01  Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma  
Yang Wo, China

EP07.05-02  NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer  
Fang-Liang Lu, China

EP07.05-03  Neoadjuvant Chemotherapy or Chemo-Io in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience  
Kaiwen Wang, USA

EP07.05-04  CDDP/TSI Followed by Maintenance TSI as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer  
Kosuke Fujiio, Japan

EP07.05-05  Adjuvant Aumolertinib in Resected EGFR-Mutated Non-small Cell Lung Cancer: Impact on Residual GGO Lesions  
Haitao Ma, China

EP07.05-06  Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer  
Dong Lin, China

EP08.01  Track: Local-Regional Non-small Cell Lung Cancer - Biomarkers

EP08.01-01  Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures  
Yi-Fan Qi, China

EP08.01-02  Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-small Cell Lung Cancer Undergoing Chemo-immunotherapy  
Rui Fu, China

EP08.01-03  Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy  
Ashley Horne, UK
<table>
<thead>
<tr>
<th>EP08.02</th>
<th>Track: Local-Regional Non-small Cell Lung Cancer - Multimodality Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP08.02-01</td>
<td>Parameters of FDG PET/CT Predicting Pathological Response to Neoadjuvant Immunotherapy in Stage II/III Non-small Cell Lung Cancer Patients</td>
</tr>
<tr>
<td>Eun Seong Lee, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>EP08.02-02</td>
<td>Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>Nicole Pringle, Australia</td>
<td></td>
</tr>
<tr>
<td>EP08.02-03</td>
<td>Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>Nicole Pringle, Australia</td>
<td></td>
</tr>
<tr>
<td>EP08.02-04</td>
<td>Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis</td>
</tr>
<tr>
<td>Melinda J Daumont, Belgium</td>
<td></td>
</tr>
<tr>
<td>EP08.02-05</td>
<td>Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study</td>
</tr>
<tr>
<td>Min Li, China</td>
<td></td>
</tr>
<tr>
<td>EP08.02-06</td>
<td>Neoadjuvant Therapy, Still a Contraindication to VATS Lobectomy or is it a New Indication?</td>
</tr>
<tr>
<td>Cengiz Gebitekin, Turkey</td>
<td></td>
</tr>
<tr>
<td>EP08.02-07</td>
<td>FDG PET Scan Based Response Assessment in Non-small Cell Lung Cancer Treated with Chemoradiotherapy and Neoadjuvant Chemotherapy</td>
</tr>
<tr>
<td>Aftab Ahmad, India</td>
<td></td>
</tr>
<tr>
<td>EP08.02-08</td>
<td>Lymphovascular Invasion Prediction with CT images in Patients with Non-small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>Misuk Lee, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>EP08.02-09</td>
<td>Comprehensive Assessment of Pulmonary Function in Patients Receiving Radical (Chemo)Radiotherapy for Carcinoma Lung</td>
</tr>
<tr>
<td>Sam David, India</td>
<td></td>
</tr>
<tr>
<td>EP08.02-10</td>
<td>Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer</td>
</tr>
<tr>
<td>Naoyuki Oka, Japan</td>
<td></td>
</tr>
<tr>
<td>EP08.02-11</td>
<td>Dosimetric Contribution of LAD Sparing Radiotherapy Plan in Patients with Postoperative Lung Cancer</td>
</tr>
<tr>
<td>Serap Akyürek, Turkey</td>
<td></td>
</tr>
<tr>
<td>EP08.02-12</td>
<td>Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients who Received Definitive RT</td>
</tr>
<tr>
<td>Serap Akyürek, Turkey</td>
<td></td>
</tr>
<tr>
<td>EP08.02-13</td>
<td>Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer</td>
</tr>
<tr>
<td>Yuki Akazawa, Japan</td>
<td></td>
</tr>
<tr>
<td>EP08.02-14</td>
<td>Prognostic Role of Baseline PET/CT Parameters in Frail Patients with Inoperable Node-Positive Stage IIB-IIIC/Recurrent NSCLC</td>
</tr>
<tr>
<td>Chukwuka Eze, Germany</td>
<td></td>
</tr>
<tr>
<td>EP08.02-15</td>
<td>Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC</td>
</tr>
<tr>
<td>Chukwuka Eze, Germany</td>
<td></td>
</tr>
<tr>
<td>EP08.02-16</td>
<td>Higher Radiation Dose to Immune Cells is a Negative Prognostic Factor in Locally Advanced Non-small Cell Lung Cancer (LA-NsCLC)</td>
</tr>
<tr>
<td>Nikhil Yegya-Raman, USA</td>
<td></td>
</tr>
<tr>
<td>EP08.02-17</td>
<td>Comparison of Long-term Survival of Patients With Locally Advanced Lung Cancer After Video-Assisted Thoracoscopic Surgery Versus Thoracotomy</td>
</tr>
<tr>
<td>Xing Wei, China</td>
<td></td>
</tr>
<tr>
<td>EP08.02-18</td>
<td>The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer</td>
</tr>
<tr>
<td>Yu Tian, China</td>
<td></td>
</tr>
<tr>
<td>EP08.02-19</td>
<td>Correlation of Quantified Metabolic Activity with Gross Tumor Volume in Patients with Non-small Cell Lung Cancer</td>
</tr>
<tr>
<td>Danijela Scepanovic, Slovakia</td>
<td></td>
</tr>
<tr>
<td>EP08.02-20</td>
<td>A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC</td>
</tr>
<tr>
<td>Neil Wallace, Australia</td>
<td></td>
</tr>
<tr>
<td>Ryuichi Waseda, Japan</td>
<td></td>
</tr>
<tr>
<td>EP08.02-22</td>
<td>Survival Outcome Comparison of Stage III and IV NSCLC Patients in Latvia and Israel: An Analysis of Treatment Approaches</td>
</tr>
<tr>
<td>Laila Roisman, Israel</td>
<td></td>
</tr>
<tr>
<td>EP08.02-23</td>
<td>Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC?</td>
</tr>
<tr>
<td>Michael MacManus, Australia</td>
<td></td>
</tr>
<tr>
<td>EP08.02-24</td>
<td>Neoadjuvant Immune Checkpoint Inhibitor Plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World</td>
</tr>
<tr>
<td>Cheng Chen, China</td>
<td></td>
</tr>
<tr>
<td>EP08.02-25</td>
<td>A Case of Persistent Complete Response to Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC</td>
</tr>
<tr>
<td>Victor Ho Fun Lee, Hong Kong</td>
<td></td>
</tr>
<tr>
<td>EP08.02-26</td>
<td>Clinical Outcome of Neoadjuvant of Tislelizumab Plus Chemotherapy for Chinese Locally Advanced NSCLC Patients</td>
</tr>
<tr>
<td>Yongsheng Wang, China</td>
<td></td>
</tr>
<tr>
<td>EP08.02-27</td>
<td>Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients</td>
</tr>
<tr>
<td>Robert Dziedzic, Poland</td>
<td></td>
</tr>
<tr>
<td>EP08.02-28</td>
<td>Do We Have to Offer Postoperative Radiotherapy in Resected Pathologic N2 Non-small Cell Lung Cancer with Extranodal Extension?</td>
</tr>
<tr>
<td>Changhoon Song, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>EP08.02-29</td>
<td>Is Moderate-intensity Stereotactic Body Radiation Therapy for Ultra-central Lung Tumor a Feasible Option?</td>
</tr>
<tr>
<td>Chai Hong Rim, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>EP08.02-30</td>
<td>Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)</td>
</tr>
<tr>
<td>Raquel Zuzin, Brazil</td>
<td></td>
</tr>
<tr>
<td>EP08.02-31</td>
<td>Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study</td>
</tr>
<tr>
<td>Yang Cheng, China</td>
<td></td>
</tr>
</tbody>
</table>
POSTER SESSIONS - ELECTRONIC POSTERS

EP08.02-32  Optimal Planning Target Volume Margins for Spirometer-Based DIBH Radiotherapy for Lung Cancer
Noriko Kishi, Japan

EP08.02-33  Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer
Lei lei Wu, China

EP08.02-34  Evaluation of Treatment Strategies for Patients with Stage IIIA Non-small Cell Lung Cancer in the Immunotherapy Era
Amy Alabaster, USA

EP08.02-35  Prognostic Impacts of Lymphovascular Invasion of Resected Lung Adenocarcinoma after Induction Chemoradiotherapy
Takaufumi Kabuto, Japan

EP08.02-36  Long Term Patient Reported Outcomes in Non Small Cell Lung Cancer Patients Who Underwent Pneumonectomy
Gizem Özçibik Isik, Turkey

EP08.02-37  Definitive Hypofractionated Radiation Therapy with or without Immuno therapy for Stage IIb-III NSCLC: An Institutional Experience
Benjamin Hopkins, USA

EP08.02-38  No Benefit for Extending Neoadjuvant Targeted Therapy Exposure Time in Resectable EGFR Mutation Non-small Cell Lung Cancer
Nan Wu, China

EP08.02-39  Dosimetric Comparison of Free-Breathing versus Respiratory Motion-managed Radiotherapy with 4D-CT Based VMAT in Lung Cancer
Sureyya Sarihan, Turkey

EP08.02-40  Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis
Shun Lu, China

EP08.03  Track: Local-Regional Non-small Cell Lung Cancer - Novel Therapies and Trials

EP08.03-01  Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials
Roberto Serna Blasco, Spain

EP08.03-02  Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer After Durvalumab Following Chemoradiotherapy
Takaaki Tokito, Japan

EP08.03-03  S-1 and CDDP with Concurrent TRT followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI
Shigeru Tanzawa, Japan

EP08.03-04  MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients
Jun Zhang, USA

EP08.03-05  Role of DCE MRI in Predicting Treatment Response to Induction Immunochemotherapy in Locally Advanced NSCLC Patients
DaQuan Wang, China

EP08.04  Track: Local-Regional Non-small Cell Lung Cancer - Toxicities of Multimodality Therapy

EP08.04-01  Predictors and Outcomes of Pneumonitis in Non-small Cell Lung Cancer Patients Treated with Consolidative Durvalumab
Chloe Lim, Canada

EP08.04-02  Evaluating Safety Profiles of Radiation-Related Toxicities in Thoracic Re-Irradiation
Rohan Patel, USA

EP08.04-03  Acute Postoperative Pain is the Most Severe at the Site of Chest Tube Insertion in Multiportal Video-assisted Thoracoscopic Surgery
Yoshifumi Sano, Japan

EP08.04-04  Development of a Risk Score to Predict Postoperative Complications in Patients with Non-small Cell Lung Cancer
Makhmudbek Mallaev, Switzerland

EP09.01  Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Effects of Local Therapies in Metastatic NSCLC

EP09.01-01  Feasibility and Survival Outcomes of “Salvage Surgery” for Initially Clinical Stage IV Non-small Cell Lung Cancer
Tomoyuki Hishida, Japan

EP09.01-02  Clinical Outcome of Palliative Thoracic Radiotherapy in Advanced Lung Cancer in the Modern Era - A Single Institution Experience
Tsz Yung Kam, China

EP09.01-03  Hypofractionated Radiotherapy for Elderly Lung Cancer Patients
Jeong Won Lee, Republic of Korea

EP09.01-04  Surgical Treatment in Non-small Cell Lung Cancer with Pulmonary Oligometastasis; 26 Years of Experience in a Single Center
Cengiz Gebitekin, Turkey

EP09.01-05  Is Palliative Thoracic Radiation Beneficial in Stage IV Non-small Cell Lung Cancer (NSCLC) In the Era of Modern Systemic Therapy?
Tithi Biswas, USA

EP09.01-06  Outcomes of Surgical Treatment for Stage IV Non-Small Cell Lung Cancer (NSCLC) in a Population-Based Cohort
Raymond Osarogiagbon, USA

EP09.01-07  Reverse Endobronchial Y-stent Implantation in Selected Cases of the Malignant Central Airway Obstruction
Jaroslaw Pieróg, Poland

EP09.02  Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Integration of Local Therapies With Systemic Therapies

EP09.02-01  Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD
Shuai Liang, China

EP09.02-02  Stereotactic Body Radiotherapy Synergizes Immuno therapy in Advanced or Recurrent NSCLC: A Single-center Experience
Dan Yao, China
Posters will be displayed in the Exhibit Hall starting [date & time]. All posters will also be available for viewing on the virtual platform.

EP09.02-03  A Phase II Study on Aggressive Local Consolidative Therapy in Combination with Chemotherapy for Oligometastatic NSCLC: TORG1529
Takaaki Tokito, Japan

EP09.02-04  Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC
Byung Jo Park, Republic of Korea

EP09.02-05  Fibrates Enhances Radiotherapy Efficacy by Elevating HDL Levels to Induce Tumor Cell Ferroptosis in NSCLC with Brain Metastasis
Xiaorang Dong, China

EP09.02-06  Long-term Efficacy of Tumor Treating Fields (TTFields 150 kHz) in Metastatic NSCLC: A Case Report
Izabela Chmielewska, Poland

EP09.03  Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Oligometastatic NSCLC

EP09.03-01  Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies
Philip Blumenfeld, Israel

EP09.03-02  Local Ablation Induces Abscopal Effects and Improves the Efficacy of Continuous ICIs in Advanced NSCLC Patients with Oligo-progression
Leilei Wu, China

EP09.04  Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Predictive and Prognostic Biomarkers

EP09.04-01  Prognostic Factors for Patients With KRAS Mutated Non-small Cell Lung Cancer and Brain Metastases
Simon Ekman, Sweden

EP09.04-02  Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer
Rui Fu, China

EP09.04-03  Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era
Itamar Averbuch, Israel

EP09.05  Track: Metastatic Non-small Cell Lung Cancer – Local Therapies - Toxicity of Local Therapies

EP09.05-01  Ionizing Radiation Induces Vascular Smooth Muscle Cell Senescence through Activating NF-κB/CTCF/p16 Pathway
Fan Tong, China

EP09.05-02  Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease
Nicholas Bucknell, Australia

EP10.01  Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

EP10.01-01  DDR1 Mediated Glycolysis Regulates the Synergistic Effect of Anlotinib and Docetaxel in Lung Cancer
Xueqin Chen, China

EP10.01-02  Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes
Jeng Shiuan Tsai, Taiwan

EP10.01-03  A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC
Alexander Drilon, USA

EP10.01-04  First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study
Yuanyuan Zhao, China

EP10.01-05  Retrospective Analysis of Real-World Treatment Patterns and Survival Outcomes for Non-small Cell Lung Cancer Patients in Thailand
Saijai Supaattagorn, Thailand

EP10.01-06  Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy
Virginia Calvo de Juan, Spain

EP10.01-07  Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study
Andree Kurniawan, Indonesia

EP10.01-08  Relationship Between Age and Chemotherapy Regimen for Elderly Patients with Advanced Lung Cancer
Ritsuya Shiba, Japan

EP10.01-09  Added Serum Albumin to Lung-mol GPA Score Improves Prediction of Overall Survival in Non-small Cell Lung Cancer Patients with Brain Metastasis
Chudanun Pinthaya, Thailand

EP10.01-10  Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression After Treatment with Durvalumab
Bushra Sheriff, USA

EP10.01-11  Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study
ShenCun Fang, China

EP10.01-12  Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital
Wulyo Rajabto, Indonesia

EP10.01-13  Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice
Shawn Ali, USA

EP10.01-14  Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis
Marko Jakopovic, Croatia

EP10.01-15  Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer
Jenny Turcott, Mexico
**EP10.01-16**  Relationship Between Impaired Fasting Glucose and Prognosis of the Disease in Patients with Advanced Stage Non-small Cell Lung Cancer  
Berna Komurcuoglu, Turkey

**EP10.01-17**  Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China  
Yan Wang, China

**EP11.01-01**  Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - Biomarker

**EP11.01-01-01**  Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study  
Alessandra Leonetti, Italy

**EP11.01-01-02**  A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma  
Nanami Yamasaki, Japan

**EP11.01-01-03**  Neutrophil to Lymphocyte Ratio in Patients Treated with Immunotherapy After Progression on Chemotherapy  
Marko Jakopovic, Croatia

**EP11.01-01-04**  Does Tumor Microvessel Density Predict Response to ImmuneCheckpoint Inhibitors in Metastatic Non-small Cell Lung Cancer?  
Akil Turna, Turkey

**EP11.01-01-05**  ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-small Cell Lung Cancer Immunotherapy Trials  
Nagaahree Seetharamu, USA

**EP11.01-01-06**  SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment  
Gregory Holt, USA

**EP11.01-01-07**  Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-1 Expression  
Chian-Wei Chen, Taiwan

**EP11.01-01-08**  GSDME-dependent Pyroptosis Affects the Prognosis and Response to Immunotherapy in Lung Adenocarcinoma  
Peiqun Cao, China

**EP11.01-01-09**  Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy  
Tong Cui, China

**EP11.01-01-10**  Immune Checkpoint Inhibitors in the Treatment of Non-small Cell Lung Cancer: Does Histology Matter?  
Khalil Choucair, USA

**EP11.01-01-11**  Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors  
Yoshiro Nakahara, Japan

**EP11.01-01-12**  Prediction of NSCLC Immunotherapy Outcomes Across Multiple Clinical Indicators  
Shanshan Xiao, China

**EP11.01-01-13**  The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy  
Yasi Xu, China

**EP11.02-01**  Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure  
Jiwon Kim, Republic of Korea

**EP11.02-02**  Phase I Study of Epacadostat in Combination with Sirolimus in Solid Tumors and PK Data  
Chao Huang, USA

**EP11.02-03**  First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis  
Tianqing Chu, China

**EP11.02-04**  Efficacy and Safety of Camrelizumab plus Fumitrexakin in Previously Treated Patients with Advanced Non-small Cell Lung Cancer  
Ming Gao, China

**EP11.02-06**  Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS  
Baohui Han, China

**EP11.02-07**  Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial  
Dae Ho Lee, Republic Of Korea

**EP11.02-08**  Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non-small Cell Lung Cancer (IMMUNOPREDICT)  
Jessica Nguyen, France

**EP11.02-09**  Rh-endostatin Combined With PD-1 Inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC  
Dong Wang, China

**EP11.02-10**  Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC: A Multi-Center Prospective Study (Endouble)  
Xiaodong Jiang, China

**EP11.03-01**  Real World Outcomes of Immunotherapy for Treatment of Advanced Stage NSCLC in Jordan  
Taher Abu Hejleh, Jordan

**EP11.03-02**  Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions  
Aliyah Pabani, Canada

**EP11.03-03**  Patient-Reported Fatigue in Lung Cancer Patients Undergoing Immunotherapy: A Real-life Study  
Mariana Picado, Portugal

**EP11.03-04**  Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC  
Shunichi Kataoka, Japan

**EP11.03-05**  Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer  
Laura Gutiérrez Sainz, Spain
**EP11.03-06**  Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-small Cell Lung Cancer Patients with Brain Metastases  
Shilian Luo, China

**EP11.03-07**  Long-term Outcomes and Toxicity in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy Containing Regimens  
Meghana Maddula, Australia

**EP11.03-08**  Multicenter Pharmacokinetic Study of Pembrolizumab for Non-small Cell Lung Cancer in Older Adults Aged Over 75 Years  
Hidehito Hornouchi, Japan

**EP11.03-09**  Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study  
Magdalena Knetki-Wróblewska, Poland

**EP11.03-10**  Similar Efficacy Observed for Frontline Immunotherapy in Ethnic-Minority Patients with Metastatic NSCLC  
Matthew Lee, USA

**EP11.03-11**  Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy  
Lauren Brown, Australia

**EP11.03-12**  Combining Immune Checkpoint Inhibitors with Radiotherapy in Advanced Non-small Cell Lung Cancer  
Yongmei Liu, China

**EP11.03-13**  Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study  
Enric Carcereny, Spain

**EP11.03-14**  The Economic Burden of Lung Cancer (NSCLC) In the County of Gävleborg - Sweden  
Hirsh Koyi, Sweden

**EP11.03-15**  Sarcopenia is a Poor Predictive Prognostic Factor for Non-small Cell Lung Cancer Patients who were Treated with Immune Check Point Inhibitors  
Sung Yong Lee, Republic of Korea

**EP11.03-16**  Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody  
Zentaro Saito, Japan

**EP11.03-17**  Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials  
Ben Ponvilawan, USA

**EP11.03-18**  Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: Less Is More?  
Mariola Blanco Clemente, Spain

**EP11.03-19**  Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations  
Tianqing Chu, China

**EP11.03-20**  Real World Experience of First Line Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) at a Tertiary Centre  
William Mullally, Australia

**EP11.03-21**  Incidence of Cardiotoxicity in Patients Treated for Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors  
Luis Raez, USA

**EP11.03-22**  Proton Pump Inhibitors’ Impact on the Effectiveness of Immune Checkpoint Inhibitors in Metastatic Non-sell Cell Lung Cancer  
Luis Raez, USA

**EP11.03-23**  Efficacy of Nivolumab + ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 >1%: A Network Meta-analysis  
Adam Lee, UK

**EP11.03-24**  The Efficacy of Immunoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC) in China  
Jiafeng Liang, China

**EP11.03-25**  A Novel Approach for Personalized Strategy of Cancer Immunotherapy with Pattern Identification: From the Results of the HARMONY Study  
Mi-kyung Jeong, Republic of Korea

**EP11.03-26**  Real-World Outcomes with Immunotherapy Compared to Chemotherapy in Metastatic NSCLC with High PD-L1 Expression  
Kaushal Parikh, USA

**EP11.03-27**  Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China  
Fengnan Wang, China

**EP11.03-28**  Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-small Cell Lung Cancer in Europe  
Ticiana Leal, USA

**EP11.03-29**  Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials  
Shalini Subramaniam, Australia

**EP11.03-30**  What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients?  
Yuki Matsumura, Japan

**EP11.03-31**  Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients who Underwent Immune Checkpoint Inhibitors  
Eun Young Kim, Republic of Korea

**EP11.03-32**  Does the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?  
Tatsuya Hirano, Japan

**EP11.03-33**  Prognostic Value of Body Mass Index and Serum Lipid for First-line Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients  
Sang Chul Lee, Republic of Korea

**EP11.03-34**  Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in NSCLC Patients?  
Eun Young Kim, Republic of Korea

**EP11.03-35**  Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients  
Jessica Bauman, USA

**EP11.03-36**  Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study  
Jiafeng Liang, China
POSTER SESSIONS - ELECTRONIC POSTERS

**EP11.03-37**  
Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small Cell Lung Cancer  
Shan Su, China

**EP11.03-38**  
Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy  
Sun Min Lim, Republic of Korea

**EP11.03-39**  
Platinum/Taxane Versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers that progressed on Platinum Doublets and Anti-PD/PD-L1  
Kang Qin, USA

**EP11.03-40**  
An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients  
Adam Sierakowiak, Sweden

**EP11.03-41**  
Successful Treatment with Pembrolizumab Alone for SMARCA4-deficient Lung Sarcomatoid with a High-TMB and PD-L1(+) A Case Report  
Youjun Deng, China

**EP11.03-42**  
Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases  
Li Kun Chen, China

**EP11.04**  
Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy - TIPs

**EP11.04-01**  
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-small Cell Lung Cancer  
Yongsheng Wang, China

**EP12.01**  
Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy - EGFR/HER2

**EP12.01-01**  
The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm who were Intolerant to Osimertinib: A Retrospective Clinical Study  
Longhua Sun, China

**EP12.01-02**  
NGS Reveals Convergent Acquired Resistance and Newly Emerging Driver Involving MET Alterations in NSCLC: A Case Report  
Chek Kun Tan, Singapore

**EP12.01-03**  
 Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study  
Tomoki Tamura, Japan

**EP12.01-04**  
Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR Sensitizing Mutations with Dose Reduction of Afatinib  
Widya Angasreni, Indonesia

**EP12.01-05**  
Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-small Cell Lung Cancer (NSCLC) Real-World Patients  
Blanca Täbara, Spain

**EP12.01-06**  
Metastatic NSCLC with G719X/S781I EGFR-mutations with Acquired BRAF V600E Mutation - Response to Osimertinib, Dabrafenib and Trametinib  
Edyta Urbanbska, Denmark

**EP12.01-07**  
Brigatinib Restores Disease Control at Second Progression on Osimertinib in Metastatic EGFR ex19del Mutated NSCLC with Acquired EML4-ALK Fusion  
Edyta Urbanbska, Denmark

**EP12.01-08**  
Benefits of Atezolizumab and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation  
Xin Lyu, China

**EP12.01-09**  
Predictive and Prognostic Value of Early Skeletal Muscle Loss During First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma  
Xin Nie, China

**EP12.01-10**  
Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer  
Fiona Desland, USA

**EP12.01-11**  
Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure  
Javier Baena, Spain

**EP12.01-12**  
Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study  
Ruei-Lin Sun, Taiwan

**EP12.01-13**  
Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC  
Nabil Dorkhom, Netherlands

**EP12.01-14**  
First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases  
Li Zhang, China

**EP12.01-15**  
Aumolertinib Combination SBRT Treated EGFR co-mutation Patients with Symptomatic Brain Metastases: A Case Report  
Xiaojuan Zhang, China

**EP12.01-16**  
The Safety and Efficacy of Aumolertinib in Advanced EGFR-Mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment  
Qinhong Zheng, China

**EP12.01-17**  
Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib  
Teerapat Majam, Thailand

**EP12.01-18**  
Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases  
Georgios Tsakonas, Sweden

**EP12.01-19**  
Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Intestinal Pneumonia Induced by Osimertinib  
Enguo Chen, China

**EP12.01-20**  
Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins)  
Andrés Aguilar, Spain

**EP12.01-21**  
A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib  
Jing Quan Zhao, China
EP12.01-22 Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC
Amanda Gibson, Canada

EP12.01-23 Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
Kijakam Thanasombunsekh, Thailand

EP12.01-24 High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom
Wei Wang, China

EP12.01-25 Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
Shencun Fang, China

EP12.01-26 Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations
ShenCun Fang, China

EP12.01-27 Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer
Tae Won Jang, Republic of Korea

EP12.01-28 A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases Including Brain Metastasis
Xiu Shan, China

EP12.01-29 Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
Jian Chun Duan, China

EP12.01-30 Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and Leptomeningeal Metastasis
Yun Fan, China

EP12.01-31 Updated First-line Osimertinib in Asian Patients with Advanced EGFR-mutated Lung Cancer
Wan Ling Tan, Singapore

EP12.01-32 Intracranial Complete Remissions and Long-Term Response in a EGFR-positive NSCLC Patient with Brain Metastases: Case Report
Hao Ran Su, China

EP12.01-33 Liquid Biopsy Reduce Time to Treatment for Patients with EGFR Mutated Advanced Nonsquamous Non-small Cell Lung Cancer: A Mexican Unit Experience
Saul Campos-Gomez, Mexico

EP12.01-34 Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung
Tadashi Nishimura, Japan

EP12.01-35 Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort
Ping Yang, USA

EP12.01-36 Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review
Bilal Khokhar, USA

EP12.01-37 Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations
Tao Tao, China

EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype
Ying Liu, USA

EP12.01-39 Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma
Xu-Hui Guan, China

EP12.01-40 The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastases
Qian Shao, China

EP12.01-41 Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib.
Amin Benyounes, USA

EP12.01-42 Long-term Survivors with EGFR Positive Non-small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort
Heather Halperin, Canada

EP12.01-43 Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer
Jieun Yang, Republic of Korea

EP12.01-44 A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib
Yan Chen, China

EP12.01-45 Real-World Outcomes of Health-Related Quality-of-Life(HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib
Jisheng Li, China

EP12.01-46 L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI
Oscar Arrieta, Mexico

Beung-chul Ahn, Republic of Korea

EP12.01-48 A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases
Xiaojuan Zhang, China

EP12.01-49 Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions
Yang Shao, China

EP12.01-50 Real-World Characteristics and Outcomes of ERBB2-Mutant Non-small Cell Lung Cancer in Latin America Patients
Helano Freitas, Brazil

EP12.01-51 Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration
Yuki Sato, Japan

EP12.01-52 A Multi-Center Observational Study of Effectiveness and Safety of First Line Aftatinib in Major Uncommon EGFR mutated NSCLC
Anh Le, Viet Nam
POSTER SESSIONS - ELECTRONIC POSTERS

**EP12.01-53**  
The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma  
Se Hyun Kwak, Republic of Korea

**EP12.01-54**  
Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Lung Cancer in Vietnam  
Chau Pham, Viet Nam

**EP12.01-55**  
Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter Single-Arm Prospective Study (ARISE)  
Gen Lin, China

**EP12.01-56**  
Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC with Brain and Leptomeningeal Metastases  
Yi-Bin Li, China

**EP12.01-57**  
Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report  
Cheng Chen, China

**EP12.01-58**  
Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment  
Qiang Wu, China

**EP12.01-59**  
Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)  
Boris Pfeiffer, Germany

**EP12.01-60**  
An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina  
Michael Pavy, USA

**EP12.01-61**  
Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer  
Andres Cardona, Colombia

**EP12.01-62**  
Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib  
Kensuke Kanaoka, Japan

**EP12.01-63**  
Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study  
Biao Yao, China

**EP12.01-64**  
Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review  
Shirish Gadgeel, USA

**EP12.01-65**  
Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC  
Andres Cardona, Colombia

**EP12.01-66**  
Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA  
Zhao Dai, China

**EP12.01-67**  
A Real World Cohort Study of First Line Afitinib in Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer in Vietnam  
Phuong Pham, Vietnam

**EP12.01-68**  
Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases  
Qinggang Zhu, China

**EP12.01-69**  
Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia  
Devi Amelia, Indonesia

**EP12.01-70**  
Anotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis  
Zhaoxia Wang, China

**EP12.01-71**  
Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure  
Shencun Fang, China

**EP12.01-72**  
Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results  
Shencun Fang, China

**EP12.01-73**  
Aumolertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy  
Feng Luo, China

**EP12.01-74**  
Increased Progression Free Survival of Patients with EGFR Positive Mutation NSCLC Treated with Afitinib in Regard to Toxicity  
Suryanti Pratiwi, Indonesia

**EP12.01-75**  
Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report  
Iván Romarico González-Espinoza, Mexico

**EP12.01-76**  
Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC  
Nir Peled, Israel

**EP12.01-77**  
Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area  
Jiagang Feng, China

**EP12.02**  
Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy - FUSIONS

**EP12.02-01**  
Novel-Acquired KANK1-ALK Fusion in An Advanced Lung Adenocarcinoma Responds to Alectinib: A Case Report  
Quanying Tang, China

**EP12.02-02**  
Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs  
Hannah Le, USA

**EP12.02-03**  
Judith Tam ALK Lung Cancer Research Initiative  
Angel Qin, USA

**EP12.02-04**  
The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: A Multi-center Retrospective Study in China  
Aiqin Gao, China

**EP12.02-05**  
PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer  
Xinyu Liu, China
EP12.02-06  Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC)  
Christine Garcia, USA

EP12.02-07  The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real-world Experience in Taiwan  
Xuet Yit Chen, Taiwan

EP12.02-08  Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-positive Lung Cancers  
Monica Chen, USA

EP12.02-09  Prevalence and Treatment of Advanced NSCLC Patients with Refined Transfection (RET)-fusion at a South Korean Centre  
Shinkyo Yoon, Republic of Korea

EP12.02-10  Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative  
D. Ross Camidge, USA

EP12.02-11  Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-line Alectinib or Brigatinib  
Jessica Bauman, USA

EP12.02-12  Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC  
Shun Lu, China

EP12.03  Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy - Other

EP12.03-01  Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy  
Michelle Dean, Canada

EP12.03-02  Previously Treated Advanced-Disease NSCLC Kras G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)  
Luna Zhan, Canada

EP12.03-03  A Case of Successful Desensitization Treatment with Tepotinib after Tepotinib-induced Rash  
Takahiro Baba, Japan

EP12.03-04  Prognostic Value of TP53 Mutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First-Line Osimertinib  
Leonardo Rojas, Colombia

EP12.03-05  How Advanced Lung Cancer Patients Receiving Immuno or Targeted Therapy Label Themselves and How Community Organizations Can Support Them  
Paul Wheatley-Price, Canada

EP12.03-06  A Retrospective Analysis of the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital  
Ayaka Saito, Japan

EP12.03-07  A Case Report of Sustained Survival of NSCLC Treated with Combination of Cell Therapy and Immunotherapy  
Francisco Heralde, III, Philippines

EP13.01  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Biomarkers and Radiomics

Wei Zhang, China

EP13.01-02  Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC  
Romana Wass, Austria

EP13.01-03  Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre  
Renu Nabariya, India

EP13.01-04  Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease  
Hakyoung Kim, Republic of Korea

EP13.01-05  Survival Characteristics in SCLC Patients Receiving Atezolizumab and Etoposide-Carboplatin  
Mi-Hyun Kim, Republic of Korea

EP13.01-06  Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)  
Masashi Ishihara, Japan

EP13.01-07  Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study  
Chi-Lu Chiang, Taiwan

EP13.01-08  Stratified Control Study of Neuroendocrine Differentiation and Potential Clinicopathologic Markers  
Li Liu, China

Shuyan Wang, China

EP13.01-10  Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility  
Somagattu Sushmitha, India

EP13.01-11  Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy  
Ruth Alvarez Cabellos, Spain

EP13.01-12  Validation of LiPi Index in SCLC  
Ruth Alvarez Cabellos, Spain

EP13.01-13  Prognostic Nutritional Index-Based Immune Risk System for Prognosis and Immunotherapy Response Prediction in Small Cell Lung Cancer  
Chaoqiang Deng, China
### EP13.02  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Case Report

**EP13.02-01**  Minimally Invasive Surgery for Endobronchial Small Cell Lung Carcinoma Following Neoadjuvant Chemotherapy  
Konstantinos Konstantinidis, Greece

**EP13.02-02**  Dynamic Transition of Molecular Subtypes in Relapsed Small Cell Lung Cancer Treated with Multimodal Therapy  
Kengo Yasuda, Japan

**EP13.02-03**  Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion  
Hui Shi, China

### EP13.03  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - First Line Therapy

**EP13.03-01**  Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study  
Yuping Sun, China

**EP13.03-02**  Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era  
Lorenzo Calvetti, Italy

**EP13.03-03**  RWD of Atezolizumab Plus Chemotherapy in First Line SCLC  
Ruth Alvarez Cabellos, Spain

**EP13.03-04**  A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer  
YK Shi, China

**EP13.03-05**  Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study  
Fanming Kong, China

**EP13.03-06**  Small Cell Lung Cancer Immune Related Adverse Events, Survival Impacts  
John Hunting, USA

**EP13.03-07**  Real-World Analysis of ICI Efficacy in ES-SCLC Patients with and without Brain Metastases: A Call for Inclusion in Clinical Trials  
Yuanzhen Cao, China

**EP13.03-08**  Developing Strategies for Delivery of Patient-Centered Care for Small Cell Lung Cancer  
Jennifer King, USA

**EP13.03-09**  Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review  
Joann Lee, Australia

**EP13.03-10**  The Survival Analysis of Immunotherapy in a Real-Word Cohort of Women Patients with Extensive-Stage Small Cell Lung Cancer  
Yuling He, China

**EP13.03-11**  Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer  
Matthew Lee, USA

**EP13.03-12**  Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era  
Tithi Biswas, USA

### EP13.04  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - LS-SCLC

**EP13.04-01**  Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer  
Tae Hoon Lee, Republic of Korea

**EP13.04-02**  Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up  
Guoping Cai, USA

**EP13.04-03**  The Impact of PCI on the Prognosis of Limited-stage SCLC Patients in the Era of MRI Surveillance  
Xiao Hu, China

**EP13.04-04**  Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC  
Xiao Hu, China

**EP13.04-05**  Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer  
Daniel Liem, Australia

### EP13.05  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - NETs

**EP13.05-01**  Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide  
Jinesh Gheeya, USA

**EP13.05-02**  Temozolomide-associated Hypermutation and Response to Immunotherapy in Advanced Pulmonary Neuroendocrine Tumors  
Wieneke Buikhuisen, Netherlands

**EP13.05-03**  A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma  
Emily Chen, Australia

**EP13.05-04**  Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma  
Yun Fan, China

**EP13.05-05**  Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens  
Junxi Xu, China

**EP13.05-06**  Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma  
Tianqing Chu, China
EP13.06  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Preclinical

EP13.06-01  Anlotinib Promotes the Phagocytosis and MI Polarization of Macrophages through Inhibiting CD47 via NF-κB Pathway in SCLC  
Haihua Yang, China

EP13.06-02  hSSB1 is Elevated and a Potential Target for Therapy in SCLC  
Amila Suraweera, Australia

EP13.06-03  Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer  
Jair Bar, Israel

EP13.06-04  Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers  
Salomon Tendler, USA

EP13.06-05  Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer  
Xiaorong Dong, China

EP13.06-06  Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer (SCLC)  
Fujun Yang, China

EP13.07  Track: Small Cell Lung Cancer and Neuroendocrine Tumors - Relapse and Salvage Therapy

Katherine Curt, USA

EP13.07-02  Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer?  
Ken Yamamoto, Japan

EP13.07-03  Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy  
Hossein Borthaei, USA

Min Wu, China

Ye Yuan, USA

EP13.07-06  Efficacy of Platinum Given after Lurbinected in Sensitive Relapsed SCLC Patients  
Jose Manuel Trigo, Spain

Faran Polani, USA

EP13.07-08  Canadian Consensus Recommendations: Use of Radiation Therapy Among Patients with ES-SCLC Receiving Immunotherapy  
Alexander Sun, Canada
### POSTER SESSIONS - ELECTRONIC POSTERS

**EP14.02**

**Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Thymic Malignancy**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP14.02-01</td>
<td>Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies</td>
<td>Xiuxiu Hao, China</td>
<td>China</td>
</tr>
<tr>
<td>EP14.02-02</td>
<td>Preoperative Steroid Pulse Therapy for Invasive Thymoma</td>
<td>Janna Berg, Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>EP14.02-03</td>
<td>Open Versus Video-Assisted and Robotic-Assisted Thymectomy for the Treatment of Thymic Neoplasms</td>
<td>Bright Hua, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>EP14.02-04</td>
<td>Identification of Risk Factors for Postoperative Acute Exacerbation of Myasthenia Gravis after Total Thymectomy</td>
<td>Kyohi Masah, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>EP14.02-05</td>
<td>Mid-Long Term Results of 3-Port Thoracoscopic Thymectomy for Masaoka Stage I-II Thymoma without Combined Resection of Surrounding Organs</td>
<td>Reo Ohtsuka, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>EP14.02-06</td>
<td>Mixed Feelings about Mixed Thymomas</td>
<td>Florit Marcuse, Netherlands</td>
<td>Netherlands</td>
</tr>
<tr>
<td>EP14.02-07</td>
<td>Atypical Response to Metronomic Chemotherapy in a Patient with Advanced Thymoma</td>
<td>Javier Baena, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>EP14.02-08</td>
<td>The Significance and Risk Factors of Lymph Node metastasis in Thymic Malignancies: A Large Population-based Database Analysis</td>
<td>Kunpang Xu, China</td>
<td>China</td>
</tr>
</tbody>
</table>

**EP14.03**

**Track: Mesothelioma, Thymoma, and Other Thoracic Tumors - Other Thoracic Malignancy**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP14.03-01</td>
<td>Is Subxiphoid Uniportal Video-Assisted Thoracoscopic Mediastinal Surgery Safe, Minimally Invasive, and Radical?</td>
<td>Yu Mori, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>EP14.03-02</td>
<td>The Impact of Expanded Indication of Robot-Assisted Thoracic Surgery for Mediastinal Tumors</td>
<td>Taketo Kato, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>EP14.03-03</td>
<td>Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy</td>
<td>Yongmei Liu, China</td>
<td>China</td>
</tr>
<tr>
<td>EP14.03-04</td>
<td>Rare but Aggressive: A Case of Primary Pulmonary Synovial Sarcoma</td>
<td>Jennifer Duke, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP14.03-05</td>
<td>Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy</td>
<td>Mark Clemens, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP14.03-06</td>
<td>PULS - An International Collaboration for Collection and Assessment of Data from Patients with PUL Monary Artery Sarcoma</td>
<td>Isabelle Opitz, Switzerland</td>
<td>Switzerland</td>
</tr>
<tr>
<td>EP14.03-07</td>
<td>Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation</td>
<td>Masakazu Takayama, Japan</td>
<td>Japan</td>
</tr>
</tbody>
</table>

**EP15.01**

**Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Nursing and Allied Health**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP15.01-01</td>
<td>Can Nurses Successfully Do Patient Advocacy: Need in Resource Poor Settings</td>
<td>S Pal, India</td>
<td>India</td>
</tr>
</tbody>
</table>

**EP15.02**

**Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Palliative Care**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP15.02-01</td>
<td>Improving the Lives of Patients Diagnosed with Lung Carcinoma: The Holistic Power of Palliative Care</td>
<td>Goran Stojanovic, Serbia</td>
<td>Serbia</td>
</tr>
<tr>
<td>EP15.02-02</td>
<td>Starting Early Palliative Care for Lung Cancer as Soon as Possible: Lesson Learned from Resource-limited Setting in Indonesia</td>
<td>Muhammad Ilham Rakasiwi, Indonesia</td>
<td>Indonesia</td>
</tr>
</tbody>
</table>
### Posters

#### EP15.03 Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care - Supportive Care

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP15.03-01</td>
<td>Technology Based Cancer Care In Rural India, An Ngo Based Approach</td>
<td>Nabanita Mandal, India</td>
<td>India</td>
</tr>
<tr>
<td>EP15.03-02</td>
<td>Implementation of an Interdisciplinary Distress Assessment and Response Program for Family Caregivers</td>
<td>Nazanin Nouriani, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>EP15.03-03</td>
<td>Assessment of the Multidisciplinary Onco-thoracic Consultation Meeting of the University Hospital Center of Tangier</td>
<td>Yassine Sbaiti, Morocco</td>
<td>Morocco</td>
</tr>
<tr>
<td>EP15.03-04</td>
<td>Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event</td>
<td>Javier de Castro, Spain</td>
<td>Spain</td>
</tr>
</tbody>
</table>

#### EP16.01 Track: Patient Advocacy

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP16.01-01</td>
<td>Virtual Educational Patient Meetings Empower, Unite Small Cell Lung Cancer Patients</td>
<td>Dusty Donaldson, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP16.01-02</td>
<td>A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges</td>
<td>Stephanie Mercier, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>EP16.01-03</td>
<td>Optimizing Treatment Outcomes for L858R EGFR+ NSCLC</td>
<td>Jo Monsen, Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>EP16.01-04</td>
<td>Standardized Screening of Thoracic Oncology Patients for Clinical Trial Eligibility Increases Enrollment</td>
<td>Daniel Gomez, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP16.01-05</td>
<td>Creation of Mental Health Support Materials for People with Lung Cancer and Healthcare Providers (HCPs)</td>
<td>Shani Shilo, Israel</td>
<td>Israel</td>
</tr>
</tbody>
</table>

#### EP17.01 Track: Global Health, Health Services, and Health Economics - Digital Solutions

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP17.01-01</td>
<td>The Lung Cancer Clinical Quality Data Platform (LUCAP): Results from a Western Australia Pilot Study</td>
<td>Jessica Nash, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>EP17.01-02</td>
<td>Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC).</td>
<td>Virginia Calvo de Juan, Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>EP17.01-03</td>
<td>Proposing Relevant Diagnosis Associated with Lung Cancer Based on Prior Diagnosis: Implementing Apriori Algorithm</td>
<td>So Yeon Kim, Republic of Korea</td>
<td>Korea</td>
</tr>
<tr>
<td>EP17.01-04</td>
<td>Lung Cancer Information System: Enabling Precision Oncology through Informatics</td>
<td>Madhusmita Behera, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP17.01-05</td>
<td>Lung Cancer (Internet-Based) Delphi (LuCID): a Delphi Consensus to Develop Australasian Thoracic Oncology Quality Indicators</td>
<td>Jessica Nash, Australia</td>
<td>Australia</td>
</tr>
</tbody>
</table>

#### EP17.02 Track: Global Health, Health Services, and Health Economics - Health Care Utilization

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP17.02-01</td>
<td>Concordance on Treatment Recommendations from Multidisciplinary Tumor Boards - Data from Driver-Mutated Lung Cancer in Focus</td>
<td>Julia Roeger, Germany</td>
<td>Germany</td>
</tr>
</tbody>
</table>

#### EP17.03 Track: Global Health, Health Services, and Health Economics - Health Economics

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP17.03-01</td>
<td>Quantitative Findings from a Survey of Health Insurance in Patients Diagnosed as Advanced Lung Cancer in Japan</td>
<td>Katsuhito Kinoshita, Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>EP17.03-02</td>
<td>Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy</td>
<td>Cloe Ying Chee Koh, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP17.03-03</td>
<td>Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer</td>
<td>Congling Gu, China</td>
<td>China</td>
</tr>
<tr>
<td>EP17.03-04</td>
<td>The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP):EvidenceBased Onamulticenter Clinicaltrialin China</td>
<td>Dawei Yang, China</td>
<td>China</td>
</tr>
</tbody>
</table>

#### EP17.04 Track: Global Health, Health Services, and Health Economics - Real World Data

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP17.04-01</td>
<td>The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales</td>
<td>Lydia Guhaniyogi, UK</td>
<td>UK</td>
</tr>
<tr>
<td>EP17.04-02</td>
<td>Global, Regional, National Burden of Lung Cancer Attributable to High Fasting Plasma Glucose</td>
<td>Minmin Wang, China</td>
<td>China</td>
</tr>
<tr>
<td>EP17.04-04</td>
<td>Survival Rate of Untreated Lung Cancer Patients at Dr. (H.C) Ir. Soekarno Hospital Bangka</td>
<td>Lijah Giovana, Indonesia</td>
<td>Indonesia</td>
</tr>
<tr>
<td>EP17.04-05</td>
<td>Research and Analysis on the Situation of Prevention and Treatment Capability of Cancer in County of China</td>
<td>Chi Du, China</td>
<td>China</td>
</tr>
<tr>
<td>EP17.04-06</td>
<td>Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small cell Lung Cancer (NSCLC) Treated with Durvalumab</td>
<td>Luis Raez, USA</td>
<td>USA</td>
</tr>
<tr>
<td>EP17.04-07</td>
<td>Lung Stereotactic Body Radiation Therapy in a Developing Country: Patterns of Safety and Treatment Toxicities</td>
<td>Renne Augusto Bart Aguiar, Brazil</td>
<td>Brazil</td>
</tr>
</tbody>
</table>
POSTER SESSIONS - ELECTRONIC POSTERS

EP17.04-08 Changing Lung Cancer Incidence Trends and Risk Patterns Among Asian Americans in Los Angeles County, California, USA
Lihua Liu, USA

EP17.05 Track: Global Health, Health Services, and Health Economics - Supportive Care
EP17.05-01 The Supportive Care Needs of Advanced Lung Cancer Patients Receiving Immuno and Targeted Therapy at Different Stages of the Disease Trajectory
Paul Wheatley-Price, Canada

EP17.06 Track: Global Health, Health Services, and Health Economics - COVID 19
Giulia Mentrasti, Italy
Elevate Your Lung Cancer Expertise!

EARLY REGISTRATION CLOSES OCTOBER 23, 2023
#NACLC23

Register Now!

Discover cutting-edge education, breakthroughs, and connections at the IASLC North America Conference on Lung Cancer!
- Insightful & innovative tumor boards
- Networking with top experts
- Dynamic sessions on prevention & screening, multimodality care, and more
- Inspiring oral abstracts and posters

ELEVATE YOUR UNDERSTANDING | IGNITE COLLABORATION
Shape the future of lung cancer care at NACLC!

MEET THE EDITOR

JTO CLINICAL AND RESEARCH REPORTS

Now indexed in PubMed Central!

September 11 | 2-3 PM SGT
Room 327

Editor-in-Chief: Emily Stone, MBBS, PhD, FRACP, St. Vincent’s Hospital, Sydney and School of Clinical Medicine, UNSW, Sydney, Australia.

Join JTO CRR Editor-in-Chief Emily Stone, MBBS, PhD, FRACP, for a Meet-the-Editor session during WCLC 2023. This session is open to all WCLC attendees.

Also plan to visit the IASLC booth in the exhibit hall to learn more about the journals, including how to become a reviewer.

jtocrr.org
07 GENERAL INFORMATION
Exhibitor Information

Exhibit Floorplan

EXHIBIT HALL FEATURES:
- Recharge Bar / Charging Station
- Collaborative Meeting Lounge
- Food & Beverages
- Business Center

LEGAL:
- Barista Bar
- Food & Beverage

Exhibitors By Name
- Abbvie
- Act Genomics
- Amgen
- Arcus Biosciences
- ASCO
- AstraZeneca
- BeiGene
- BMS
- Boehringer Ingelheim International GmbH
- Burning Rock DX
- Daiichi Sankyo, Inc.
- Erbe Singapore
- ESTS
- Gilead Sciences, Inc
- Global Lung Cancer Coalition
- GSK
- Guardant
- IASLC Booth
- IASLC Membership Lounge
- IASLC Patient Advocacy Lounge
- Janssen Asia Pacific
- Korean Association for Lung Cancer
- MSD
- NGeneBio Co, Ltd
- Olympus
- Pfizer Oncology
- Regeneron (Commercial)
- Regeneron (Medical)
- Roche (Exhibit)
- Roche (Meeting)
- Sanofi
- Scanlan International
- Seagen

Exhibitors By Booth Number
- Regeneron (Medical) A101
- Abbvie A105
- Arcus Biosciences A109
- Scanlan International A114
- Coreline Soft A115
- BMS A117
- NGeneBio Co, Ltd A118
- Act Genomics A119
- IASLC Membership Lounge A120
- IASLC Patient Advocacy Lounge A122
- Burning Rock DX A130
- Seagen A131
- IASLC Booth A137
- Sanofi B101
- GSK B103
- Daiichi Sankyo, Inc. B105
- Amgen B111
- Roche (Exhibit) C101
- Janssen Asia Pacific C113
- Regeneron (Commercial) C119
- Boehringer Ingelheim International GmbH C125
- MSD C131
- Pfizer Oncology C147
- AstraZeneca D101
- BeiGene D125
- Gilead Sciences, Inc D131
- Guardant D140
- Roche (Meeting) D147
- ASCO D159
- Olympus D160
- Erbe Singapore D161
- ESTS Tabletop #1
- Global Lung Cancer Coalition Tabletop #2
- Korean Association for Lung Cancer Tabletop #3
AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

www.abbvie.com

Act Genomics

ACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo, Bangkok and Wales (UK). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary Al algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action”.

www.actgenomics.com

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies and has reached millions of patients globally.

www.amgen.com

Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well-characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, follow us on Twitter.

www.arcusbio.com

AstraZeneca

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

www.astazeneca.com

BeiGene

BeiGene is a global biotechnology company with a mission to ensure medicines are accessible to people facing cancer and life-threatening diseases, wherever they live. Our founding belief is that there is a better way to bring medicines to patients around the world. As a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. United by a sense of urgency and a commitment to reach far more patients around the world Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Basel, Beijing and Cambridge, Mas., yet this is just the beginning. That’s why we say, “Cancer has no borders, and neither do we.”

www.beigene.com

ASC

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations. Through research, education, and promotion of the highest quality, equitable patient care, members work to create a world where cancer is prevented or cured, and every survivor is healthy.

www.asco.org
Boehringer Ingelheim International GmbH

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

pro.boehringer-ingelheim.com/inoncology

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines focused on serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

www.bms.com

Burning Rock Dx

Burning Rock Dx (NASDAQ: BNR) is committed to providing NGS-based testing for cancer patients, biomarker detection and companion diagnostic development services to pharmaceutical partners, and NGS-based multi-cancer early detection testing. We focus on providing tumor genomic data solutions, clinical trial solutions, integrated CDx development, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.

us.brbiotech.com

Coreline Soft

Coreline Soft is a leading AI solution company specializing in CT image analysis. Our flagship product, aview, offers a range of innovative solutions for lung cancer screening and other pulmonary diseases. With global recognition and partnerships with prestigious medical institutions, Coreline is revolutionizing the field of CT imaging, empowering medical professionals, and enhancing early detection of cancer worldwide.

www.corelinesoft.com

Daiichi Sankyo, Inc.

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

www.daiichisankyo.com

Erbe

As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world. Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients. The portfolio comprises devices and instruments for electrosurgery, thermofusion, plasmasurgery, cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology. Erbe employs more than 1000 people worldwide, over 650 of them in Germany. Approx. 170 employees work in research and development. The intensive collaboration with renowned users from medical schools and hospitals is the key to success with which Erbe successfully furthers developments in medicine.

de.erbe-med.com

ESTS

ESTS is the largest international general thoracic surgery organisation with more than 1650 members from all continents. The Society’s mission is to improve quality in the specialty, from clinical and surgical management of patients to education, training and credentialing of thoracic surgeons worldwide. The 32nd European Conference on General Thoracic Surgery will be held 26-28 May 2024, Barcelona, Spain.

Gilead Sciences, Inc

Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.

www.gilead.com
**Global Lung Cancer Coalition**

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

www.lungcancercoalition.org

---

**GSK**

GSK is committed to maximising patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, tumour cell targeting therapies and synthetic lethality.

Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, and antibody-drug conjugates, either alone or in combination.

www.gsk.com

---

**Guardant Health**

Guardant Health AMEA is a wholly owned subsidiary of Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext®, Guardant360 Response™, and GuardantINFINITY™ tests for patients with advanced-stage cancer, and Guardant Reveal™ for patients with early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. Follow us on LinkedIn, Twitter and Facebook.

www.guardanthealthamea.com

---

**Janssen Asia Pacific**

At Janssen Oncology, we have a bold vision – the elimination of cancer. This is what drives us to push the boundaries of science to help patients live cancer-free for longer than ever before. On the back of 30 years of innovation in oncology, our first-in-class therapies in solid tumors and hematological malignancies have extended lives and established new standards of care. Yet we continue to pursue every avenue to suppress, destroy and ultimately eliminate cancer – seeking not just incremental, but monumental change as we concentrate on where we can make the biggest difference. It is this focus on the needs of patients and their families that has propelled us to be among the top 5 and fastest growing oncology companies globally, with no less than ten transformational therapies approved in the last decade. We focus on making hope and possibility a reality. Harnessing cutting-edge research platforms for personalized medicines, we continue to pursue the most compelling science to give an increasing number of people more time to live well, live longer and live cancer-free. At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism and Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Janssen Asia Pacific, a division of Johnson and Johnson International (Singapore) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

www.janssen.com

---

**Korean Association for Lung Cancer**

The Korean Association for Lung Cancer (KALC) has been based in Korea since 2000, and we are currently working to promote collaborative research and multidisciplinary approaches to cure lung cancer and identify and support creative and innovative lung cancer research. Furthermore, we establish guidelines and propose policies for lung cancer prevention, diagnosis, and treatment, and provide evidence-based information about lung cancer for our members and the general public. In accordance with our working statements, we organize the KALC International Conference annually in which we endeavor to share the latest advances in research, together with our developing theories on lung cancer. The conference format involves up-to-the-minute lectures and presentations followed by in-depth discussions between lecturers and attendees. We believe this conference will provide an optimal experience for all participants to learn, share, and discuss the very latest information obtained from their research.

(*) KALC 2023: Nov. 30 - Dec. 1, 2023, Seoul, Korea

www.kalcic.or.kr

---

**MSD**

At MSD, our goal is to translate breakthrough science into innovative oncology medicines. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry.

www.msd.com
ROCHE

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Roche in Oncology: Our mission has been to turn science into breakthroughs to deliver better outcomes for everyone facing a cancer diagnosis. Today, we're studying treatments for a wide array of cancers, with nearly 150 ongoing clinical trials and 22 breakthrough therapy designations in oncology. Our research is backed by our investment of over 13B CHF in R&D, more than any other healthcare company in the world. We are committed to personalising cancer care for all patients and continue to focus on developing innovative medicines across various types of haematologic malignancies and solid tumours. We are leveraging multiple treatment approaches, including targeted therapies, cancer immunotherapies, cell and gene therapies, and next generation vaccines, and bringing innovation into earlier stages of disease to maximise a chance of cure.

www.roche.com

SANOFI

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

www.sanofi.com

REGENERON

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

www.regeneron.com
Scanlan International

Celebrating Over 100 Years and Our Journey Continues! Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

www.scanlaninternational.com

Seagen

Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.

www.seagen.com
Industry Sponsored Symposia - SATURDAY, SEPTEMBER 9

07 GENERAL INFORMATION

Industry Sponsored Symposia

Saturday, September 9, 2023

10:45 - 11:45 IS01: Industry Sponsored Symposium by Abbvie: The Expanding Role of Precision Medicine with Antibody Drug Conjugates in NSCLC

ROOM: 405C, LEVEL 4

Chair: Ross Camidge, USA

10:45 Introduction and Opening Remarks

Ross Camidge, USA

10:50 Current NSCLC Treatment Landscape and Expanding Treatment Options with Antibody Drug Conjugates

David Planchard, France

11:00 Getting to Know ADCs: Differentiating Composition and Mechanisms of Action

David Planchard, France

11:10 Latest Evidence and Ongoing Trials of ADCs

David Planchard, France

11:20 c-Met Overexpression a Novel Target in NSCLC

Umberto Malapelle, Italy

11:30 Integrating ADCs with Novel Biomarkers into Clinical Practice: Cracticalities, Challenges, and Future Directions

Umberto Malapelle, Italy

11:40 Discussion/Questions

Refreshments Provided

13:15 - 14:15 IS05: Industry Sponsored Symposium by Sanofi: Hitting the Mark: Emerging Biomarkers in Advanced NSCLC

ROOM: 405C, LEVEL 4

Chair: Benjamin Besse, France

13:15 Welcome and Overview of the Current Treatment Landscape in Advanced NSCLC: Where Are We Headed?

Benjamin Besse, France

13:20 The Role of Emerging Biomarkers in Advanced NSCLC

Mari Mino-Kenudson, USA

13:40 Clinical Developments with ADCs in Advanced NSCLC

Benjamin Besse, France

14:00 Group Discussion

Refreshments Provided


ROOM: 405B, LEVEL 4

Chair: Caicun Zhou, China

14:30 Welcome and Introductions

Caicun Zhou, China

14:35 Where the Road May Lead in the Management of Patients with EGFR Exon 20 Insertion Mutations

Darren Lim, Singapore

14:50 The Way Forward in Managing Common EGFR Mutations

Hiroaki Akamatsu, Japan

15:10 One for the Road: Panel Discussion and Best Practice Sharing

15:25 Meeting Close

Caicun Zhou, China

14:30 - 15:30 IS08: Industry Sponsored Symposium by Boehringer Ingelheim: Past, Present, and Future of Personalized Care in Lung Cancer: HER2 and DLL3 Targeted Therapies in Focus

ROOM: 405A, LEVEL 4

Chair: Byoung Chul Cho, Republic of Korea

14:30 Welcome and Introduction of Speakers

Byoung Chul Cho, Republic of Korea

14:32 The Past: A Brief History of Personalized Therapy in Lung Cancer

Herbert Loong, Hong Kong

14:47 Improving the Present: Selective HER2 TKI in NSCLC

Byoung Chul Cho, Republic of Korea

15:02 Advancing Towards the Future: Targeting DLL3 in SCLC

Yasushi Goto, Japan

15:25 Panel Discussion and Audience Q&A

15:30 Key Take-aways and Closing Remarks
Industry Sponsored Symposium - SATURDAY, SEPTEMBER 9, 2023

15:45 - 16:45 IS10: Industry Sponsored Symposium by Pfizer: Maximising the Potential in ALK+ NSCLC: Enhancing Outcomes and Improving Patient Care

ROOM: 405C, LEVEL 4

Chair: Tony Mok, Hong Kong

15:45 Welcome and Introduction
Tony Mok, Hong Kong

15:50 Updates in the 1L ALK+ NSCLC Treatment Landscape
Tony Mok, Hong Kong

16:08 Contemporary Strategies Beyond 1L ALK TKIs
Yi-Long Wu, China

16:21 Managing Adverse Events in ALK+ NSCLC
Narjust Florez (Duma), USA

16:36 Future Directions in ALK+ NSCLC Care
Tony Mok, Hong Kong

Refreshments Provided
SATELLITE CME SYMPOSIUM

12:00 - 13:00  ISO3: Satellite CME Symposium by PVI, PeerView Institute for Medical Education, Supported by Gilead: A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment with TROP2-Targeting ADCs and Rational Combinations

ROOM: 405A, LEVEL 4
Chair: Stephen Liu, USA

12:00 Welcome and Introduction
Stephen Liu, USA
12:05 MasterClass 1: Comprehending the Fundamental Concepts of ADCs and TROP2 in Lung Cancer
All
12:20 MasterClass 2: Unleashing the Potential of TROP2-Targeting ADCs and Rational Combinations
All
12:35 Practicum: Integrating TROP2-Targeting ADCs Into the Treatment Landscape of Lung Cancer
All
12:50 Summary and Audience Q&A

SATELLITE CME SYMPOSIUM


ROOM: 406, LEVEL 4
Chair: James Chih-Hsin Yang, Taiwan

15:45 Welcome and Introduction of Speakers
James Chih-Hsin Yang, Taiwan
15:50 Genomic Testing in NSCLC: Tailoring the Appropriate Testing Methodology to Treatment Goal
Fernando Lopez-Rios, Spain
16:05 Optimizing Integration of Molecular Testing in the Clinics: Applying the Guidelines
Justin Gainor, USA
16:20 Personalizing Therapy in NSCLC With a Rare Molecular Alteration: Clinical Cases
16:40 Q&A Session and Concluding Remarks
Sunday, September 10, 2023

Industry Sponsored Symposia

13:45 - 14:45  IS12: Industry Sponsored Symposium by AstraZeneca: The Road Ahead: Navigating Developments in Resectable NSCLC

ROOM: 405B, LEVEL 4
Chair: Roy Herbst, USA

13:45 Welcome and Introduction
Roy Herbst, USA

13:48 Optimising Outcomes in Resectable NSCLC for Patients with Actionable Mutations
Roy Herbst, USA

14:01 Exploring IO Treatment Options in Patients with Resectable NSCLC Without Actionable Mutations
David Harpole, USA

14:14 Neoadjuvant, Adjuvant, or Perioperative? That is the Question!
Jarushka Naidoo, Ireland

14:27 Expert Panel Discussion and Q&A

13:45 - 14:45  IS13: Industry Sponsored Symposium by Amgen: Transforming Care for Patients with Advanced Lung Cancer

ROOM: 405C, LEVEL 4
Chair: Ferdinandos Skoulidis, USA

13:45 Novel Targets in Lung Cancer: What Does the Future Hold?
Ferdinandos Skoulidis, USA

13:50 Current and Future Directions of KRASG12C Inhibitors in Advanced NSCLC
Alessandra Curioni-Fontecedro, Switzerland

14:10 Re-shaping SCLC Treatment in the Immune-Oncology Era
Taofeek Owonikoko, USA

14:27 Panel Discussion and Q&A

13:45 - 14:45  IS14: Industry Sponsored Symposium by MSD: Reaching New Heights: Building on the Foundation of Immuno-Oncology

ROOM: 405B, LEVEL 4
Chair: Marina Garassino, USA

18:30 Welcome - Audience Poll Question Practice
Marina Garassino, USA

18:35 Paradigm Shifts in Early Stage NSCLC Treatment
Marina Garassino, USA

18:55 Raising the Bar in 1L NSCLC - What's Coming?
Alfredo Addeo, Switzerland

19:10 Moving the Needle in Mesothelioma
Corey Langer, USA

19:25 Summary and Close
Marina Garassino, USA

18:30 – 19:30  IS15: Industry Sponsored Symposium by Novocure: A Spotlight on Tumor Treating Fields in Thoracic Oncology

ROOM: 405C, LEVEL 4
Chair: Sanjay Popat, UK

18:30 Welcome and Introduction
Sanjay Popat, UK

18:35 From MoA to Clinical Efficacy with TTFields Therapy
Rachel Grossman, Israel

18:50 Building Evidence for TTFields Therapy in Thoracic Oncology
Joachim Aerts, Netherlands

19:10 Discussion and Q&A

19:25 Close
Sanjay Popat, UK
Satellite CME Symposia - SUNDAY, SEPTEMBER 10

Sunday, September 10, 2023

Satellite CME Symposia

SATELLITE CME SYMPOSIUM


ROOM: 406, LEVEL 4

Chair: Wong Seng Weng, Singapore

13:45  Welcome and Introduction
Wong Seng Weng, Singapore

Wong Seng Weng, Singapore

14:03  What Next? Future Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy
Pasi A. Jänne, USA

14:18  What Can We Do Today vs Tomorrow? Optimizing Patient Outcomes Following TKI and Chemotherapy
Solange Peters, Switzerland

14:33  “Ask the Faculty” and Take-Home Messages

SATELLITE CME SYMPOSIUM

18:30 - 19:30  IS16: Satellite CME Symposium by AGILE, Supported by Merck KGaA: MET Inhibition in Metastatic NSCLC “In the Spotlight”

ROOM: 406, LEVEL 4

Chair: Paul Paik, USA

18:30  Welcome and Introduction
Paul Paik, USA

18:33  Have You MET Gene Aberrations in NSCLC?
Keith Kerr, UK

18:38  Panel Discussion and Q&A

18:46  Have You MET the New Molecular-Driven Therapies in NSCLC?
Paul Paik, USA

18:56  Panel Discussion and Q&A

19:04  Have You MET NSCLC in Clinical Practice?
Ross Camidge, USA

19:14  Panel Discussion and Q&A

19:22  Our Message Worth Sharing: Key Takeaways
Paul Paik & Ross Camidge, USA

19:28  Closing Remarks
Paul Paik, USA
### Industry Sponsored Symposia - Monday, September 11, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Symposium Title</th>
<th>Room</th>
<th>Chair</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 - 14:15</td>
<td>IS17: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: ADCs in Lung Cancer: Where We Are and Where We Are Going</td>
<td>406, LEVEL 4</td>
<td>Sandip Patel, USA</td>
<td>Sandip Patel, USA, Myung-Ju Ahn, Republic of Korea</td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td>IS18: Industry Sponsored Symposium by AstraZeneca: Tailoring Treatment in Metastatic NSCLC: Advances in Targeted Therapy and Post-progression Treatment Options</td>
<td>405B, LEVEL 4</td>
<td>Ross Soo, Singapore</td>
<td>Ross Soo, Singapore, Chee Lee, Australia, Natasha Leighl, Canada, Ticiana Leal, USA, Julia Rotow, USA</td>
</tr>
<tr>
<td>19:00 - 20:00</td>
<td>IS20: Industry Sponsored Symposium by GSK: Tackling Unmet Needs for Patients With NSCLC: Latest Scientific Advances &amp; Investigational Approaches</td>
<td>405B, LEVEL 4</td>
<td>Koichi Goto, Japan</td>
<td>Koichi Goto, Japan, Ben Solomon, Australia, Lizza Hendriks, Netherlands</td>
</tr>
<tr>
<td>19:00 - 20:00</td>
<td>IS22: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: Taking Aim at HER2-Driven NSCLC</td>
<td>406, LEVEL 4</td>
<td>Stephanie Saw, Singapore</td>
<td>Stephanie Saw, Singapore, Yasushi Yatabe, Japan, Hossein Borghaei, USA, Julia Rotow, USA</td>
</tr>
</tbody>
</table>

### Refreshments Provided

- Refreshments Provided for IS17
- Refreshments Provided for IS18
- Refreshments Provided for IS20
- Refreshments Provided for IS22
Monday, September 11, 2023

Satellite CME Symposia

**SATELLITE CME SYMPOSIUM**

19:00 - 20:00  IS21: Satellite CME Symposium by Med Learning Group, Supported by Regeneron Pharmaceuticals: Applying Multidisciplinary Expertise and Heterogeneous Skills in Clinical Practice: Transforming Non-Small Cell Lung Cancer Treatment with Immunotherapy

**ROOM: 405C, LEVEL 4**

Chair: David Carbone, USA

- 19:00 Introduction
  David Carbone, USA
- 19:05 Clinical Practice Guidelines – Immunotherapy in Advanced NSCLC
  David Carbone, USA
- 19:15 Evolving Immunotherapy Agents – Transforming Lung Cancer Care
  David Planchard, France
- 19:30 The Relevance of Biomarkers in NSCLC
  David Carbone, USA
- 19:40 Immunotherapy Related Adverse Events – NSCLC
  David Planchard, France
- 19:50 Case-Based Discussion
  All
- 19:55 Conclusions and Q&A
  All

Tuesday, September 12, 2023

Satellite CME Symposia

**SATELLITE CME SYMPOSIUM**


**ROOM: 406, LEVEL 4**

Chair: Melissa Johnson, USA

- 13:15 Introduction: Recognizing Current Gaps and Opportunities for Improvement With Novel ADCs in Lung Cancer
  Melissa Johnson, USA
- 13:20 Getting to Know ADCs as the Next Frontier in Precision Lung Cancer Care: Foundational Concepts
  All
- 13:30 Focus on ADCs Targeting HER3, TROP2, and Others in Lung Cancer: Latest Evidence and Ongoing Trials
  All
- 13:50 How to Leverage Research on ADCs Targeting HER3, TROP2, and Others to Accelerate Progress in the Clinic: Practicalities, Challenges, and Future Directions
  All
- 14:05 Audience Q&A, Reflections, and Conclusions
  All
Webinars are an important part of IASLC’s offerings—providing education and insight to those in the thoracic cancer community. Attendees represent multiple specialties, and geographical regions, and are IASLC members, patients, and non-members. Our webinars address topics of interest, professional practice gaps, and provide competency-based learning.

We are thrilled to introduce the Microlearning Insights Series—a fresh and exciting approach to education tailored to modern learners’ needs. We at IASLC firmly believe that short-form education can be highly effective in keeping up with the rapid changes in knowledge. As a testament to this, we are thrilled to introduce our Insights Conference coverage, which aims to spread key topic points from sessions and abstracts discussed in various meetings across the globe. We’re confident that this new method of learning will be a game-changer for many eager learners out there!
GENERAL INFORMATION
Opening Hours and Other Conference Information

REGISTRATION | DELEGATE HELP DESK | VIRTUAL PLATFORM HELP DESK
Level 3 Concourse
Friday, September 8 15:00 – 19:00
Saturday, September 9 07:00 – 20:30
Sunday, September 10 07:00 – 16:30

SPEAKER READY ROOM & LOUNGE
320, Level 3
Friday, September 8 15:00 – 19:00
Saturday, September 9 07:00 – 20:30
Sunday, September 10 07:00 – 16:30
Monday, September 11 07:00 – 17:00
Tuesday, September 12 07:00 – 15:45

EXHIBIT HALL
401 – 403, Level 4
Saturday, September 9 20:00 – 21:30
Sunday, September 10 10:15 – 19:30
Monday, September 11 09:45 – 20:00
Tuesday, September 12 09:45 – 14:15

POSTER DISPLAY
P1 Sunday, September 10 10:00 – 19:30
P2 Monday, September 11 10:00 – 20:00

POSTER PRESENTERS IN ATTENDANCE
P1 Sunday, September 10 17:30 – 19:30
P2 Monday, September 11 18:00 – 20:00

PRESS & MEDIA WORK ROOM
328, Level 3
Saturday, September 9 08:00 – 18:00
Sunday, September 10 08:00 – 18:00
Monday, September 11 08:00 – 18:00
Tuesday, September 12 08:00 – 16:00

PRESS CONFERENCE SCHEDULE
327, Level 3
Saturday, September 9 13:00 – 14:00
Sunday, September 10 10:35 – 11:30
Monday, September 11 10:05 – 11:00
Tuesday, September 12 10:05 – 11:00

WELCOME RECEPTION
Exhibit Hall, 401 – 403, Level 4
Saturday, September 9 20:00 – 21:30

POSTER VIEWING RECEPTIONS
Exhibit Hall, 401 – 403, Level 4
P1 Sunday, September 10 17:30 – 19:30
P2 Monday, September 11 18:00 – 20:00

EMERGENCY SERVICES AND FIRST AID
Dial 999 for Police or 995 for Fire & Ambulance. In case of fire at the Suntec Singapore Convention & Exhibition Centre, use the stairs and NOT the elevator for exit. Please follow the Suntec Singapore Convention & Exhibition Centre instructions in case of emergency.

PRESS & MEDIA WORK ROOM
Refreshments Provided

Lunch Provided

NETWORKING BREAKS
Exhibit Hall, 401 – 403, Level 4
Sunday, September 10 10:30 – 11:15
Monday, September 11 10:00 – 10:45
Tuesday, September 12 10:00 – 10:45

NETWORKING LUNCHES
Exhibit Hall, 401 – 403, Level 4
Sunday, September 10 13:45 – 14:45
Monday, September 11 13:15 – 14:15
Tuesday, September 12 13:15 – 14:15

IASLC AWARD CEREMONY
405B, Level 4
Saturday, September 9 17:00 – 18:00

IASLC BOARD OFFICE HOURS
Exhibit Hall, 401 – 403, Level 4
Collaborative Meeting Lounge
Sunday, September 10 10:40 – 11:10
Monday, September 11 10:10 – 10:40

IASLC BUSINESS MEETING
Nicol 1, Level 3
Tuesday, September 12 10:00 – 10:45

MEDIA POLICIES
Please visit wclc2023.iaslc.org/press-media/ for more information on press and media policies.

CONTINUING MEDICAL EDUCATION (CME) AND CERTIFICATE OF ATTENDANCE
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 91.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Visit wclc2023.iaslc.org/cme-information/ for more information on how to obtain CME credits and your Certificate of Attendance.

NURSING / PRAYER ROOM
IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer area.

NURSING ROOM:
Level 3, Next to Room 323

PRAYER ROOM:
Level 3, Across from Room 307

MEDIA POLICIES
Please visit wclc2023.iaslc.org/press-media/ for more information on press and media policies.
GENERAL INFORMATION
Virtual Platform

VIRTUAL PLATFORM FAQ
Check out our Virtual Platform FAQ for more information and useful tips! Walkthrough videos are available for desktop and mobile device access.

Virtual Platform Link: https://meetingsapp.iaslc.org/event/wclc2023

Virtual Platform Features:
• Full Scientific Schedule
• Abstract Book, Program Book
• Venue and Exhibit Floor Plan
• Presentation Slides and Recordings (Within 24 Hours)
• ePosters (Online View During the Conference) and Downloadable PDFs for all Traditional Posters and ePosters after the Conference
• Opportunity to Create Personalized Calendar
• Networking Features to Connect with Delegates and Faculty
• Notification Alerts

DOWNLOAD THE FREE OFFICIAL WCLC 2023 VIRTUAL PLATFORM
The Virtual Platform offers a convenient way to stay up-to-date on the latest Conference information. The platform is available for desktop and mobile devices. All sessions will be audio recorded and made available along with the presentation slides on the Virtual Platform within 24 hours after the session. Abstracts as well as all posters will also be accessible via this Virtual Platform after the Conference.

Log-in details were sent to your registered email. If you need assistance, you can visit the Virtual Platform Help Desk in the registration area or send an email to: wclc2023-registration@icsevents.com.
## GENERAL INFORMATION

### Venue Floorplans

**Suntec, Singapore - Level 3**

[Map of Suntec, Singapore - Level 3]

**Suntec, Singapore - Level 4**

[Map of Suntec, Singapore - Level 4]
CREATING HOPE THROUGH INNOVATION

At Eisai, everything we do is guided by a simple principle: patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. We call this human health care or hhc, giving first thoughts to patients and their families and helping increase the benefits health care provides.

Our hhc mission is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.

TO LEARN MORE, PLEASE VISIT WWW.EISAI.COM/US
CORP-US2790 ©2023 Eisai Inc. All rights reserved. September 2023

Find WCLC News at ILCN.org

Stay informed on all things IASLC at ILCN.org — the official news source of the only global association dedicated to the multidisciplinary study of lung cancer.

IASLC 2023 World Conference on Lung Cancer
SEPTMBER 9-12, 2023 | SINGAPORE

FREE WIFI
GET CONNECTED!
We are delighted to offer FREE WIFI for all WCLC 2023 delegates!

NETWORK: WCLC23_FREE_WiFi@SuntecSingapore
Save the Date

2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

SEE YOU IN SAN DIEGO!
Join us to celebrate the IASLC’s 50th Anniversary at WCLC 2024

wclc2024.iaslcl.org